



US006794167B2

(12) **United States Patent**  
Parales et al.(10) **Patent No.:** US 6,794,167 B2  
(45) **Date of Patent:** Sep. 21, 2004(54) **MODIFIED NAPHTHALENE  
DIOXYGENASES AND METHODS OF USE**(75) Inventors: **Rebecca Parales**, Iowa City, IA (US);  
**David Gibson**, Iowa City, IA (US); **Sol  
Resnick**, Encinitas, CA (US); **Kyoung  
Lee**, Kyongnam (KR)(73) Assignee: **University of Iowa Research  
Foundation**, Iowa City, IA (US)(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.(21) Appl. No.: **09/843,250**(22) Filed: **Apr. 26, 2001**(65) **Prior Publication Data**

US 2003/0022335 A1 Jan. 30, 2003

**Related U.S. Application Data**(63) Continuation of application No. PCT/US99/25079, filed on  
Oct. 26, 1999.(60) Provisional application No. 60/105,575, filed on Oct. 26,  
1998.(51) **Int. Cl.**<sup>7</sup> ..... **C12N 9/02**; C12P 7/00;  
C12P 7/02; C12Q 1/26; C07K 17/00(52) **U.S. Cl.** ..... **435/189**; 435/25; 435/132;  
435/155; 435/156; 530/350(58) **Field of Search** ..... 435/189, 25, 132,  
435/155, 156; 530/350(56) **References Cited****U.S. PATENT DOCUMENTS**

4,476,296 A	10/1984	Ballard et al.	528/481
4,508,822 A	4/1985	Taylor	435/155
4,548,737 A	10/1985	Ballard et al.	252/500
4,876,200 A	10/1989	Schofield et al.	435/253.3
5,470,728 A	11/1995	Grund	435/156

**FOREIGN PATENT DOCUMENTS**

EP	0076606	4/1983	C12P/7/02
EP	0125767	11/1984	H01L/23/30
EP	0154162	9/1985	C08F/8/00
EP	0336719	10/1989	C12N/15/00
WO	93/09240	5/1993	C12P/7/22
WO	93/09241	5/1993	C12P/7/22

**OTHER PUBLICATIONS**Mondello et al., *Applied and Environmental Microbiology*  
63(8):3096–3103, Aug. 1997.\*Jiang et al., *J. Bacteriol.* 178(11):3133–3139, 1996.\*Bork, *Genome Research*, 10:398–400, 2000.\*Seffernick et al., *J. Bacteriol.* 183(8):2405–2410, 2001.\*Broun et al., *Science* 282:1315–1317, 1998.\*Witkowski et al., *Biochemistry* 38:11643–11650, 1999.\*Brown, S.M., et al., “The Use of Arene–cis–Diols in Syn-  
thesis”, *In: Organic Synthesis: Theory and Applications*, 2,  
pp. 113–176, (1993).Carless, H.A., et al., “The Use of Cyclohexa–3,5–Diene–1,  
2–Diols in Enantiospecific Synthesis”, *Tetrahedron: Asym-  
metry Report* No. 9, v. 3 (7), pp. 795–826, (1992).Denome, S., et al., “Metabolism of dibenzothiophene and  
naphthalene in pseudomonas strains: complete DNA  
sequence of an upper naphthalene catabolic pathway”, *J.  
Bacteriol.*, 175 (21), *Accession No. AAA16131, Database  
GenBank*, 6890–6901, (Apr. 26, 1993).Denome, S., et al., “Metabolism of dibenzothiophene and  
naphthalene in Pseudomonas Strains: complete DNA sequence  
of an upper naphthalene catabolix pathway”, *J. Bacterol.*,  
175 (21), *Accession No. AA16125, Database GenBank*,  
6890–6901, (Jun. 12, 1993).Denome, S., et al., “Metabolism of dibenzothiophene and  
naphthalene in pseudomonas strains: complete DNA  
sequence of an upper naphthalene catabolic pathway”, *J.  
Bacteriol.*, 175 (21), *Accession No. AAA16129, Database  
GenBank*, 6890–6901, (Jun. 12, 1993).Denome, S., et al., “Metabolism of dibenzothiophene and  
naphthalene in pseudomonas strains: complete DNA  
sequence of an upper naphthalene catabolic pathway”, *J.  
Bacteriol.*, 175 (26), *Accession No. AAA16130, Database  
GenBank*, 6890–6901, (Jun. 12, 1993).Fuenmayor, S., et al., “Pseudomonas sp. U2”, *Accession No.  
AAD12619 Database GenBank*, 1, (Feb. 4, 1999).Hudlicky, T., et al., “An Evolutionary Perspective of Micro-  
bial Oxidations of Aromatic Compounds in Enantioselective  
Synthesis: History, Current Status, and Perspectives”, *In:  
Advances in Asymmetric Synthesis*, 1, pp. 271–312, (1995).  
Jerina, D.M., et al., “Cis–1, 2–Dihydroxy–1, 2–Dihy-  
dronaphthalene: A Bacterial Metabolite from Naphthalene”,  
*Archives of Biochemistry and Biophysics*, 142, pp. 394–396,  
(1971).Kauppi, B., et al., “Structure of an aromatic–ring–hydroxy-  
lating dioxygenase—naphthalene 1,2–dioxygenase”, *Struc-  
ture*, 6 (5), pp. 571–586, (1998).Klecka, G.M., et al., “Metabolism of Dibenzo [1,4]dioxan  
by a Pseudomonas Species”, *The Biochemical Journal*, 180  
(3), pp. 639–645, (1979).

(List continued on next page.)

*Primary Examiner*—Rebecca E. Prouty*Assistant Examiner*—Delia Ramirez(74) *Attorney, Agent, or Firm*—Schwegman, Lundberg,  
Woessner & Kluth, P.A.(57) **ABSTRACT**

The invention provides an NDO or NDO related complex comprising at least one alpha-subunit polypeptide that comprises: 1) a substituted amino acid at the position corresponding to position 352 in NDO, 2) a substituted amino acid at the position corresponding to position 201, 202, 260, 316, 351, 358, 362, or 366 in NDO, or 3) a substituted amino acid at the position corresponding to position 352 in NDO, and a substituted amino acid at the position corresponding to position 201, 202, 260, 316, 351, 358, 362, or 366 in NDO; or a catalytically active fragment thereof. The invention also provides DNA encoding such polypeptides, host cells augmented by such DNA, and methods for using the enzymes or host cells to provide useful and novel synthons. The invention also provides novel compounds prepared with the complexes or methods of the invention.

**15 Claims, 2 Drawing Sheets**

## OTHER PUBLICATIONS

Kolb, H.C., et al., "Catalytic Asymmetric Dihydroxylation", *Chem. Rev.*, 94, pp. 2483-2494, 2503-2515, 2526-2527, 2530-2531, and 2538-2541, (1994).

Ley, S.V., "Stereoselective synthesis of inositol phosphates", *Pure & App. Chem.*, 62 (10), pp. 2031-2034, (1990).

Resnick, S.M., et al. "Diverse reactions catalyzed by naphthalene dioxygenase from *Pseudomonas* sp strain NCIB 9816", *Journal of Industrial Microbiology*, 17, pp. 438-457, (1996).

Ribbons, D.W., et al., "Biodegradations Yield Novel Intermediates for Chemical Synthesis", *In: Advances in Applied Biotechnology Series, vol. 4, Biotechnology and Biodegradation*, D. Kamely, et al., (Eds), The Portfolio Publishing Company, The Woodlands, TX, pp. 213-245, (1990).


Sheldrake, G.N., "Chapter 6: Biologically Derived Arene cis-Dihydrodiols as Synthetic Building Blocks", *In: Chirality in Industry*, A.N. Collins, et al., (Eds.), John Wiley & Sons, Ltd., pp. 127-166, (1992).

Torok, D.S., et al., "Desaturation and Oxygenation of 1,2-Dihydronaphthalene by Toluene and Naphthalene Dioxygenase", *Journal of Bacteriology*, 177 (20), pp. 5799-5805, (Oct. 1995).

Wackett, L.P., et al., "Benzylic Monooxygenation Catalyzed by Toluene Dioxygenase from *Pseudomonas putida*", *Biochemistry*, 27, pp. 1360-1367, (1988).

Widdowson, D.A., et al., "The Use of Substituted Cyclohexadiene Diols As Versatile Chiral Synthons", *Janssen, Chimica Acta*, 8 (3), pp. 3-9, (1990).

\* cited by examiner-



NDO ENZYME

FIG. 1




FIG. 2

## MODIFIED NAPHTHALENE DIOXYGENASES AND METHODS OF USE

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Patent Application No. PCT/US99/25079, filed Oct. 26, 1999 which in turn claims priority to U.S. Provisional Application No. 60/105,575, filed Oct. 26, 1998.

### GOVERNMENT FUNDING

The invention described herein was made with U.S. Government support under United States Public Health Service grant number R01 GM29909 awarded by the National Institute of General Medical Sciences. The United States Government has certain rights in the invention.

### BACKGROUND OF THE INVENTION

Interest in the substrate specificity of bacterial dioxygenases stems from initial studies on the degradation of benzene and toluene more than 25 years ago. A mutant strain of *Pseudomonas putida* (strain F39/D) was shown to oxidize benzene and toluene to cis-1,2-dihydroxycyclohexa-3,5-diene (cis-benzene dihydrodiol) and cis-(1S, 2R)-dihydroxy-3-methylcyclohexa-3,5-diene (cis-toluene dihydrodiol), respectively (D. T. Gibson, et al., *Biochemistry*, 1970, 9, 1631–1635; D. T. Gibson, et al., *Biochemistry*, 1970, 9, 1626–1630; and V. M. Kopal et al., *J. Am. Chem. Soc.*, 1973, 95, 4420–4421).

The enzyme catalyzing these reactions, toluene dioxygenase (TDO), is capable of producing enantiomerically pure cyclohexadiene cis-diols from a wide range of aromatic substrates. D. T. Gibson, et al., *Microbial Degradation of Organic Compounds* (Gibson, D. T., ed.), pp. 181–251, Marcel Dekker, New York, N.Y. (1984); D. T. Gibson, et al., *Pseudomonas: biotransformations, pathogenesis, and evolving biotechnology*, (Silver, S. et al., ed.), pp. 121–132, American Society for Microbiology, Washington D.C. (1990); G. N. Sheldrake, *Chirality in Industry: the Commercial Manufacture and Application of Optically Active Compounds* (Collins, A. N. et al., eds.), pp. 127–166, John Wiley & Sons, Chichester, UK (1992); Stabile, M. R., Ph.D. thesis. Virginia Polytechnic Institute and State University, Blacksburg, Va. (1995); and D. R. Boyde and G. N. Sheldrake, *Nat. Prod. Rep.* 1988, 15, 309–324.

In contrast to the body of work relating to TDO, relatively little attention has been paid to the related enzyme naphthalene dioxygenase. Cells of *Pseudomonas* sp NCIB 9816-4 contain an inducible multi-component enzyme system designated NDO, which initiates naphthalene catabolism by catalyzing the addition of both atoms of molecular oxygen and two hydrogen atoms to the substrate to yield enantiomerically pure (+)-cis-(1R,2S)-dihydroxy-1,2-dihydronaphthalene (D. M. Jerina et al. *Arch. Biochem. Biophys.* 1971, 142, 394–396). NDO has a relaxed substrate specificity and catalyzes the deoxygenation of many related 2- and 3-ring aromatic and hydroaromatic (benzocyclic) compounds to their respective cis-diols.

The potential of NDO to form products of opposite chirality to those formed by TDO was first noted in 1988 during studies on the oxidation of indan. The major product formed by TDO was (-)-(1R)-indanol (84% enantiomeric excess [ee]) whereas NDO produced (+)-(1S)-indanol (>92% ee) (L. P. Wackett et al., *Biochemistry*, 1988, 27, 1360–1367. Subsequent studies with NDO revealed further

differences in substrate specificity and suggested that this enzyme is an additional source of chiral intermediates and synthons for the enantiospecific synthesis of biologically active products. S. M. Resnick et al. *Journal of Industrial Microbiology*, 1996, 17, 438–457.

NDO belongs to a family of bacterial enzymes that have an essential role in the recycling of carbon in nature. These enzymes are especially important in the degradation of aromatic hydrocarbons and related environmental pollutants. Knowledge of the NDO reaction mechanism is thus important in the development of bioremediation strategies for cleaning up environments contaminated with hazardous aromatic compounds. An attractive alternative to bioremediation is the application of 'green chemistry,' which refers to the production of industrial chemicals by processes that do not generate hazardous waste. For example, a recombinant strain of *Escherichia coli* expressing NDO, has been used to synthesize indigo dye from glucose. cis-Arene diols produced by NDO and toluene dioxygenase have been used in the synthesis of many products of biological and economic importance.

Knowledge of the types of reactions catalyzed by NDO and the range of substrates oxidized by NDO is based largely on biotransformation studies with cis-naphthalene dihydrodiol dehydrogenase (DDH) mutants, recombinant strains expressing NDO and purified NDO components. *Pseudomonas* sp 9816/11 is a DDH mutant of strain 9816-4 (G. M. Klecka and G. T. Gibson, *Biochem J.*, 1979, 180, 639–645) which accumulates cis-naphthalene-1,2-dihydrodiol when induced cells are incubated with naphthalene and a suitable carbon source (D. S. Torok, *J. Bacteriol.* 1995, 177, 5799–5805. Studies with purified dioxygenase components have been crucial in the identification of reactions catalyzed by NDO in the absence of other host-associated enzyme activities which, through subsequent catalysis, have the potential to affect product distribution and/or stereochemistry.

In addition to cis-dihydroxylation, NDO also catalyzes a variety of other oxidations which include monohydroxylation, desaturation (dehydrogenation), O- and N-dealkylation and sulfoxidation reactions. S. M. Resnick et al. *Journal of Industrial Microbiology*, 1996, 17, 438–457. Many of the reactions catalyzed by NDO and other microbial dioxygenases yield hydroxylated compounds that can serve as chiral intermediates or chiral synthons for a variety of compounds of interest to pharmaceutical and specialty chemical industries.

Despite the wide range of useful oxygenated materials that can be prepared with TDO and NDO, there is currently a need for additional oxygenated chiral synthons that can be used to prepare therapeutically useful compounds, or useful intermediates. In particular, there is a need for additional chiral synthons that differ from the TDO and NDO products by absolute configuration or by the site of oxygenation. There is also a need for new methods to prepare hydroxylated aryl compounds for use in the polymer, resin, pharmaceutical or rubber industry, which generate less industrial waste than currently available methods. Further, there is a need for novel enzymes possessing structures, stabilities, or reactivities that differ from the native enzymes.

### SUMMARY OF THE INVENTION

The crystal structure of NDO has recently been published by B. Kauppi et al. *Structure*, 1998, 6, no. 5, 571–586. Based on this structure, the amino acid at position 352 is located at the active site of NDO. As described hereinbelow, site-

directed mutagenesis was used to construct DNA molecules that encode NDO mutants having amino acid substitutions at position 352. Changing the amino acid at position 352 from phenylalanine to valine provided an enzyme (SEQ ID NO:2, encoded by SEQ ID NO:1) that gives a change in the preferred absolute configuration of the 1,2-dihydroxy-1,2-dihydronaphthalene formed from naphthalene. This enzyme also gave a change in the regioselectivity of the products obtained from oxidation of biphenyl and phenanthrene.

Accordingly, the invention provides an NDO or NDO related complex comprising a plurality of polypeptides, wherein the complex comprises at least one alpha-subunit polypeptide that comprises: 1) a substituted amino acid (e.g. valine or leucine) at the position corresponding to position 352 in NDO, 2) a substituted amino acid at the position corresponding to position 201, 202, 260, 316, 351, 358, 362, or 366 in NDO, or 3) a substituted amino acid at the position corresponding to position 352 in NDO, and a substituted amino acid at the position corresponding to position 201, 202, 260, 316, 351, 358, 362, or 366 in NDO; or a catalytically active fragment thereof. The complexes of the invention can preferably be isolated and purified.

The invention also provides an isolated and purified polypeptide having Swiss-prot data base Accession Number P23094 that comprises an amino acid other than phenylalanine at position 352, or a catalytically active variant, or a catalytically active fragment thereof. Preferably, the amino acid at position 352 is a naturally occurring amino acid. More preferably, the polypeptide is SEQ ID NO:2, 32, 33, 34, 35, or 36.

The invention also provides an isolated and purified NDO related polypeptide wherein the amino acid at the position corresponding to position 352 in NDO has been replaced with another amino acid, or a catalytically active fragment or catalytically active variant thereof. Preferably, the amino acid at the position corresponding to position 352 in NDO is a naturally occurring amino acid. More preferably, the amino acid at the position corresponding to position 352 in NDO is valine.

Site-directed mutagenesis was also used to construct DNA molecules that encode NDO mutants having an amino acid substitution at position 201, 202, 260, 316, 351, 352, 358, 362, or 366. Accordingly, the invention provides an isolated and purified NDO wherein the amino acid at position 201, 202, 260, 316, 351, 352, 358, 362, or 366 has been replaced with another amino acid, or a catalytically active variant, or a catalytically active fragment thereof.

Changing the amino acid at position 352 in NDO from phenylalanine to valine provided an enzyme (SEQ ID NO:2, encoded by SEQ ID NO:1) that gives a change in the preferred absolute configuration of the 1,2-dihydroxy-1,2-dihydronaphthalene formed from naphthalene. This enzyme also gave a change in the regioselectivity of the products obtained from oxidation of biphenyl and phenanthrene. The invention also provides an isolated and purified DNA segment encoding a polypeptide of the invention, or a variant or fragment thereof.

The invention also provides a primer or probe having about 80% nucleic acid sequence identity with a DNA segment encoding a polypeptide of the invention, or a variant or fragment thereof.

The invention also provides an expression cassette comprising a promoter operably linked to a DNA segment encoding a polypeptide of the invention or a variant or fragment thereof.

The invention also provides a host cell, the genome of which is augmented by a DNA segment encoding a polypep-

ptide of the invention, or a catalytically active variant or fragment thereof.

The invention also provides a method to produce a catalytically active polypeptide comprising culturing a host cell transformed with a DNA segment encoding a polypeptide of the invention, or a catalytically active variant or fragment thereof, so that the host cell expresses the polypeptide, variant or fragment.

The invention also provides a method for preparing cis-naphthalene dihydrodiol (e.g. (-)-(1S,2R)-cis-naphthalene dihydrodiol) comprising contacting naphthalene with a polypeptide of the invention, or a catalytically active variant or fragment thereof.

The invention also provides a method for preparing cis-naphthalene dihydrodiol (e.g. (-)-(1S,2R)-cis-naphthalene dihydrodiol) comprising contacting a host cell of the invention with naphthalene.

The invention also provides a method for preparing cis-biphenyl-3,4-dihydrodiol (e.g. (-) or (+) cis-biphenyl-3,4-dihydrodiol) comprising contacting biphenyl with a polypeptide of the invention, or a catalytically active variant or fragment thereof. The method may optionally further comprise dehydrating the cis-biphenyl-3,4-dihydrodiol to give 4-hydroxybiphenyl.

The invention also provides a method for preparing cis-biphenyl-3,4-dihydrodiol (e.g. (-)-cis-biphenyl-3,4-dihydrodiol) comprising contacting a host cell of the invention with biphenyl. The method may optionally further comprise dehydrating the (-)-cis-biphenyl-3,4-dihydrodiol to give 4-hydroxybiphenyl.


The invention also provides a method for preparing cis-phenanthrene-1,2-dihydrodiol (e.g. cis-(1S,2R)-phenanthrene-1,2-dihydrodiol) comprising contacting phenanthrene with a polypeptide of the invention, or a catalytically active variant or fragment thereof.

The invention also provides a method for preparing cis-phenanthrene-1,2-dihydrodiol (e.g. cis-(1S,2R)-phenanthrene-1,2-dihydrodiol) comprising contacting a host cell of the invention with phenanthrene.

The invention also provides a method to oxidize an aromatic compound to a corresponding dihydrodihydroxy compound comprising contacting the aromatic compound with a polypeptide of the invention, or a catalytically active variant or fragment thereof.


The invention also provides a method to oxidize an aromatic compound to a corresponding dihydrodihydroxy compound comprising contacting the aromatic compound with a host cell of the invention.

The invention also provides a method to prepare an optically active cis-cyclohexadiene of formula (I):



wherein one of  $R_1$  and  $R_2$  is hydrogen and the other is phenyl, 2-phenylvinyl, 2-phenylethynyl, or vinyl, wherein any phenyl ring may optionally be substituted with 1, 2, or 3 substituents independently selected from the group consisting of hydroxy, halo, carboxy, cyano, nitro, trifluoromethyl, amino,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxycarbonyl, and  $(C_1-C_6)$ alkoxy, comprising contacting a corresponding compound of formula (II):

5



with a polypeptide of the invention, or a catalytically active variant or fragment thereof, or with a host cell of the invention. Preferably, R<sub>1</sub> is phenyl or 4-hydroxyphenyl. The method may optionally comprise dehydrating the resulting compound of formula I.

The invention also provides a method to prepare cis-1,2-dihydroxyindan comprising contacting indene with a polypeptide of the invention, or a catalytically active variant or fragment thereof, or with a host cell of the invention.

The invention also provides a method to prepare 1,2-dihydroxy-1,2,3,4-tetrahydronaphthalene comprising contacting 1,2-dihydronaphthalene with a polypeptide of the invention, or a catalytically active variant or fragment thereof, or with a host cell of the invention.

The invention also provides a method to prepare 1,2-dihydroxy-1,2-dihydrophenanthrene or 3,4-dihydroxy-3,4-dihydrophenanthrene comprising contacting phenanthrene with a polypeptide of the invention, or a catalytically active variant or fragment thereof, or with a host cell of the invention.

The invention also provides novel compounds and intermediates disclosed herein, as well as crystallized forms of the polypeptides disclosed herein. Preferably, the invention provides a crystallized form of SEQ ID NO:26.

Polypeptides of the invention provide a biosynthetic route to the either enantiomer of cis-naphthalene dihydrodiol, to either enantiomer of cis-biphenyl-3,4-dihydrodiol, and to either enantiomer of cis-phenanthrene-1,2-dihydrodiol. These products can be used in the synthesis of new polymers and pharmaceutical products. For example, arene cis-diols are useful starting materials for stereospecific organic synthesis (S. M. Brown, et al., *Organic Synthesis: Theory and Applications* (Hudlicky, T., ed.), pp. 113–176, JAI Press, Greenwich, Conn. (1993); and T. Hudlicky and J. W. Reed, *Adv. Asymm. Synth.* 1995, 1, 271–312). They can undergo a variety of reactions including asymmetric Diels-Alder reactions, epoxidation, photochemical oxygenation, metallation, diol cleavage, diene cleavage, carbene additions and ozonolysis. They have been used to prepare a variety of synthetic products that are not readily obtainable by conventional chemical synthesis. Examples include conduritols, inositol phosphates, pinitol enantiomers, prostanoid and terpene synthons, and complex natural products such as (-)-zeylena and (+)-lycoricidine.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the effect of specific amino acid substitutions in an alpha-subunit having SEQ ID NO: 26 on the regioselectivity of a naphthalene dioxygenase during the oxidation of biphenyl.

FIG. 2 illustrates the effect of specific amino acid substitutions in an alpha-subunit having SEQ ID NO: 26 on the regioselectivity of a naphthalene dioxygenase during the oxidation of phenanthrene.

#### DETAILED DESCRIPTION

The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl,

6

(ii) alkoxy, denote both straight and branched groups; but refer only to an individual radical such as “propyl” embraces only the straight chain radical, a branched chain isomer such as “isopropyl” being specifically referred to.

5 The term “amino acid,” comprises the residues of the natural occurring amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g. phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, alpha-methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine).

As used herein, the terms “isolated and/or purified” refer to in vitro preparation, isolation and/or purification of a nucleic acid molecule, sequence or segment of the invention, so that it is not associated with in vivo substances. Thus, with respect to an “isolated nucleic acid molecule sequence or segment”, which includes a polynucleotide of DNA or RNA or of synthetic origin or some combination thereof, the “isolated nucleic acid molecule sequence or segment” (1) is not associated with all or a portion of a polynucleotide in which the “isolated nucleic acid molecule” is found in nature, (2) can be operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence. An isolated nucleic acid molecule means a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA. The term “oligonucleotide” referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide subset with 200 bases or fewer in length. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g., for probes or primers; although oligonucleotides may be double stranded, e.g., for use in the construction of a variant. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. The term “naturally occurring nucleotides” referred to herein includes deoxyribonucleotides and ribonucleotides. The term “modified nucleotides” referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term “oligonucleotide linkages” referred to herein includes oligonucleotide linkages such as phosphorothioate, phosphorodithioate, phosphoselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilate, phosphoroamidate, and the like. An oligonucleotide can include a label for detection, if desired.

The term “isolated polypeptide” means a polypeptide encoded by DNA or RNA, including polypeptides that are synthetic in origin, or some combination thereof, which isolated polypeptide (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

The term “selectively hybridize” means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments of the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to

nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence identity between the polynucleotides, oligonucleotides, variants, and fragments of the invention and a nucleic acid sequence of interest is at least about 65%, and more typically with preferably increasing identities of at least about 70%, about 90%, about 95%, about 98%, and 100%. See Sambrook et al. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor (1989).

The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

The term "NDO related polypeptide (or complex)" means a polypeptide (or complex) that belongs to the same family of bacterial enzymes as NDO or TDO. Preferably, an NDO related polypeptide has substantial identity with NDO. More preferably, an NDO related polypeptide is encoded by the DNA sequence having Genbank Accession number M60405, M23914, AF010471, AF004284, M83949, AF004283, AB004059, D84146, AF036940, U49504, or U62430.

The term "catalytically active," when applied to a polypeptide or a polypeptide variant or fragment of the invention, means that the variant or fragment catalyzes one or more of the reactions catalyzed by NDO or an NDO related polypeptide (see for example S. M. Resnick, et al., *Journal of Industrial Microbiology*, 1996, 17, 438-457). Preferably, a catalytically active polypeptide, or a catalytically active variant, or fragment catalyzes one or more of the reactions catalyzed by NDO. More preferably, a catalytically active polypeptide, or a catalytically active variant, or fragment catalyzes the oxidation of an aromatic substrate to give the corresponding dihydrodihydroxy compound (e.g. the oxidation of biphenyl or phenanthrene to 3,4-dihydroxy-3,4-dihydrobiphenyl or 1,2-dihydroxy-1,2-dihydrophenanthrene, respectively).

The term "biologically active" with respect to a fragment or variant of a polypeptide means that the fragment or variant has at least about 10%, preferably at least about 50%, and most preferably at least about 90%, the activity of the reference polypeptide. The activity of a polypeptide of the invention can be measured by methods well known to the art including, but not limited to, the ability of the peptide to elicit a sequence-specific immunologic response when the peptide is administered to an organism, e.g., chicken, goat, sheep or mice. The invention also provides polypeptides, as well as fragments and variants thereof, that are useful to elicit a sequence-specific immunologic response when the peptide is administered to an organism (e.g. a mammal).

When applied to a polypeptide the term "fragment" means a portion of the reference polypeptide that comprises the amino acid that corresponds to amino acid 352 in SEQ ID NO:26. Preferably the portion of the reference polypeptide also comprises at least about 10, 50, or 500 additional amino acids of the reference peptide. More preferably, the portion of the reference polypeptide comprises at least about 1000 or 1500 additional amino acids or the reference peptide.

When applied to a nucleotide sequence the term "fragment" means a portion of the reference nucleotide sequence that 1) encodes the amino acid corresponding to amino acid 352 in SEQ ID NO:26, and 2) encodes a catalytically active polypeptide. Preferably the portion of the reference nucleotide sequence also comprises at least about 30, 60, 150, or 300, nucleoside bases of the reference nucleotide sequence. More preferably, the portion of the reference nucleotide sequence also comprises at least about 600, 900, or 1200 nucleoside bases of the reference nucleotide sequence.

The following terms are used to describe the sequence relationships between two or more polynucleotides: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity".

A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length DNA or gene sequence given in a sequence listing, or may comprise a complete DNA or gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity.

A "comparison window", as used herein, refers to a conceptual segment of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482, by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48: 443, by the search for similarity method of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. (U.S.A.)* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is selected.

The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. "Percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms "substantial identity" as used herein denote a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least about 85 percent sequence identity, preferably at least about 90 to about 95 percent



sequence identity, more usually at least about 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 20–50 or 50–200 nucleotides, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the window of comparison.

As applied to polypeptides, the term “substantial identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least about 80 percent sequence identity, preferably at least about 80 percent sequence identity, more preferably at least about 90 percent sequence identity, and most preferably at least about 99 percent sequence identity. Alternatively two polypeptide sequences have substantial identity if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M. O., in Atlas of Protein Sequence and Structure, 1972, volume 5, National Biomedical Research Foundation, pp. 101–110, and Supplement 2 to this volume, pp. 1–10. Preferably, the two sequences have substantial identity if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. When a percent sequence identity is given, it means that the stated percentage of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred.

As used herein, “substantially pure” means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, about 90%, about 95%, and about 99%. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

When applied to a polypeptide the term “variant,” means a polypeptide that 1) has substantial identity with but is not identical to the reference polypeptide; and 2) is identical to the reference polypeptide at the position corresponding to amino acid 352 in SEQ ID NO:26.

When applied to a nucleotide sequence, the term “variant” means a nucleotide sequence that 1) has substantial identity with but is not identical to the reference sequence; and 2) encodes the same amino acid as the reference sequence at the position encoded by the reference sequence that corresponds to amino acid 352 in SEQ ID NO:26.

The variant DNA molecules of the invention may include DNA molecules with “silent” substitutions. For example, a preferred embodiment of the invention is an isolated and purified DNA molecule comprising a preselected DNA segment encoding SEQ ID NO:2, wherein the DNA segment comprises SEQ ID NO:1, or variants of SEQ ID NO:1, having nucleotide substitutions which are “silent” (see Table 1). That is, when silent nucleotide substitutions are present

in a codon, the same amino acid is encoded by the codon with the nucleotide substitution as is encoded by the codon without the substitution. “Silent” nucleotide substitutions in SEQ ID NO:1 which can encode a peptide having SEQ ID NO:2 can be ascertained by reference to Table 1 and page D1 in Appendix D in Sambrook et al., *Molecular Cloning: A Laboratory Manual* (1989). Nucleotide substitutions can be introduced into DNA segments by methods well known to the art. See, for example, Sambrook et al., supra.

TABLE 1

Amino Acid	Codon
Phe	UUU, UUC
Ser	UCU, UCC, UCA, UCG, AGU, AGC
Tyr	UAU, UAC
Cys	UGU, UGC
Leu	UUA, UUG, CUU, CUC, CUA, CUG
Trp	UGG
Pro	CCU, CCC, CCA, CCG
His	CAU, CAC
Arg	CGU, CGC, CGA, CGG, AGA, AGG
Gln	CAA, CAG
Ile	AUU, AUC, AUA
Thr	ACU, ACC, ACA, ACG
Asn	AAU, AAC
Lys	AAA, AAG
Met	AUG
Val	GUU, GUC, GUA, GUG
Ala	GCU, GCC, GCA, GCG
Asp	GAU, GAC
Gly	GGU, GGC, GGA, GGG
Glu	GAA, GAG

Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

Specifically, (C<sub>1</sub>-C<sub>6</sub>)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; and (C<sub>1</sub>-C<sub>6</sub>)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy.

*Pseudomonas* sp NCIB 9816-4 contain an inducible multicomponent enzyme system designated naphthalene dioxygenase (NDO) which catalyzes the formation of cis-naphthalene dihydrodiol. The system consists of an iron-sulfur flavoprotein (reductase<sub>NAP</sub>), a Rieske [2Fe-2S] protein (ferredoxin<sub>NAP</sub>), and an iron-sulfur protein (ISP<sub>NAP</sub>), which serves as the terminal oxygenase component. ISP<sub>NAP</sub> has an α<sub>3</sub>β<sub>3</sub> subunit component and each α subunit contains a Rieske [2Fe-2S] cluster and mononuclear iron. The Rieske cluster is believed to be an electron storage center that transfers electrons to mononuclear iron which is responsible for dioxygen activation and ultimately the catalytic reaction.

## 11

The genes encoding the NDO complex in *Pseudomonas* sp. NCIB 9816-4 have been cloned and expressed in *Escherichia coli* (W-C Suen and D. T. Gibson, *Gene*, 1994, 143, 67-71; and W-C Suen Ph.D. Thesis The University of Iowa, Iowa City, Iowa, 1993). The nucleotide sequences of the genes encoding reductase<sub>NAP</sub> (nahAa), ferredoxin<sub>NAP</sub> (nahAb), and ISP<sub>NAP</sub> (nahAcAd) have been determined and show 93.3%, 93.3%, 96.9%, and 94.8% identity, respectively, at the predicted amino acid level with the isofunctional genes carried by the well-studied NAH7 plasmid in *P. putida* G7 (S. Kurkele, *Gene*, 1988, 73, 355-362; M. J. Simon, *Gene*, 1993, 127, 31-37).

A number of dioxygenases with a structure similar to NDO have been identified. For example, the dioxygenases shown in Table 2 have  $\alpha$  subunits with greater than 80% amino acid identity to naphthalene dioxygenase from *Pseudomonas* sp. strain NCIB 9816-4 (calculated using GAP Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.). Because of their similarity to NDO in structure and function, it is reasonable to believe that modifying these polypeptides by replacing the amino acid corresponding to F352 in NDO with valine, will provide novel polypeptides that have similar advantageous properties compared to the native polypeptides. Accordingly, the invention also provides the following DNA molecules (SEQ ID No.'s 3-13) that have been modified to encode valine at the position corresponding to the F352 amino acid in NDO, as shown in Table 2.

TABLE 2

Genbank Accession Number	Amino Acid Corresponding to F352 in NDO	SEQ ID NO. For Modified DNA Sequence	SEQ ID NO. For Corresponding Polypeptide
M60405	F352	SEQ ID NO:3	SEQ ID NO:14
M23914	F352	SEQ ID NO:4	SEQ ID NO:15
AF010471	F352	SEQ ID NO:5	SEQ ID NO:16
AF004284	F352	SEQ ID NO:6	SEQ ID NO:17
M83949	F352	SEQ ID NO:7	SEQ ID NO:18
AF004283	F352	SEQ ID NO:8	SEQ ID NO:19
AB004059	F352	SEQ ID NO:9	SEQ ID NO:20
D84146	F352	SEQ ID NO:10	SEQ ID NO:21
AF036940	F350	SEQ ID NO:11	SEQ ID NO:22
U49504	I350	SEQ ID NO:12	SEQ ID NO:23
U62430	T355	SEQ ID NO:13	SEQ ID NO:24

The invention also provides the polypeptides (SEQ ID No.'s 14-24) that are encoded by the DNA molecules of SEQ ID No.'s 3-13. The invention also provides a host cell, the genome of which is augmented by a DNA molecule having SEQ ID NO:3-13.

In addition to the enantiospecific cis-dihydroxylation of naphthalene, NDO catalyzes dioxygenation of a variety of multicyclic and heterocyclic aromatic compounds to produce, in many cases, chiral cis-dihydrodiols. The mutant and recombinant strains expressing polypeptides of the invention allow the synthesis of cis-diols in high yields and/or high enantiomeric purity. For example, substrates which are oxidized to cis-dihydrodiols by NDO include indene, 1,2-dihydronaphthalene, benzocyclohept-1-ene, anthracene, phenanthrene, dibenzo[1,4]dioxan, acenaphthylene, 1- and 2-substituted naphthalenes, biphenyl, fluorene, dibenzofuran, dibenzothiophene, 9,10-dihydroanthracene, and 9,10-dihydrophenanthrene.

The DNA segment having Genbank Accession Number U49496 is SEQ ID NO:25. The polypeptide having Swiss-prot data base Accession Number P23094 is SEQ ID NO:26.

The invention will now be illustrated by the following non-limiting Examples.

## 12

## EXAMPLES

## Example 1

## Construction of Site-Directed Mutations

*Escherichia coli* strains DH5 $\alpha$  (Life Technologies, Gaithersburg, Md.) and JM109(DE3) (Promega Corp., Madison, Wis.) were used for subcloning and gene expression experiments, respectively. Competent *E. coli* strains ES 1301 and JM109 were purchased from Promega Corp. and used in the site-directed mutagenesis procedure described below.

*E. coli* strains were grown at 30 or 37° C. in Luria-Bertani (LB) medium (R. W. Davis, et al. Advanced Bacterial Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1980), or Terrific Broth (TB) medium (Lee, S. -Y., and S. Rasheed, *BioTechniques*, 1990, 9, 676-679). To maintain plasmids, ampicillin or tetracycline was added to final concentrations of 150 and 12  $\mu$ g/ml, respectively. JM109(DE3) strains carrying plasmids of interest were maintained on minimal medium plates (MSB) (R. Y. Stanier, et al., *J. Gen. Microbiol.*, 1966, 43, 159-271) containing 10 mM glucose, 0.1 mM thiamine, and ampicillin. For plates, MSB was solidified with 1.8% Agar Noble (Difco Laboratories, Detroit, Mich.) and LB was solidified with 1.5% Bactoagar (Difco Laboratories).

Mutagenesis of nahAc (encoding the naphthalene dioxygenase  $\alpha$  subunit) was carried out with the Altered Sites II in vitro Mutagenesis System according to the manufacturer's instructions (Promega Corp.). A 1.5-kb KpnI-XbaI fragment carrying the 3' half of the nahAc gene and the complete nahAd gene from pDTG141 (Suen, W.-C, Gene expression of naphthalene dioxygenase from *Pseudomonas* sp. NCIB 9816-4 in *Escherichia coli* Ph.D. thesis. The University of Iowa, Iowa City, Iowa, 1991) was cloned into KpnI-XbaI-digested pALTER-1 (Promega Corp.). The resulting plasmid, designated pMASTER-1, was used as the template for mutagenesis.

The mutagenic oligonucleotide (5'-TTCAGCG AACGGTCGGGCCTGC-3') (SEQ ID NO:37) was designed such that the restriction pattern of the plasmid was altered (eliminating a Psp1406I site shown by underlined bases; T-G base change shown in bold) to facilitate screening for clones carrying the desired mutation. The same T-G base change alters the TTC codon specifying phenylalanine to GTC, which specifies valine.

The phosphorylated oligonucleotide used for mutagenesis was synthesized by Genosys Biotechnologies Inc., Midland, Tex. pMASTER-1 (2  $\mu$ g) was denatured at room temperature for 5 min in the presence of 200 mM NaOH, 0.2 mM ethylenediamine tetraacetic acid (EDTA) in a 20  $\mu$ l volume. The denatured plasmid DNA was precipitated by addition of 2 M ammonium acetate (2  $\mu$ l; pH 4.6) and 100% ethanol (75  $\mu$ l) and incubated at -70° C. for 30 minutes. After centrifugation for 15 minutes at 14,000 rpm in an Eppendorf centrifuge, the DNA pellet was dried under vacuum and dissolved in 10 mM Tris, 1 mM EDTA (100 ml; pH 8.0).

The primer annealing reaction was carried out with the following components in a final volume of 20  $\mu$ l: denatured pMASTER-1 (10  $\mu$ l); tetracycline repair oligonucleotide (1  $\mu$ l; 5'-GCCGGCCTCTTGCGGGATATCGTCCA-3') (SEQ ID NO:38); ampicillin knockout oligonucleotide (1  $\mu$ l; 5'-GTTGCCATTGCTGCAG-GCATCGTGGTG-3') (SEQ ID NO:39); phosphorylated mutagenic oligonucleotide 1.25 pmol; 10 $\times$  annealing buffer (2  $\mu$ l; 200 mM Tris-HCl, pH 7.5, 100 mM MgCl<sub>2</sub>, 500 mM NaCl).

## 13

The mixture was heated at 75° C. for 5 minutes and cooled slowly (1° C. per min) to 45° C., then more rapidly to room temperature. The synthesis reaction mix contained the products of the annealing reaction and the following: sterile distilled water (5  $\mu$ l); 10 $\times$  synthesis buffer (3  $\mu$ l); 100 mM Tris-HCl (pH 7.5), 5 mM deoxyribonucleotides, 10 mM adenosine triphosphate, 20 mM dithiothreitol; T4 DNA polymerase (1  $\mu$ l); T4 DNA ligase (1  $\mu$ l).

The mixture was incubated at 37° C. for 90 minutes. A portion of this mixture (1.5  $\mu$ l) was used to transform 100  $\mu$ l of ES 1301mutS competent cells. The transformation mix was incubated on ice for 10 minutes, heated at 42° C. for 45 seconds and then incubated on ice for 2 minutes. LB (900  $\mu$ l) was added and the culture was incubated at 37° C. for 30 minutes without shaking. After incubation, 500  $\mu$ l of this culture was diluted with 4.5 ml of LB containing 1.25  $\mu$ g/ $\mu$ l ampicillin and incubated over night at 37° C. with shaking. Plasmid DNA was purified from the overnight culture as described by Lee, S.-Y., and S. Rasheed, *BioTechniques*, 1990, 9, 676–679, and was used to transform JM109 using standard procedures similar to those described by F. M. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York, 1993.

The transformation mixture was plated on LB plates containing ampicillin. Colonies were screened for tetracycline sensitivity on LB plates containing 12  $\mu$ g/ml tetracycline. Plasmid DNA purified from ampicillin resistant, tetracycline sensitive strains was digested with AclI (New England Biolabs, Beverly, Mass.) and the restriction pattern was compared to that of unmutagenized pMASTER-1 using standard molecular biology methods (for example see F. M. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York, 1993). The nucleotide sequences of both strands of the entire insertion in pMASTER-1 were determined for one mutant plasmid that contained the restriction site change.

Fluorescent automated DNA sequencing was carried out by the University of Iowa DNA Facility using an Applied Biosystems 373A automated DNA sequencer. After verification of each mutation by restriction digestion and sequence analysis, the 1.5-kb KpnI-XbaI fragments carrying each mutation were individually cloned into KpnI-XbaI-digested pDTG141 (which contains the nahAaAbAcAd genes for the naphthalene dioxygenase reductase, ferredoxin and  $\alpha$  and  $\beta$  subunits of the oxygenase, respectively). The resulting plasmids were introduced into JM109(DE3) for expression studies. After this subcloning step, the presence of the mutation was verified by restriction analysis and one sequencing run with a primer that generated sequence in the region of the mutagenized base and continued past the KpnI junction.

## Example 2

## Biotransformations

To produce induced cells for biotransformation studies, JM109(DE3) carrying the plasmid (pDTG141-F352V) [F=phenylalanine; V=valine] was grown in flasks at 30° C. in minimal medium (MSB) (R. Y. Stanier, et al., *J. Gen. Microbiol.*, 1966, 43, 159–271) containing 10 mM glucose, 0.1 mM thiamine, and 150  $\mu$ g/ml ampicillin with shaking (200 rpm). JM109(DE3)(pDTG141) was grown under iden-

## 14

tical conditions to provide the wild-type control. Isopropyl- $\beta$ D-thiogalactopyranoside (IPTG) was added to a final concentration of 100  $\mu$ M when culture turbidity reached 0.6–0.8 at 660 nm. After a 2.5 hour induction period, biotransformation reactions were initiated. Cultures were spiked with 20 mM glucose, 100 mM phosphate buffer (pH 7.2), and 0.025% (w/v) substrate (e.g. naphthalene, biphenyl, phenanthrene). Cultures were incubated at 30° C. with shaking (250 rpm) for up to 18 hours. Samples were taken periodically and cells were removed by centrifugation.

Culture supernatants were extracted with sodium hydroxide-washed ethyl acetate and analyzed by thin layer chromatography (S. M. Resnick, et al., *FEMS Microbiol. Lett.*, 1993, 113, 297–302). All extracts were analyzed by gas chromatography-mass spectrometry (GC-MS) as previously described (S. M. Resnick, *S. Appl. Environ. Microbiol.*, 1994, 60, 3323–3328). In some cases, dihydrodiol products were derivatized with approximately equimolar amounts of phenyl boronic acid at room temperature prior to injection onto the GC column.

Generally, biotransformation products were most easily detected by thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and/or gas chromatography-mass spectrometry (GC/MS). Preparative TLC, HPLC, column or radial dispersion chromatography are commonly used for the isolation of oxidation products prior to nuclear magnetic resonance (NMR) structural determination and/or stereochemical analysis.

Results from the biotransformation studies are shown in Table 3.

TABLE 3

40 NDO Polypeptide	Enantiomeric Composition of cis- naphthalene 1,2-	Dihydrodiols From		Dihydrodiols From	
		Biphenyl	Phenanthrene	Phenanthrene	Biphenyl
		%2,3	%3,4	%3,4	%1,2
Wild Type	>99	87.2	12.8	91.3	8.7
352-valine	92.4	4.4	95.6	17.0	83.0

In the biotransformations described above, incubation of biphenyl with host cells carrying the plasmid (pDTG141-F352V) yielded predominantly 3,4-dihydroxy-3,4-dihydrobiphenyl. This is in contrast to results obtained with the wild type cells, which yielded predominantly the 2,3-dihydroxy-2,3-dihydrobiphenyl. Additionally, incubation of phenanthrene with host cells carrying the plasmid (pDTG 141-F352V) yielded predominantly 1,2-dihydroxy-1,2-dihydrophenanthrene, rather than the corresponding 3,4 isomer preferentially formed from the wild type cells.

Thus, the polypeptides of the invention and the host cells of the invention are useful for preparing chiral diols for use in the polymer, resin, pharmaceutical or rubber industry. In particular, the polypeptides of the invention and the host cells of the invention are useful for preparing (–)-cis-3,4-dihydroxy-3,4-dihydrobiphenyl, and a single enantiomer (1S,2R) of cis-1,2-dihydroxy-1,2-dihydrophenanthrene.

The compound (–)-cis-3,4-dihydroxy-3,4-dihydrobiphenyl can be dehydrated to provide 4-hydroxybiphenyl, which is useful for the manufacture of rubber and resins (see The Merck Index (Martha Windholz,

## 15

ed.), 10 ed., 7187 (p-phenylphenol) Merck & Co. Inc. New Jersey, USA). Thus, the invention also provides an environmentally benign route to this useful compound. Additionally, the polypeptides-of the invention and the host cells of the invention may be useful for carrying out bioremediation.

## Example 3

## (+)-cis-(1R,2S)-Dihydroxy-1,2-dihydronaphthalene

cis-Dihydroxy-1,2-dihydronaphthalene formed by naphthalene dioxygenase was purified for chiral HPLC analysis by preparative-layer chromatography (A. M. Jeffrey, et al. *Biochemistry*, 1975, 14, 575-583; S. M. Resnick, S. *Appl. Environ. Microbiol.*, 1994, 60, 3323-3328). Chiral stationary-phase liquid chromatography (CSP-HPLC) was used to resolve the two enantiomers of cis-naphthalene dihydrodiol with a Chirocel OJ column (Chiral Technologies, Exton, Pa.) as described by S. M. Resnick, S. *Appl. Environ. Microbiol.*, 1994, 60, 3323-3328. Under these conditions, the (+)-(1R,2S) and (-)-(1S,2R) enantiomers of cis-naphthalene dihydrodiol eluted with retention times of 30 and 33 minutes, respectively.

## Example 4

## (-)-cis-Biphenyl-3,4-dihydrodiol

A 6 L culture of JM109(DE3)(pDTG141-F352V) was grown in a 10 L Biostat B fermentor (B.Braun Biotech International, Melsungen, Germany) in MSB at 27° C. Automated addition of NH<sub>4</sub>OH was used to maintain the pH at 7.3, and a slow glucose feed was used to maintain dissolved O<sub>2</sub> concentration at approximately 25% saturation. The culture was induced for 3 hours with 150 μM IPTG when the optical density of the culture (660 nm) reached 0.8. After 17 hours incubation with 0.025% (w/v) biphenyl, cells were harvested by centrifugation and the culture supernatant was extracted with ethyl acetate and concentrated as described previously (S. M. Resnick, et al., *FEMS Microbiol. Lett.*, 1993, 113, 297-302). Two purification methods were employed: 1) multiple elution preparative thin layer chromatography with a 95:5 mixture of chloroform and acetone as eluting solvent as previously described (D. S. Torok, et al., *J. Bacteriol.*, 1995, 177, 5799-5805); and 2) radial dispersion chromatography eluting with a step gradient of chloroform-methanol (S. M. Resnick, S. *Appl. Environ. Microbiol.*, 1994, 60, 3323-3328).

Over 150 mg of biphenyl 3,4-dihydrodiol was obtained from 500 mg crude product. The purity of the compound was determined by thin layer chromatography. The positions of the hydroxyl groups on the aromatic ring were determined by <sup>1</sup>H NMR analysis. The enantiomeric purity was determined to be >97% by subjecting the corresponding phenylboronate derivative to gas-chromatography-mass spectrometry analysis (see S. M. Resnick et al., *J. Org. Chem.*, 1995, 60, 3546-3549). Physical properties of the compound were as follows: λ<sub>max</sub> (in methanol) 276 and 228 nm, ε<sub>276</sub>=4, 336±574 and ε<sub>228</sub>=18,580±1621; calculated mass of the phenyl boronate derivative (C<sub>18</sub>H<sub>15</sub>O<sub>2</sub>B) was 274.1165, found mass, 274.1160; [α]<sub>D</sub> -37.5±3.8 (c=0.5 g/100 mL, methanol) as determined using a Jasco P1020 polarimeter with a Na 589 nm lamp.

## 16

Using a procedure similar to that described in Example 3, cis-biphenyl 2,3-dihydrodiol and cis-biphenyl 3,4-dihydrodiol were separated following multiple elution preparative thin layer chromatography. Under the same chiral HPLC conditions used to separate enantiomers of cis-naphthalene dihydrodiols, the (+)- and (-)-enantiomers of cis-biphenyl 3,4-dihydrodiol eluted with retention times of 31 and 28 minutes, respectively. The (+)-(2R,3S) and (-)-(2S,3R) enantiomers of cis-biphenyl 2,3-dihydrodiol eluted with retention times of 28 and 33 min, respectively.

## Example 5

## 4-Hydroxybiphenyl

Acid-catalyzed dehydration of biphenyl 3,4-dihydrodiol gave predominantly 4-hydroxybiphenyl. The addition of 50 mM HCl (final concentration) to a 0.3 mM solution of biphenyl 3,4-dihydrodiol in methanol at room temperature gave complete dehydration in minutes.

## Example 6

## Mutations in NDO

Bacterial strains and plasmids. Bacterial strains and plasmids used in this study are listed in Table 4. *Escherichia coli* strains DH5α and JM109(DE3) were used for subcloning and gene expression experiments, respectively. Competent *E. coli* strains ES1301 and JM109 were purchased from Promega Corp., Madison, Wis. and used in the site-directed mutagenesis procedure described below.

Media and growth conditions. *E. coli* strains were grown at 37° C. in Luria-Bertani (LB) medium (12), or Terrific Broth (TB) medium. Antibiotics were added to the following final concentrations as appropriate: ampicillin, 150 μg/ml; tetracycline, 12.5 μg/ml. To produce induced cells for biotransformation studies, JM109(DE3) strains carrying plasmids of interest were grown at room temperature 30° C. in minimal salts medium (MSB) containing 10 mM glucose, 0.1 mM thiamine, and ampicillin. Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 100 μM when culture turbidity reached 0.6-0.8 at 660 nm. After a 2 hour induction, biotransformations were initiated as described below. For plates, MSB was solidified with 1.8% Noble Agar (Difco Laboratories, Detroit, Mich.) and LB was solidified with 1.5% Bactoagar (Difco Laboratories).

Molecular techniques. Plasmid DNA was isolated as described previously (S-Y Lee, S. Rasheed, *Biotechniques*, 1990, 9, 676-679) or by using the Qiagen Midi Kit (Qiagen, Inc., Chatsworth, Calif.). For nucleotide sequencing, DNA was further purified using a Centricon-100 filter unit (Amicon, Inc., Beverly, Mass.). Restriction digests were performed as suggested by the enzyme suppliers (New England Biolabs, Inc., Beverly, Mass.; Promega Corp., Madison, Wis.). DNA fragments were purified from gel slices using the GeneClean Spin Kit according to the manufacturer's instructions (BIO101, Vista, Calif.). Ligation reactions, transformation of *E. coli* strains and agarose gel electrophoresis were performed by standard procedures.

TABLE 4

Strains and plasmids used in this study		
Strain or plasmid	Relevant Characteristics <sup>a</sup>	Source or Reference
<i>E. coli</i> strains		
DH5 $\alpha$	$\Delta$ (lacZYA-argF)U169, hdsR17 relA1, supE44, endA1, recA1, thi gyrA96, $\phi$ 80dlacZAM15	Life Technologies, Gaithersburg, MD
JM109	endA1, recA1, gyrA96 thi, hdsR17 relA1, supE44, $\Delta$ (lac-proAB), mcrA, [F', traD36, proAB <sup>+</sup> , lacI <sup>q</sup> ZAM15]	C. Yanisch-Perron et al., <i>Gene</i> , 1985 33:103–119.
JM109(DE3)	endA1, recA1, gyrA96 thi, hdsR17 relA1, supE44, $\Delta$ (lac-proAB), mcrA, [F', traD36, proAB <sup>+</sup> , lacI <sup>q</sup> ZAM15], $\lambda$ (DE3)	Promega Corp., Madison, Wis.
ES1301 mutS	Km <sup>r</sup> , lacZ53, mutS201::Tn5, thyA36, rha-5, metB1, deoC, IN(rrnD–rrnE)	Promega Corp., Madison, Wis.
Plasmids		
pDTG141	Ap <sup>r</sup> , nahAaAbAcAd (encoding the naphthalene dioxygenase components reductase <sub>NAP</sub> , ferredoxin <sub>NAP</sub> and large and small subunits of the oxygenase, respectively) under the control of the T7 promoter of p17-5	W.-C. Suen, 1991. Ph.D. Thesis. The University of Iowa, Iowa City, IA.
pMASTER-1	Tc <sup>r</sup> , Ap <sup>r</sup> , pALTER-1 carrying the KpnI-XbaI fragment of pDTG141 (nahAc'Ad)	R.E. Parales et al., <i>J. Bacteriol.</i> 1999, 181:1831–1837.

<sup>a</sup>Km<sup>r</sup>, kanamycin resistance; Ap<sup>r</sup>, ampicillin resistance; Tc<sup>r</sup>, tetracycline resistance

Site-directed mutagenesis. Mutagenesis of nahAc was carried out with the Altered Sites II in vitro Mutagenesis System according to the manufacturer's instructions (Promega Corp., Madison, Wis.). Plasmid pMASTER-1 (R. E. Parales et al., *J. Bacteriol.*, 1999, 181, 1831–1837), which contains the 3' end of the nahAc gene and the complete nahAd gene (which encode the  $\alpha$  and  $\beta$  subunits of NDO, respectively), was used as the template for mutagenesis. Each mutagenic oligonucleotide was designed with a silent mutation that altered the restriction pattern of the plasmid (Table 5) to facilitate screening for clones carrying the desired mutation. Phosphorylated oligonucleotides used for mutagenesis were synthesized by Genosys Biotechnologies Inc., Midland, Tex. The nucleotide sequences of both strands of the entire insertion in pMASTER-1 were determined for each mutant. Fluorescent automated DNA sequencing was carried out by the University of Iowa DNA Facility using an Applied Biosystems 373A automated DNA sequencer.

After verification of each mutation by restriction digestion and sequence analysis, the 1.5-kb KpnI-XbaI fragments carrying each mutation were individually cloned into KpnI-XbaI-digested pDTG141. After this subcloning step, the presence of each mutation was verified by restriction and sequence analyses. The resulting derivatives of pDTG141 were introduced into JM109(DE3) for expression studies and in this way each protein isoform was produced from an identical expression system.

Whole cell biotransformations. Induced *E. coli* cultures (50 ml) were supplemented with 20 mM glucose and 80 mM phosphate buffer (pH 7.2). Solid substrates (naphthalene, biphenyl, or phenanthrene) were added to a final concentration of 0.025% (w/v). Cultures were incubated at 30° C. with shaking (250 rpm) for 15–18 h. To obtain cells for large scale biotransformations to produce cis-biphenyl 3,4-dihydrodiol, JM109(DE3)(pDTG141-F352V) was grown at 27° C. in MSB containing glucose, thiamine, and ampicillin in a 10 L Biostat B fermentor (B. Braun Biotech International,

Melsungen, Germany). Automated addition of NH<sub>4</sub>OH was used to maintain the pH at 7.3, and a slow glucose feed rate was used to maintain the dissolved O<sub>2</sub> concentration at approximately 25% saturation.

Cultures were induced for 3 hours with 150  $\mu$ M IPTG when the optical density of the culture (660 nm) reached approximately 0.7. Induced cultures (5.5 L) were incubated at 27° C. for 14–17 h with 0.025% (w/w) substrate (biphenyl or phenanthrene), high agitation (700 rpm), automated pH control (pH 7.5) and a slow glucose feed.

Indigo formation. JM109(DE3) strains carrying pDTG141 derivatives with the various mutations were grown overnight at 37° C. on nitrocellulose filters placed on MSB agar plates containing 10 mM glucose, 1 mM thiamine, and 150  $\mu$ g/ml ampicillin. Dried Whatman #1 filter papers that had been soaked in a 10% solution of indole dissolved in acetone were placed in the Petri dish covers after colony formation. Production of indigo from indole vapor by NDO was observed as colonies turned blue. No induction was carried out for these studies.

Separation and identification of products. Culture supernatants from whole cell biotransformation experiments were extracted with sodium hydroxide-washed ethyl acetate and analyzed by thin layer chromatography (TLC). Phenyl boronic acid (PBA) derivatives (A. B. Herbert, European Patent EP 0379300A2) were prepared as previously described (S. M. Resnick, D. T. Gibson, *Appl. Environ. Microbiol.* 1996, 62, 4073–4080). PBA-derivatized extracts were analyzed by gas chromatography-mass spectrometry (GC-MS) as previously described (S. M. Resnick, D. T. Gibson, *Appl. Environ. Microbiol.* 1996, 62, 3355–3359). cis-Naphthalene dihydrodiol was purified by preparative-layer chromatography (PLC) with chloroform-acetone (8:2) (S. M. Resnick, et al., *Appl. Environ. Microbiol.* 1994, 60, 3323–3328).

TABLE 5

Amino acid substitutions in the $\alpha$ subunit of NDO generated by site-directed mutagenesis			
Mutation	Mutagenic oligonucleotide <sup>a</sup>	Restriction site	Indigo change formation <sup>b</sup>
N201A	5'-GAGGCACCCGCGGA <u>AGCTT</u> TTGTGGGAGATGCA-3' (SEQ ID NO:40)	HindIII	+
N201Q	5'-GCACCCGCGGA <u>ACAAT</u> TTGTGGGAGATGCA-3' (SEQ ID NO:41)	Tsp509I	+
N201S	5'-CCGCGGAAA <u>AGCTT</u> TTGTGGGAG-3' (SEQ ID NO:42)	HindIII	++
F202L	5'-CCGCGGAAA <u>AGCTT</u> TTGTGGGAGATG-3' (SEQ ID NO:43)	HindIII	-
F202V	5'-CGCGGAAA <u>ACGTT</u> TTGTGGGAGATG-3' (SEQ ID NO:44)	AclI	++
V260A	5'-ATATTCAGGT <u>CGCCAT</u> AGCCGAG-3' (SEQ ID NO:45)	FspI	++
V260L	5'-GGACGGATATTCAGGGCTCCATAGCCGAGACTTG-3' (SEQ ID NO:46)	BanII	++
V260N	5'-GACGGATATTCAGGTA <u>ACCAT</u> AGCCGAGACTTG-3' (SEQ ID NO:47)	BstEII	++
W316A	5'-GGTGTTTTCAAAGT <u>TCGCCA</u> ACCCGATCGAC-3' (SEQ ID NO:48)	NruI	+++
T351N	5'-CTGTTTCAGCGA <u>AACTT</u> TCGGGCCTGCT-3' (SEQ ID NO:49)	remove AclI	++
T351R	5'-CTGTTTCAGCGA <u>AGGTT</u> TCGGGCCTGCT-3' (SEQ ID NO:50)	remove AclI	+
T351S	5'-CTGTTTCAGCGA <u>AGCTT</u> TCGGGCCTGCT-3' (SEQ ID NO:51)	HindIII	+++
F352L	5'-TTCAGCGA <u>ACGCT</u> TCGGGCCTGC-3' (SEQ ID NO:52)	remove AclI	++
F352V	5'-TTCAGCGA <u>ACGGT</u> TCGGGCCTGC-3' (SEQ ID NO:37)	remove AclI	+
W358A	5'-GGCCTGTGGCTTCGCGGAAAGCGACGACA-3' (SEQ ID NO:53)	none	-
D362A	5'-GAAAGCGA <u>CCCAAT</u> GACAAT-3' (SEQ ID NO:54)	BsaHI	-
M366W	5'-ACGACAATGCA <u>ATTGGG</u> AAACAGCTTCGC-3' (SEQ ID NO:55)	MfeI	++

<sup>a</sup>Underlined bases indicate the position of the introduced or eliminated restriction site. Base changes are in bold.

<sup>b</sup>Indigo formation was monitored after 8 h as described in Materials and Methods.

+++ , colonies dark blue (corresponds to JM109(DE3)(pDTG141), expressing wild-type NDO;

++ , colonies medium blue;

+ , colonies pale blue;

- , no blue color (corresponds to negative control, JM109(DE3)(pT7-5).

<sup>c</sup>Colonies pale blue after 12 h.

Regioisomers of biphenyl dihydrodiol were separated by PLC (1.0 or 2.0 mm thickness; E. Merck Industries, Inc., Gibbstown, N.J.) using multiple elution (3–4 developments) with chloroform-acetone (9:1). *cis*-Biphenyl 3,4-dihydrodiol was also purified by radial-dispersion chromatography (RDC) using a Chromatotron (Harrison Research, Palo Alto, Calif.). Extracts in chloroform containing 0.1% triethylamine were applied to 2.0 mm-thick silica plates and eluted at a flow rate of 7 ml/min with a chloroform-acetone step gradient (0 to 15% acetone in 3% steps over 1 h; 0.1% triethylamine was present at each step). Fractions (8 ml) were analyzed by TLC, and those containing *cis*-biphenyl 3,4-dihydrodiol were combined and concentrated at 35° C. under reduced pressure.

Chiral stationary-phase HPLC was used to resolve the enantiomers of *cis*-naphthalene dihydrodiol. A Chiralcel OJ column (Chiral Technologies, Exton, Pa.) was used as described previously (S. M. Resnick, et al., *Appl. Environ. Microbiol.* 1994, 60, 3323–3328). Under these conditions, the (+)-(1R,2S)- and (-)-(1S,2R)-enantiomers of *cis*-naphthalene dihydrodiol eluted with retention times of 30 and 33 minutes, respectively. Proton (<sup>1</sup>H) nuclear magnetic resonance (NMR) spectra were acquired on the Varian UNITY-500 500 MHz spectrometer in the College of Medicine NMR Facility at the University of Iowa. All spectra

were obtained using an 8 second relaxation delay, a 5 second acquisition time, a spectral width of 12 ppm and a 90 degree pulse width of 6.6 microseconds. Samples were prepared as described by S. M. Resnick, et al., *Appl. Environ. Microbiol.* 1994, 60, 3323–3328). Optical rotations were determined at 25° C. using a Jasco P1020 polarimeter with a 589 nm Na lamp. The results are the average of rotations given by three independently purified *cis*-biphenyl 3,4-dihydrodiol samples. High resolution mass spectra were recorded (by Dr. Lynn Teesch, HR-MS facility, The University of Iowa) on a VG ZAB-HF mass spectrometer equipped with direct inlet probe. Absorbance spectra (200 to 350 nm) were recorded on a Beckman DU-70 spectrophotometer.

Chemicals. Naphthalene was obtained from Fisher Scientific Co., Pittsburg, Pa. Indole, biphenyl, phenanthrene, and 4-hydroxybiphenyl were purchased from Aldrich Chemical Co., Milwaukee, Wis. Synthetic (+/-)-*cis*-naphthalene dihydrodiol and homochiral (+)-*cis*-naphthalene dihydrodiol were prepared as previously described (A. H. Jaffrey et al., *J. Org. Chem.*, 1974, 39, 1405–1407; S. M. Resnick and D. T. Gibson, *Biodegradations*, 1993, 4, 195–203). Synthetic *cis*-phenanthrene 9,10-dihydrodiol was provided by Dr. Derek Boyd.

Construction and preliminary analysis of modified NDO proteins. Nine positions near the active site in the  $\alpha$  subunit

of NDO were chosen for site-directed mutagenesis. Based on the crystal structure of NDO, Asn-201, Phe-202, Val-260, Trp-316, Phe-352, Trp-358 and Met-366 are located near enough to the mononuclear iron to interact with substrates in the active site. Asn-201 is positioned too far from the iron atom to be a ligand in the crystallized form of NDO, but was suggested as a possible ligand during some stage of the catalytic cycle. According to the NDO structure, Asp-362 is one of three amino acids that coordinate the iron at the active site. Asp-362 was replaced by alanine in order to disrupt iron coordination. Amino acid substitutions were also made at Thr-351, since the corresponding amino acid has been shown to be critical in determining polychlorinated biphenyl (PCB) congener specificity in biphenyl dioxygenase.

Site-directed mutations made in the a subunit of NDO are shown in Table 5. In most cases, small hydrophobic amino acids (alanine, valine, and leucine) were substituted for larger hydrophobic amino acids such as phenylalanine and tryptophan in order to change the size and/or shape of the active site pocket. In some cases, amino acid substitutions were chosen based on alignments of various related dioxygenase sequences.

Indigo formation was used as an initial screen for NDO activity. Freshly grown cells of JM109(DE3) carrying modified pDTG141 plasmids were incubated in the presence of indole. Most strains carrying mutant NDO enzymes formed blue colonies in the presence of indole. Strains producing NDO isoforms F202L and D362A formed white colonies, suggesting that either these enzymes were inactive or that indole was not a substrate for the modified enzymes. The strain carrying the W358A substitution in NDO formed pale blue colonies upon extended incubation with indole, indicating very weak activity with indole as substrate.

Production of mutant NDO  $\alpha$  subunits. Formation of mutant  $\alpha$  subunits was verified in Western blots using whole-cell protein samples from induced JM109(DE3) carrying modified pDTG141 plasmids. A monoclonal antibody specific for the a subunit of NDO was used R. E. Parales, et al., *J. Bacteriol.*, 1998, 180, 2337–2344). Results show that all mutant constructs formed full length  $\alpha$  subunits and there were minor variations in the amounts of each mutant protein produced. More importantly, these show results demonstrate that the inability of isoforms D362A and F202L to produce products was not due to the absence of protein.

Biotransformations with naphthalene as substrate. Wild-type NDO converts naphthalene to cis-naphthalene 1,2-dihydrodiol. Biotransformations with naphthalene resulted in the formation of cis-naphthalene 1,2-dihydrodiol by all NDO isoforms with the exception of F202L and D362A, which formed no product. W358A transformations were very inefficient, with less than 5% of the substrate transformed within 15 h as judged by GC-MS analysis of extracted culture supernatants. The wild-type and all mutant NDO enzymes formed enantiomerically pure (>99%) (+)-(1R,2S)-cis-naphthalene dihydrodiol except for those with amino acid substitutions at Phe-352. Isoforms F352V and F352L formed 92% and 96% (+)-(1R,2S)-cis-naphthalene dihydrodiol, respectively. This result shows the importance of a specific amino acid, Phe-352, in determining the enantioselectivity of NDO.

Biotransformations with biphenyl as substrate. Wild-type NDO oxidized biphenyl to two metabolites which were detected by TLC. The major metabolite ( $R_f$ , 0.2) and the minor metabolite ( $R_f$ , 0.18) dehydrated to phenolic products ( $M^+$ , 170) when analyzed by GC-MS. These results suggested that both metabolites were dihydrodiol isomers and

this was confirmed by GC-MS of their stable respective phenyl boronic acid derivatives which gave molecular ions at  $m/e$  274. The major metabolite (87% relative yield) had a retention time of 13.8 min and was identical to cis-2,3-dihydroxy-1-phenylcyclohexa-4,6-diene (cis-biphenyl 2,3-dihydrodiol) produced from biphenyl by *Sphingomonas yanoikuyae* B8/36 (formerly *Beijerinckia* sp. strain B8/36) (D. T. Gibson et al., *Biochem. Biophys. Res. Commun.* 1973, 50, 211–219). The minor product (13% relative yield) had a retention time of 14.2 min and was identified as cis-3,4-dihydroxy-1-phenylcyclohexa-1,5-diene (cis-biphenyl 3,4-dihydrodiol; see below).

Isoforms F202L and D362A formed no products from biphenyl. Isoforms N201A and W358A formed only a trace amount of cis-biphenyl 2,3-dihydrodiol. Amino acid substitutions at N201, F202, V260, W316, and T351 had slight effects on the regioselectivity of NDO as seen by the product distributions shown in FIG. 1. However, both NDO isoforms with changes at position 352 formed cis-biphenyl 3,4-dihydrodiol as the major product. The isoform with the largest specificity change, F352V, formed 96% cis-biphenyl 3,4-dihydrodiol.

Identification and characterization of cis-biphenyl 3,4-dihydrodiol. The second product ran slightly slower than cis-biphenyl 2,3-dihydrodiol on TLC plates and, when analyzed by GC-MS as its PBA derivative, had a retention time of 14.2 min compared to 13.8 min for the PBA derivative of cis-biphenyl 2,3-dihydrodiol. The products formed from biphenyl by the F352V isoform were isolated by RDC. Approximately 140 mg of crude extract was applied to a 2.0 mm-thick silica chromatotron plate and eluted as described in the Materials and Methods to allow isolation of 40–60 mg pure cis-biphenyl 3,4-dihydrodiol and 1–2 mg of cis-biphenyl 2,3-dihydrodiol (fractions eluting before the 3,4-diol). The 3,4-regiochemistry of the diol and  $^1H$  NMR shift assignments were established by chemical shift multiplicities and independent H—H decoupling experiments. The 3,4-regiochemistry of the dihydrodiol was apparent by decoupling at H-3 (4.31 ppm) which reduced the multiplicity of the H-2 signal (ddd, 6.16) to a singlet with fine splitting. Acid dehydration resulted in the formation of a product that coeluted with authentic 4-hydroxybiphenyl in TLC and GC-MS analyses.

Physical characteristics of the cis-biphenyl 3,4-dihydrodiol were as follows:  $\lambda_{max}$  [MeOH], 204, 228, and 276 nm,  $\epsilon_{204}=11,860$ ,  $\epsilon_{228}=18,580$ , and  $\epsilon_{276}=4,336 M^{-1}cm^{-1}$ ; calculated mass for the phenylboronate derivative,  $^{12}C_{18}^{1}H_{15}^{16}O_2^{11}B$ , 274.1160, found mass 274.1165; mass spectrum of phenyl boronate derivative  $m/z$  (relative intensity), 174 ( $M^+$ , 100), 170 (55), 152 (11), 142 (84), 115 (22), 77 (6);  $[\alpha]_D -37.5 \pm 4.4$ ,  $n_D = 1.530$  (c 0.5, MeOH);  $^1H$  NMR (chloroform),  $\delta$  4.21 (ddd,  $J=6.4, 4.0, 1.5$  Hz, H-4), 4.31 (dd,  $J=6.4, 4.2$  Hz, H-3), 6.09 (ddd,  $J=9.8, 4.0, 0.8$  Hz, H-5), 6.16 (ddd,  $J=4.2, 1.7, 0.7$  Hz, H-2), 6.37 (dt,  $J=9.9, 1.6$  Hz, H-6), 7.30 (tt, 1H aromatic-p), 7.37 (m, 2H, aromatic-m), 7.46 (m, 2H, aromatic-o).

Biotransformations with phenanthrene as substrate. Since many of the amino acid substitutions would be predicted to increase the size of the NDO active site, a larger substrate, phenanthrene, was tested. Identification of the three regioisomers of cis-phenanthrene dihydrodiol were carried out by comparing GC-MS data with cis-3,4-dihydroxy-3,4-dihydrophenanthrene (cis-phenanthrene 3,4-dihydrodiol) and cis-1,2-dihydroxy-1,2-dihydrophenanthrene (cis-phenanthrene 1,2-dihydrodiol) produced by *S. yanoikuyae* B8136 (D. M. Jerina et al., *J. Am. Chem. Soc.* 1976, 98, 5988–5996), and synthetic cis-9,10-dihydroxy-9,10-

dihydrophenanthrene (cis-phenanthrene 9,10-dihydrodiol). The PBA derivatives of cis-phenanthrene 9,10-dihydrodiol, cis-phenanthrene 3,4-dihydrodiol and cis-phenanthrene 1,2-dihydrodiol had GC retention times of 18.0, 19.1, and 20.2 min, respectively. Wild-type NDO from *Pseudomonas* sp. strain NCIB 9816-4 formed a 9:1 mixture of cis-phenanthrene 3,4-dihydrodiol and cis-phenanthrene 1,2-dihydrodiol (FIG. 2). These results are similar to those obtained with NDO from *Pseudomonas* sp. strain 119 and biphenyl dioxygenase from *S. yanoikuyae* B8/36 (D. M. Jerina et al., *J. Am. Chem. Soc.* 1976, 98, 5988-5996).

With the exception of isoforms F202L and D362A, all mutant NDO enzymes formed products with phenanthrene as substrate. Amino acid substitutions at all positions changed product ratios to some extent. Isoforms V260A and W358A preferentially oxidized phenanthrene at the C3 and C4 positions, forming almost no cis-phenanthrene 1,2-dihydrodiol (FIG. 2). Several isoforms, including N201A, N201S, F202V, W316A, T351R, F352V, F352L, and M366W produced a significantly greater proportion of cis-phenanthrene 1,2-dihydrodiol than did wild-type NDO (FIG. 2). Of particular interest is the result with the F352V isoform. This enzyme had the opposite regioselectivity to wild-type NDO, forming 83% cis-phenanthrene 1,2-dihydrodiol in contrast to wild type, which formed 90%

tution of Val for Asn260 in 2NTDO resulted in an enzyme that no longer oxidized the aromatic ring of 2-nitrotoluene, forming only the monooxygenation product 2-nitrobenzylalcohol (J. V. Parales and D. T. Gibson, *Abstracts of the 99th General Meeting of the American Society for Microbiology*, 1999, Q-249, p-579). The opposite change in specificity did not occur with the NDO isoform V260N. Like wild-type NDO, the V260N isoform did not oxidize the aromatic ring of 2-nitrotoluene, but formed only 2-nitrobenzyl alcohol.

Toluene dioxygenase, which has a Trp residue at the position corresponding to 366 in NDO, dihydroxylates the aromatic ring of toluene to form cis-toluene dihydrodiol. However, the M366W isoform of NDO oxidized toluene to benzyl alcohol, the same product formed by the wild-type enzyme. Changing Trp-316 to Ala resulted in a minor change in regioselectivity with phenanthrene. Changing this conserved amino acid to Phe in 2NTDO had a slight effect on the stereochemistry of cis-naphthalene dihydrodiol formed from naphthalene (J. V. Parales and D. T. Gibson, *Abstracts of the 99th General Meeting of the American Society for Microbiology*, 1999, Q-249, p-579).

TABLE 6

Position <sup>b</sup>	Comparison of amino acids at the active sites of selected dioxygenase $\alpha$ subunits							NDO mutations
	Enzyme <sup>a</sup>							
	NDO <sub>9816-4</sub>	2NTDO <sub>JS42</sub>	DNTDO <sub>DNT</sub>	TDO <sub>FI</sub>	BPDO <sub>LB400</sub>	BPDO <sub>KF707</sub>		
201	Asn	Asn	Asn	Gln	Gln	Gln	Ala, Gln, Ser	
202	Phe	Phe	Phe	Phe	Phe	Phe	Leu, Val	
260	Val	Asn	Val	Leu	Ser	Met	Ala, Leu, Asn	
316	Trp	Trp	Phe	Trp	Trp	Trp	Ala	
351	Thr	Ser	Ser	Thr	Asn	Thr	Asn, Arg, Ser	
352	Phe	Ile	Thr	Phe	Phe	Phe	Leu, Val	
358	Trp	Trp	Trp	Phe	Phe	Phe	Ala	
362	Asp	Asp	Asp	Asp	Asp	Asp	Ala	
366	Met	Met	Met	Trp	Trp	Trp	Trp	

<sup>a</sup>Enzymes: 2NTDO, 2-nitrotoluene dioxygenase from *Pseudomonas* sp. strain JS42 (49); DNTDO, 2,4-dinitrotoluene dioxygenase from *Burkholderia* sp. strain DNT (64); TDO, toluene dioxygenase from *Pseudomonas putida* F1 (67); BPDO<sub>LB400</sub>, biphenyl dioxygenase from *Burkholderia* sp. strain LB400 (18); BPDO<sub>KF707</sub>, biphenyl dioxygenase from *Pseudomonas pseudoalcaligenes* KF707 (K. Taira et al., *J. Biol. Chem.*, 1992, 267:4844-4853.)

<sup>b</sup>Position numbers refer to NDO. Alignments were carried out with the Pileup program (Wisconsin Sequence Analysis Package: Genetics Computer Group, Madison, Wisc.) using a gap weight of 3.5 and a gap length of 0.1.

cis-phenanthrene 3,4-dihydrodiol. The F352L isoform oxidized phenanthrene to a small amount (5% of the total product) of cis-phenanthrene 9,10-dihydrodiol (FIG. 2).

Table 6 shows the amino acids in related dioxygenases that are located at positions corresponding to those mutated in NDO. Some amino acids listed in Table 6 are conserved in all of the enzymes shown (Phe-202 and Asp-362). In other cases, amino acids are not conserved and an amino acid in NDO was changed to one present in one of the other enzymes. Some of the NDO mutations were chosen based on the identification of amino acids critical for determining substrate specificity in other dioxygenases. In NDO, Thr-351, when changed to Asn, had a minor effect on product formation from phenanthrene. Replacement of this amino acid with Arg in NDO had a slight effect on product formation from biphenyl and a larger effect when phenanthrene was provided as the substrate (FIGS. 1 and 2). This position corresponds to the important amino acid in BPDO<sub>LB400</sub> Asn-377 that was mentioned above.

Changes at Val-260 in NDO resulted in minor changes in product formation with biphenyl and phenanthrene. Substi-

The amino acid at position 352 appears to play an important role in controlling both the stereochemistry of cis-naphthalene dihydrodiol formed from naphthalene, as well as the regioselectivity with substrates such as biphenyl and phenanthrene. In addition, a product that is not made by wild-type NDO, cis-phenanthrene 9,10-dihydrodiol, was formed from phenanthrene by the F352L isoform.

To compare substrate specificities of NDO and the new NDO isoforms with those of the closely related enzymes 2NTDO and DNTDO, biotransformations were carried out with biphenyl and phenanthrene. Both were found to be poor substrates for 2NTDO and DNTDO. Both enzymes made a trace amount of cis-biphenyl 2,3-dihydrodiol from biphenyl, and DNTDO made a trace amount of phenanthrene 3,4-dihydrodiol from phenanthrene. It is not clear at this time why biphenyl and phenanthrene are such poor substrates for 2NTDO and DNTDO.

In NDO, Asp-205 is located between the two redox centers at the junction of two adjacent subunits. Substitution of Asp-205 by glutamine resulted in an isoform of NDO



with no activity (R. E. Parales, et al. *J. Bacteriol.*, 1999, 181, 1831–1837). In the glutamine-containing enzyme, electron transfer between the Rieske center and the mononuclear iron was shown to be blocked, indicating that Asp-205 is essential for this electron transfer step to occur (R. E. Parales, et al. *J. Bacteriol.*, 1999, 181, 1831–1837). Iron at the active site of NDO is coordinated by His-208, His-213, and Asp-362. All three of these residues are conserved in the ring-hydroxylating dioxygenases whose sequences have been determined to date.

The corresponding histidine residues in toluene dioxygenase, from *P. putida* F1 (His-222 and His 228) were replaced with alanine residues and these substitutions resulted in completely inactive enzymes (H. Jiang, et al., *J. Bacteriol.* 19%, 178, 3133–3139). The inability to detect products from four different substrates indicates that substitution of Ala at position 362 results in an inactive form of NDO. No activity was detected in crude cell extracts of the D362A isoform with either oxygen uptake assays or product formation assays with <sup>14</sup>C-naphthalene. These results are consistent with the identification of Asp-362 as a ligand to the mononuclear iron at the active site.

Asn-201, a possible fourth iron-coordinating amino acid was observed in the crystal structure of NDO. This residue was too far from the iron atom to serve as a ligand in the crystallized form of the enzyme, but was suggested as a possible ligand during a step in the catalytic cycle (B. Kauppi, et al., *Structure*, 1998, 6, 571–586). Amino acid substitutions at Asn-201 resulted in enzymes with reduced but significant activity, indicating that this residue does not participate in the coordination of iron at the active site. Crude cell extracts of the N201A and N201Q isoforms had 5–10% of the activity of wild-type NDO. Results presented in FIGS. 1 and 2 suggest that Asn-201 may play a minor role in determining regioselectivity with biphenyl and phenanthrene as substrates. However, Asn-201 may be more important for maintaining appropriate interactions between a subunits through its hydrogen bond with Tyr-103 near the Rieske center in an adjacent  $\alpha$  subunit (B. Kauppi, et al., *Structure*, 1998, 6, 571–586). Substitution of an alanine at Asn-201 would disrupt this hydrogen bond and could affect the flow of electrons from the Rieske center to the mononuclear iron, thus reducing enzyme activity. The incorporation of the larger Gln residue at this position may prevent the normal interaction of  $\alpha$  subunits even though Gln would be capable of forming a hydrogen bond with Tyr-103. The N201S isoform showed 35–40% of the wild-type NDO activity, indicating that serine is a reasonably good substitute for Asn at this position (B. V. Plapp, *Methods Enzymol.*, 1995, 249, 91–119).

Of the three substrates tested, the most significant effects of mutations at the active site were observed with the largest substrate, phenanthrene. This is not an unexpected result since the substrate pocket is of limited size and larger substrates are likely to come in contact with more amino acids in the active site. Many of the mutations involved the substitution of a small hydrophobic amino acid for a larger one, and in most cases this type of substitution did not severely reduce the activity of the enzyme as can sometimes occur (M. S. Caffrey, *Biochimie*, 1994, 76, 622–630). However, one exception was the substitution of Trp-358 by Ala, which resulted in an enzyme with very poor activity with naphthalene and biphenyl, but somewhat better activity with the larger substrate phenanthrene.

Another exception was isoform F202L, which failed to form products with all substrates tested. The reason that this substitution resulted in an inactive enzyme while isoform

F202V had good activity is not understood. Somewhat surprisingly, mutations that introduced changes in polarity or charge (V260N, T351R) resulted in enzymes with good activity toward hydrophobic substrates. In general, most changes at the active site, with the exception of those that affect iron binding (Asp-362) and electron transfer (Asp-205) were tolerated well, suggesting that there is significant flexibility in the range of amino acids that can be introduced at the active site. This suggests that oxygenases with novel catalytic capabilities can be generated by introducing single or multiple mutations near the active site.

#### Example 7

##### Other Mutants Related to SEQ ID NO:25

Using procedures similar to those described in Example 1 (as described below), NDO mutant genes encoding glycine, alanine, threonine, leucine, isoleucine, tryptophane, or tyrosine instead of phenylalanine at position 352 were also prepared. Table 7 shows the SEQ ID No's for these DNA sequences and for proteins they encode.

TABLE 7

Amino Acid At Position 352	SEQ ID NO: For Modified Sequence	SEQ ID NO: For Corresponding Polypeptide
glycine	SEQ ID NO:27	SEQ ID NO:32
alanine	SEQ ID NO:28	SEQ ID NO:33
threonine	SEQ ID NO:29	SEQ ID NO:34
leucine	SEQ ID NO:30	SEQ ID NO:35
isoleucine	SEQ ID NO:31	SEQ ID NO:36
tryptophane	SEQ ID NO:56	SEQ ID NO:58
tyrosine	SEQ ID NO:57	SEQ ID NO:59

Activity of modified NDO proteins. The formation of indigo from indole was used to screen for NDO activity. Freshly grown colonies JM109(DE3) carrying modified pDTG141 plasmids were incubated in the presence of indole. Strains producing NDO enzymes with the mutations F352W and F352Y formed white colonies, suggesting that these enzymes were inactive or that indole was no longer a substrate for the modified enzymes. All other NDO isoforms constructed in this study appeared to be active. Table 8 shows the substitutions in the  $\alpha$  subunit of NDO generated by site-directed mutagenesis.

TABLE 8

Mutation	Mutagenic Oligonucleotide	SEQ ID NO:	Indigo Formation
F352G	5'-GTT <b>CAGCGA</b> <u>ACGGG</u> CGGGCCTGCTGG-3'	60	+
F352A	5'-GTT <b>CAGCGA</b> <u>ACGGC</u> CGGGCCTGCTGG-3'	61	+
F352T	5'-GTT <b>CAGCGA</b> <u>ACGAC</u> CGGGCCTGCTGG-3'	62	+
F352I	5'-GTT <b>CAGCGA</b> <u>ACGAT</u> CGGGCCTGCTGG-3'	63	+
F352L	5'-TTCAGCGA <u>ACGCT</u> CGGGCCTGTC-3'	52	+
F352W	5'-GTT <b>CAGCGA</b> <u>ACGTG</u> GGGGCCTGCTGG-3'	64	-
F352Y	5'-TTCAGCGA <u>ACGTA</u> CGGGCCTGCTGG-3'	65	-

Underlined bases in Table 8 indicate the position of the eliminated restriction site, AclI. BAase changes are in bold. Indigo formation was monitored after 8 hours; (+) indicates pale blue colonies, (-) indicates no blue color.

Regioselectivity of Modified NDO Proteins. Biotransformations with naphthalene resulted in the formation of cis-1,2-dihydroxy-1,2-dihydronaphthalene (cis-naphthalene dihydrodiol) by all NDO isoforms with substitutions at position 352 except F352Y, which formed no product. NDO-F352W transformations were very inefficient. In contrast to wild-type NDO, all enzymes with amino acid substitutions at position 352 formed small amounts of the (-)-enantiomer of cis-naphthalene dihydrodiol from naphthalene as determined from chiral HPLC analysis (Table 9).

TABLE 9

NDO Enzyme	cis-Naphthalene 1,2-dihydrodiol	cis-Biphenyl 2,3-dihydrodiol	cis-Biphenyl 3,4-dihydrodiol
NDO (wild type)	>99% (+)-(1R,2S)	>95% (+)-(2R,3S)	>98% (+)-(3R,4S)
F352G	98% (+)-(1R,2S)	>95% (+)-(2R,3S)	60% (+)-(3R,4S)
F352A	96% (+)-(1R,2S)	>95% (+)-(2R,3S)	65% (+)-(3R,4S)
F352T	93% (+)-(1R,2S)	>95% (+)-(2R,3S)	60% (-)-(3S,4R)
F352V	92% (+)-(1R,2S)		77% (-)-(3S,4R)
F352I	94% (+)-(1R,2S)	>95% (+)-(2R,3S)	53% (+)-(3R,4S)
F352L	96% (+)-(1R,2S)	>95% (+)-(2R,3S)	70% (+)-(3R,4S)

When biphenyl was used as a biotransformation substrate, wild-type NDO converted it to an 87:13 mixture of cis-biphenyl 2,3-dihydrodiol and cis-biphenyl 3,4-dihydrodiol. However, a major change in regioselectivity with biphenyl was seen when amino acid substitutions were introduced at F352. All active mutant NDO enzymes with changes at this position formed cis-biphenyl 3,4-dihydrodiol as the major product (Table 10). The F352Y isoform formed no detectable product from biphenyl, and F352W formed only a trace amount of cis-biphenyl 2,3-dihydrodiol.

TABLE 10

Enzyme	Bi-phenyl 2,3-diol	Biphenyl 3,4-diol	phenanthrene 3,4-diol	phenanthrene 1,2-diol	phenanthrene 9,10-diol
NDO	87	13	90	10	—
F352G	32	68	79	21	—
F352A	23	77	53	47	—
F352T	8	92	59	41	—
F352V	4	96	17	83	—
F352L	15	85	64	31	5
F352I	17	83	76	24	—

Like wild-type NDO, isoforms F352G, F352A, F352T, F352I and F352L formed cis-phenanthrene 3,4-dihydrodiol as the major product from phenanthrene, although product ratios varied significantly depending on the enzyme (Table 10). The F352V isoform had the opposite regioselectivity, forming primarily (83%) cis-phenanthrene 1,2-dihydrodiol. Isoforms F352W and F352Y did not form detectable amounts of product from phenanthrene.

The enantiomeric composition of cis-biphenyl 2,3-dihydrodiol was unaffected by amino acid substitutions at this position, but that of the cis-biphenyl 3,4-dihydrodiol was significantly different in all cases from that formed by wild type (Table 9). Isoforms F352V and F352T formed the opposite enantiomer of cis-biphenyl 3,4-dihydrodiol as wild-type NDO (Table 9).

Absolute stereochemistry of cis-biphenyl 3,4-dihydrodiol. The formation of diastereomeric 2-(1-methoxyethyl)-phenyl boronic acid (MPBA) derivatives of the F352V-generated cis-biphenyl 3,4-dihydrodiol provided a means for determining the enantiomeric purity of the compound. The results also allow an empirical prediction of

absolute configuration based on trends for vicinal cis-diols with a benzylic hydroxymethine (S. M. Resnick, et al., *J. Org. Chem.*, 1995, 60, 3546–3549). These trends were employed in the absence of MPBA directional shift data for a series of cis-3,4-dihydrodiols of known absolute configuration. Proton ( $^1\text{H}$ ) nuclear magnetic resonance (NMR) spectra were acquired on the Bruker AMX-600 MHz NMR spectrometer at 600.14 MHz in the University of Iowa High-Field NMR Facility. All spectra were obtained using a 14 s recovery delay, a 4.06 s acquisition time, a spectral width of 13.4 ppm and a 90 degree pulse width of 7.5  $\mu\text{s}$ . Samples were prepared as previously described (S. M. Resnick et al., *J. Org. Chem.*, 1995, 60, 3546–3549; S. M. Resnick et al., *Appl. Environ. Microbiol.*, 1994, 60, 3323–3328).  $^1\text{H}$ -NMR analysis ( $d_6$ -benzene) showed that the methoxy signal of the derivative formed with the (-)-cis-3,4-biphenyl dihydrodiol and (S)-MPBA was shifted downfield ( $\Delta\delta$ +21 ppb; 3.1987 ppm) relative to the corresponding signal of the (R)-MPBA derivative. The enantiomeric purity of the major diol was approximately 75%, based on integration of the methoxy groups of the major and minor MPBA diastereomers. This result confirms the data obtained by chiral HPLC analysis (Table 9). The downfield shifted methoxy signal for the (S)-MPBA derivative would indicate an S-configuration at the benzylic carbon for a 2,3-dihydrodiol. Application of this trend to the hydroxymethine nearest the benzylic position allows the suggestion of S-stereochemistry at C-3, and an absolute configuration of (-)-cis-(3S,4R)-biphenyl dihydrodiol.

Preparation of enantiomerically pure (-)-cis-(3S,4R)-biphenyl dihydrodiol. Three dihydrodiol dehydrogenases were tested for the ability to oxidize the (+)- and (-)-enantiomers of cis-biphenyl 2,3- and 3,4-dihydrodiols. Toluene dihydrodiol dehydrogenase from *Pseudomonas putida* F1 (J. E. Rogers and D. T. Gibson, *J. Bacteriol.*, 1977, 130, 1117–1124) was shown to specifically attack the (+)-enantiomers of both dihydrodiols at a significant rate. Plasmid pDTG511 carries the todD gene encoding toluene dihydrodiol dehydrogenase from *P. putida* F1 (G. J. Zylstra and D. T. Gibson *Aromatic Hydrocarbon Degradation: a molecular approach*, p. 183–203, in K. Setlow (ed.) *Genetic Engineering: Principles and Methods*, vol. 13, Plenum Press, New York). A bacterial strain was constructed which produces the F352V isoform of NDO and toluene dihydrodiol dehydrogenase. When this strain, JM109(DE3)(pDTG 141-F352V)(pDTG5 11), was used in biotransformations with biphenyl, the only dihydrodiol detected by chiral HPLC analysis was (-)-cis-biphenyl 3,4-dihydrodiol. The (+)-enantiomers of cis-biphenyl 2,3-dihydrodiol and cis-biphenyl 3,4-dihydrodiol were completely converted to the respective catechols, compounds which were easily separated from the dihydrodiol by preparative thin layer chromatography.

Absolute stereochemistry of cis-phenanthrene 3,4-dihydrodiol and 1,2-dihydrodiol. The formation of diastereomeric MPBA derivatives of the F352V-generated mixture of cis-phenanthrene dihydrodiols provided a means for determining the enantiomeric purity of the compounds. The results also allow an empirical prediction of absolute configuration based on trends for vicinal cis-diols with a benzylic hydroxymethine (S. M. Resnick et al., *J. Org. Chem.*, 1995, 60, 3546–3549). Samples were prepared as previously described (S. M. Resnick et al., *J. Org. Chem.*, 1995, 60, 3546–3549; S. M. Resnick et al., *Appl. Environ. Microbiol.*, 1994, 60, 3323–3328). Proton ( $^1\text{H}$ ) nuclear magnetic resonance (NMR) spectra were acquired as described above. An upfield directional shift for the methoxy signal of many

(S)-MPBA derivatives of polyaromatic cis-1,2-dihydrodiols is indicative of an R-configuration at the benzylic position of the cis-diol. For the cis-phenanthrene 1,2-dihydrodiol, the methoxy signal of the (S)-MPBA derivative was +72 ppb downfield from the corresponding signal of the opposite diastereomer formed with (R)-MPBA and predicting an S-configuration at the benzylic center.

Based on trends previously documented, the absolute configuration of the major dihydrodiol formed by F352V from phenanthrene is cis-(1S,2R)-phenanthrene dihydrodiol (91% e.e., approx. 83% relative yield). The facial selectivity in this case was the opposite to that shown for wild type biphenyl dioxygenase from *Sphingomonas yanoikuyae* B8/36. Analysis of the (±)-MPBA derivative of the isolated cis-phenanthrene dihydrodiol fraction formed by B8/36 showed resolution of the mixed racemates (of 3,4- and 1,2-diols) with minor methoxy signals of the 1,2-diol at 3.148 and 3.220 ppm. The same sample derivatized with (S)-MPBA showed the upfield shift for the methoxy signal at 3.148 ppm which corresponds to the an R-configuration of the benzylic center consistent with and confirmed by the previously determined (1R,2S)-configuration (M. Koreeda et al., *J. Org. Chem.*, 1978, 43, 1023–1027). The results of the above stereochemical correlation also suggest that the empirical application of the trends in the directional shifts of polycyclic aromatic diols appears to be valid for both the “bay-region” cis-3,4- and “non-bay region” cis-1,2-dihydrodiols of phenanthrene.

The minor diol formed from phenanthrene by F352V was identified as cis-(3S,4R)-phenanthrene dihydrodiol (>95% e.e., 17% relative yield). This assignment is based on the correlation of the methoxy signal at 3.115 ppm (but not 3.241 ppm) in the (S)-MPBA derivative of the F352V minor phenanthrene 3,4-dihydrodiol with that of the identical directional shifts of the known B8/36 cis-phenanthrene 3,4-dihydrodiol derivatives.

Relative activities of the mutant NDO enzymes. Cultures (50 ml in 500 ml flasks) were grown and induced, and biotransformations with naphthalene or biphenyl were initiated as described previously. Samples (1 ml each) were taken at 30 minute intervals over a period of 5 hours. Cells were removed by centrifugation and pellets were stored at -20° C. for protein determinations. cis-Naphthalene dihydrodiol formation was monitored at 262 nm ( $\epsilon=8114 \text{ M}^{-1}\text{cm}^{-1}$ ). cis-Biphenyl 2,3-dihydrodiol formation was monitored at 303 nm ( $\epsilon=13,600 \text{ M}^{-1}\text{cm}^{-1}$ ; (2)). cis-Biphenyl 3,4-dihydrodiol formation was monitored at 276 nm ( $\epsilon=4340 \text{ M}^{-1}\text{cm}^{-1}$ ; (5)) using a correction for the absorbance of cis-biphenyl 2,3-dihydrodiol at this wavelength. The extinction coefficient of cis-biphenyl 2,3-dihydrodiol at 276 nm (the Amax of cis-biphenyl 3,4-dihydrodiol) was determined to be  $7950 \text{ M}^{-1}\text{cm}^{-1}$  using purified cis-biphenyl 2,3-dihydrodiol from *S. yanoikuyae* B8/36 (2). The concentration of cis-biphenyl 3,4-dihydrodiol was calculated using the ratios of products

formed by each mutant enzyme and subtracting the contribution of cis-biphenyl 2,3-dihydrodiol. Absorbance of the negative control strain (JM109(DE3)(pT7-5) was subtracted at each time point. Protein concentrations were determined by the method of Bradford (M. M. Bradford, *Anal. Biochem.* 1976, 72, 248–254) after boiling cell pellets for 1 h in 0.1 N NaOH. Bovine serum albumin was used as the standard. Rates reported are the averages of three independent experiments.

The in vivo rates of formation of cis-naphthalene dihydrodiol by wild-type and mutant NDO enzymes are shown in Table 11.

TABLE 11

NDO Enzyme	Naphthalene dihydrodiol formation		Biphenyl 2,3-dihydrodiol formation		Biphenyl 3,4-dihydrodiol formation	
	Specific Activity (nmol/min/mg)	Relative Activity (%)	Specific Activity (nmol/min/mg)	Relative Activity (%)	Specific Activity (nmol/min/mg)	Relative Activity (%)
NDO	20.4	100	4.81	100	0.95	100
F352G	7.4	37	<0.05	<1	<0.25	<26
F352A	9.9	49	0.07	1	0.25	26
F352T	15.6	77	0.14	3	0.73	77
F352V	16.9	83	0.15	3	0.94	99
F352I	16.5	81	0.16	3	0.74	78
F352L	19.5	96	0.21	4	0.82	86

The F352L isoform produced cis-naphthalene dihydrodiol at wild-type rates, while the F352T, F352V, and F352I isoforms were slightly less efficient, with rates 75–85% that of wild-type NDO. The F352G and F352A enzymes were the least efficient in catalyzing this reaction. A similar trend is seen in the rates of formation of cis-biphenyl 3,4-dihydrodiol from biphenyl by the enzymes with substitutions at position 352 (Table 11). The F352T, V, I and L isoforms formed product at slightly reduced rates compared to wild-type NDO, while F352A was significantly slower and F352G rates were not measurable. In contrast, all enzymes with substitutions at position 352 were severely defective in forming cis-biphenyl 2,3-dihydrodiol from biphenyl (Table 11). These studies demonstrate that the amino acid substitutions at position 352 result in enzymes with a decreased tendency to oxidize at the 2,3-position of biphenyl. However, the rate of oxidation at the 3,4-position of biphenyl was not improved in the mutant enzymes.

All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 65

<210> SEQ ID NO 1

<211> LENGTH: 2265

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A sequence encoding an NDO mutant.

&lt;400&gt; SEQUENCE: 1

```

gagggtagag aaatcgaatg ccccttgcac caaggtcggg ttgacgtttg cacaggcaaa    60
gccctgtgag cccccgtgac acagaacatc aaaacatata cagtcaagat tgagaacctg    120
cgcgtaatga ttgatttgag ctaagaatth taacaggagg cccccgggc cctagagcgt    180
aatcaccccc attccatcct ttttaggtga aaacatgaat tacaataata aaatcttggg    240
aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac tttccaaca    300
tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattcc    360
tgccccgggc gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctcccggca    420
gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt    480
gagcgtggaa gccggcaatg ccaaaggtht tgtttgacgc taccacggct ggggcttcgg    540
ctccaacggt gaactgcaga gcgttcattt tgaaaaagat ctgtacggcg agtcgctcaa    600
taaaaaatgt ctggggttga aagaagtcgc tcgctgggag agcttccatg gcttcatcta    660
cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggtg    720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctctc caggcaaggt    780
tgtgatcaag gccaaactga aggcacccgc ggaaaacttt gtgggagatg cataccacgt    840
gggttgagc caccgctctt cgcttcgctc gggggagtct atcttctcgt cgctcgtctg    900
caatgcggcg ctaccacctg aaggcgcagg cttgcaaatg acctccaaat acggcagcgg    960
catgggtgtg ttgtgggagc gatattcagg tgtgcatagc gcagacttgg ttccggaatt   1020
gatggcattc ggaggcgcac agcaggaaa gctgaacaaa gaaattggcg atgttcgccc   1080
tcggatttat cgacgccacc tcaactgcac cgttttcccg aacaacagca tgctgacctg   1140
ctcgggtgth ttcaaagtat ggaacccgat cgacgcaaac accaccgagg tctggacctg   1200
cgccattgtc gaaaaagaca tgcttgagga tctcaagcgc cgcttgcccg actctgttca   1260
gcgaacggtc gggcctgctg gcttctggga aagcgcgac aatgacaata tggaaacagc   1320
ttcgcaaac ggcaagaaat atcaatcaag agatagtgat ctgctttcaa accttggttt   1380
cggtgaggac gtatacggcg acgcggtcta tccaggcgtc gtcggcaaat cggcgatcgg   1440
cgagaccagt tatcgtggtt tctaccgggc ttaccaggca cacgtcagca gctccaactg   1500
ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg   1560
ctaacagacg agtcgacct gatgatcaat attcaagaag acaagctggt ttccgcccac   1620
gacgccgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc   1680
actacgctgc tgaccaggga agcgcatttg ttggacattc aggttacccg tgcttggtta   1740
gagcactcgc tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgocagct    1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaa ttttcagcaa   1860
ctgaaagtgc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg   1920
cgctttactc gctttatcac caacgtccag gccgcaatgg acgtaaatga caaagagcta   1980
cttcacatcc gctccaactg cattctgcac cgggcacgac gtggcaatca ggtcogatgc   2040
ttctacgccg cccgggaaga taaatggaaa cgtggcgaag gtggagtacg aaaattggtc   2100
cagcgattcg tcgattaccg agagcgcata cttcagacgc acaatctgat ggtctttctg   2160
tgattcagtg accattttta caaatggtca ctgcaaccgc ggtcaccatt aatcaaaggg   2220

```

-continued

aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg

2265

```

<210> SEQ ID NO 2
<211> LENGTH: 449
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:1

<400> SEQUENCE: 2

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln
 1             5             10            15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys
 20            25            30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile
 35            40            45

Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val
 50            55            60

Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val
 65            70            75            80

Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala
 85            90            95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly
 100           105           110

Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu
 115           120           125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe
 130           135           140

His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met
 145           150           155           160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His
 165           170           175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys
 180           185           190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His
 195           200           205

Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe
 210           215           220

Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu
 225           230           235           240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly
 245           250           255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe
 260           265           270

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg
 275           280           285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn
 290           295           300

Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp
 305           310           315           320

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met
 325           330           335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Val
 340           345           350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr

```

-continued

355			360			365									
Ala	Ser	Gln	Asn	Gly	Lys	Lys	Tyr	Gln	Ser	Arg	Asp	Ser	Asp	Leu	Leu
	370						375				380				
Ser	Asn	Leu	Gly	Phe	Gly	Glu	Asp	Val	Tyr	Gly	Asp	Ala	Val	Tyr	Pro
385					390					395					400
Gly	Val	Val	Gly	Lys	Ser	Ala	Ile	Gly	Glu	Thr	Ser	Tyr	Arg	Gly	Phe
				405					410						415
Tyr	Arg	Ala	Tyr	Gln	Ala	His	Val	Ser	Ser	Ser	Asn	Trp	Ala	Glu	Phe
			420					425					430		
Glu	His	Ala	Ser	Ser	Thr	Trp	His	Thr	Glu	Leu	Thr	Lys	Thr	Thr	Asp
		435					440					445			

Arg

<210> SEQ ID NO 3  
 <211> LENGTH: 9841  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

<400> SEQUENCE: 3

```

gaattcatca ggaagacatt caaatgaacg taaacaataa gggcagcgtc tgtatttgcg      60
gcagcgaaat gctccctaaa ttcctcattt accccatctg aggattgctt tatgacagta    120
aagtggattg aagcagtcgc tctttctgac atccttgaag gtgacgtcct cggcgtgact    180
gtcagaggca aggagctggc gctgtatgaa gttgaaggcg aaatctacgc taccgacaac    240
ctgtgcacgc atggttccgc ccgcatgagt gatggttatc tcgagggtag agaaatcgaa    300
tgccccttgc atcaaggctc gtttgacgtt tgcacaggca aagccctgtg cgcacccgtg    360
acacagaaca tcaaaacata tccagtcaag attgagaacc tgcgcgtaat gattgatttg    420
agctaagaat tttaacagga ggcacccccg gccctagagc gtaatcacc ccatccatc     480
tttttaggt gaaaacatga attacaataa taaaatcttg gtaagtgaat ctggtctgag    540
ccaaagcac ctgattcatg gcgatgaaga acttttcaa catgaactga aaaccatttt    600
tgcgcggaac tggtttttc tcaactatga tagcctgatt cctgcccccg gcgactatgt    660
taccgaaaa atggggattg acgaggtcat cgtctcccgg cagaacgacg gttcgattcg    720
tgcttttctg aacgtttgcc gccatcgtgg caagacgctg gtgagcgtgg aagccggcaa    780
tgccaaaggt tttgtttga gctatcacgg ctggggcttc ggctccaacg gtgaactgca    840
gagcgttcca tttgaaaaag atctgtacgg cgagtcgctc aataaaaaat gtctggggtt    900
gaaagaagtc gctcgcgtgg agagcttcca tggcttcac tacggttgct tcgaccagga    960
ggcccctcct cttatggact atctgggtga cgctgcttgg tacctggaac ctatgttcaa   1020
gcattccggc ggtttagaac tggctggtcc tccaggcaag gttgtgatca aggccaactg   1080
gaaggcacc gcgaaaaact ttgtgggaga tgcataccac gtgggttga cgcacgcgtc   1140
ttcgtctcgc tcgggggagt ctatcttctc gtcgctcgtt ggcaatgcgg cgctaccacc   1200
tgaaggcgca ggcttgcaaa tgacctcaa atacggcagc ggcatgggtg tgttgggga    1260
cggatattca ggtgtgcata gcgcagactt ggttccggaa ttgatggcat tcggaggcgc   1320
aaagcaggaa aggtgaaca aagaaattgg cgatgttcgc gctcggattt atcgcagcca   1380
cctcaactgc accgttttcc cgaacaacag catgctgacc tgctcgggtg ttttcaaagt   1440
    
```

-continued

---

atggaacccg atcgacgcaa acaccaccga ggtctggacc tacgccattg tcgaaaaaga	1500
catgcctgag gatctcaagc gccgcttggc cgactctggt cagcgaaacg tcgggcctgc	1560
tggtctctg gaaagcgacg acaatgacaa tatggaaaca gcttcgcaa acggcaagaa	1620
atatcaatca agagatagtg atctgctttc aaaccttggg ttcggtgagg acgtatacgg	1680
cgacgcggtc tatccaggcg tcgtcggcaa atcggcgatc ggcgagacca gttatcgtgg	1740
tttctaccgg gcttaccagg cacacgtcag cagctccaac tgggctgagt tcgagcatgc	1800
ctctagtact tggcatactg aacttacgaa gactactgat cgctaacaga cgagtcgacc	1860
atgatgatca atattcaaga agacaagctg gtttccgcc acgacgcga agagattctt	1920
cgtttcttca attgccacga ctctgctttg caacaagaag cactacgct gctgaccag	1980
gaagcgcat tgttgacat tcaggcttac cgtgcttggg tagagcactg cgtggggtca	2040
gaggtgcaat atcaggtcat ttcacgcgaa ctgcgcgag cttcagagcg tcgttataag	2100
ctcaatgaag ccatgaacgt ttacaacgaa aattttcagc aactgaaagt tcgagttgag	2160
catcaactgg atccgcaaaa ctggggcaac agcccgaagc tgcgctttac tcgctttatc	2220
accaacgtcc aggccgaat ggacgtaaat gacaaagagc tacttccat ccgctccaac	2280
gtcattctgc accgggcacg acgtggcaat caggtcagtg tctctacgc cgcccggaa	2340
gataaatgga aacgtggcga aggtggagta cgaattgg tccagcgatt cgtcgattac	2400
ccagagcgca tacttcagac gcacaatctg atggtctttc tgtgattcag tgaccatfff	2460
tacaaatggt cactgcaacc gcggtcacca ttaatcaaag ggaatgtacg tgtatgggca	2520
atcaacaagt cgtttcgata accggtgcag gctcaggaat cggctcga ctggttcggt	2580
cctttaagtc ggccggttat tacgtatccg ctctcgtacg aaacgaggag caagaggcg	2640
ttctttgcaa agagtcaag gacgcactcg agattgtagt gggcgatgc cgggaccacg	2700
caacaaatga gaagctgata aagcaacaa tcgatagatt cggctatctt gattgtttta	2760
ttgcaaatgc cggtatctgg gattacatgc tgagcatcga agagccttg gagaaaatat	2820
cgagcagttt tgacgaata ttcgacatta atgtcaagag ctatttcagt ggcacagtg	2880
ccgccctgcc ggaactgaaa aagactaacg gatcagtggt gatgaccgct tcggtgtcgt	2940
cccatgcggt cgggtggtgt ggttcttct acatcgccag caagcatgcg gtgctcggta	3000
tggttaagtc tttggctac gaattggccc ccgaagtctg cgtgaacgct gtttcgccg	3060
ggggcaccgt gacgtctctg tcggtcccgc cgagcggcg tttcgacaaa atgcacatga	3120
aagacatgcc cggcatcgac gatatgatca aaggtctcac gcctcttggg tttgcagcca	3180
agcccgaaga cgtggtggca ccctatattg tgctggcttc gcgaaagcaa gaaaaattca	3240
tcaccggcac cgtgattagc attgatggcg gtatggcgct cggctcgaag tgagcttgta	3300
gccgatcaga agttatagac acatttcagg tgacgcccc tgaagacaaa actgtttatc	3360
aataacgcct ggatcgattc tagtgaccag cagaccttc agcgcataca ccccgctcagc	3420
agcagtgagg tgactgagag cgcaaacgcc acagtgacgg acgcgataaa ggcggcgcaa	3480
gcggccgagg agcgttcaa gacctggaag gccgttgac cttcagagcg tcgccgctt	3540
ctcctaaagg tcgccgatgt catggaaagt aaaacacca agttcatcga agtgatggcc	3600
atggaggagg gagcttccgc cctttgggcc ggattcaacg tccatgcgct tgccaatgtg	3660
ttccagagag ctgcctcgct ggctacccaa attcagggtg aaaccatccc aacggacaaa	3720
gccgaaacgc tctcaatgac actacgtcag ccggtcgcc cgatcctaag catcgttcca	3780
tggaacggca ccgacgtgct tcgggcacga gccatcgctt atccgctggt ctgtggcaac	3840

-continued

---

actgtggtgt tcaaaggctc tgaatttagt cccgcgacgc atgccctgat caccagtgct	3900
gtgcaggaag ccgggctgcc cgctggcggtg ctcaattacc tcaactcttc gcctgaccgt	3960
tcgcccgaga tcgctgacgc actgatctct gccaaaggaga tccgccgat caacttcacg	4020
ggttccaccc gcgtgggcag cattatcgcg cagaaagccg cgcaacacct caagcgctgc	4080
ctgctggagc tcggcggcaa gtccccgctt attgttctgg atgatgcaga catcgatgcg	4140
gcggtcaagg cagcgggtgt cggtagcttc ctgttccaag gtcagatctg catgtccact	4200
gagcgcttga tcggttatga gaagatagcc gacgaatttg tcgcaaaatt tgcgaaaaa	4260
actaagcgtc tgagcgcagg cgaccctgct gtaactggcg actgcatcat cggcccgatg	4320
gtctcgccaa attcgggtga gcggatcaat ggtttgttca aagacgcgat cgacaaagg	4380
gcaaaagtgt tttggcggcg cttggcccaa ggtgcgctca tgccggccac gatcctggat	4440
cacgtcaaat ctgacatgcg gatttacgat gaggagacct ttggtcccat caccgtggtg	4500
atccgttcta aaggcgaagc agagccctgc cgcattgcca acgacagcgt ctatggcctg	4560
tcgtcgggcg tatttggcgg cgacatcaac cgcgctctac gcgtgggtat gtccatcgaa	4620
tatggttctg tacacatcaa cggctcgacc gtccagaacg aggcgcaggc tccttacgga	4680
ggaccaaga acaccggcta cgggcgcttc gacggccgtg ctgtaatcga cgagttcaca	4740
gagatcaagt ggctgaccat cgaaccttct gagcagcaat atccctctctg ataagcacta	4800
actcccagga atcaaatat gagtaagcaa gctgcagtta tcgagctcgg atacatgggt	4860
atctcggta aggacctga tgcgtggaaa tcatttgcca cggatatgct aggtctgcaa	4920
gttcttgatg agggtgagaa ggaccgttct tatctgcgga tggattactg gcatcatcgg	4980
atcgtagtcc atcacaacgg acaggacgac ttggagtacc taggctggcg ttagccggc	5040
aagccggagt tcgaagctct gggtaaaa cttattgatg ccggttaca gatccgcctc	5100
tcgcaaaaag ttgaggtcga ggagcgtatg gtgttgggtc tgatgaagac agaagatccg	5160
ggcggcaacc cgaccgagat attctggggc ccccgatcg acatgagcaa cccgttccat	5220
cccggctgcc ccctgcacgg aaagtttgtg accggtgacc aaggcttggg ccattgcctc	5280
gttcgcaaa ccgacgtcgc agaagctcat aagttttata gcctgctggg cttccgtggg	5340
gacgtcgaat accggattcc gttgccaac ggcattgact cgaactgct gttcatgcat	5400
tgcaacgccc gtgatcactc cattgctttt ggtgccatgc ccgctgcaaa acgactcaat	5460
cacttgatgc ttgagtacac ccatatgga gacttgggat acacgcacca acagtttgta	5520
aagaacgaaa ttgacattgc cttgcagctt ggcattcacg ccaacgacaa ggcgttgacg	5580
ttctatggtg caacgccttc gggctggctc attgagcccg gctggcgagg tgccacggcc	5640
atagatgaag cggagtatta cgtcggcgac atcttcggcc atggcgtgga ggcactgga	5700
tatggcctg atgtaaaact gagctaaaga tgcgcgctcg ttggcgagg ctctagtcca	5760
gcatcttcat acgcaaccaa ccttgacagg cgatgagatc aaaggacgtt aaagcgaagg	5820
ggaagtgggt cgggcatgct gcataccgat ccatgacatt tgtttcatag tatataggta	5880
gataggtgaa tcaagcgtt agtcaactag tggacacatc tgttccatga ggctatctac	5940
tatctattca aaacaagaat aataaatag atgaaaataa taatgataaa aagaacgatt	6000
tgtcttgggt atcctctatt ctggttgcca agccccacat gggccgaaga gtcgccttgg	6060
acgtaccgta ttggtatgac taatgtagct ttcgatgcta gcgcaaaagt atacttaaat	6120
ggtcagcggg tgccaggagg aagcgtgat gcgagcgata acaacgcgct tacattcgac	6180



-continued

---

ttcggctacg ccatcaacga ccagtggaat gtacgtgcga ttgtcggat tccgcctaca	6240
actaaagtga cgggcgcagg cacacttcoct ggtatccagc tggggaaaat aacttacgct	6300
ccaacagtat taacgttgaa ctataacctc cccgctttgg gtcccgttcg ccctcacata	6360
ggtgcgggag tcaattacac gcggattttt gaaagtccgg acgctaactt aaaatcggtc	6420
gatgccgacc acgcttggtc ccccgcgcta catgttggtg ccgatattga cgtaaacgt	6480
ggttggttcg ttagcattga tatccggaag ttataacctga aaaccgacgc atcagggtac	6540
ttggggccac aggagcgtaa agcacgggta actcttgacc cattaactaac ttcgatcgcg	6600
atcggacgcc aattctgatg attctgttta aagttcttta tctatctaac cgcaaagggt	6660
gtttccatgt cgaataaaat tatgaaaacg tcgcgtctta ccgccgaaga tatcaacggc	6720
gcctggacta taatgccac accctcgacg cctgatgctt ctgattggcg cagcactgcc	6780
accgtggact tagaagagac tgcccgcata gttgaagagc tgattgcagc tgggtcacaac	6840
ggtattctaa gtatgggtac ttttggtgag tgcgccacgt tgacctggga tgaaaaacgt	6900
gattatgtct cgacgattgt cgagaccatt cgtggtcgcg tgccttattt ctgtggcacg	6960
acagccttaa atacccgaga agtcatccgc cagaccgag agcttatcga tattggcgcc	7020
aacggcacta tgctcggggt gccgatgtgg gtgaagatgg acctgcctac agcggttcag	7080
ttctatcgtg atgttcgaga tgcggtagca gaggctgcca ttgcgattta cgccaacccc	7140
gaagcattca agttcgactt ccctcgcaca ttctgggcag agatgtccaa aattccgag	7200
gtagtgactg cgaagtatct aggcacgga atgcttgact tggacctgag actggcacc	7260
aacatccgct tccttccca cgaagatgac tattacgcgg ccgcacgcat caatcccag	7320
cgcataaccg cgttctggtc aagcggggcc atgtgcggcc cggctaccgc catcatgtt	7380
ctgacgaaag tgggtcgggc caagagcacc ggtgactggg ccaaggccaa agccatctc	7440
gatgatatgc gtgcagccga ctcgacattg tttccgcgtg gcgacttttc ggagttctc	7500
aagtataata tcgggcttga aaaggcacgg atggatgcgg ctggttggtc caaggctggg	7560
ccctgcgctc cgcctacaa ccttgttcca gaagactacc tcgctggtgc acagaaatca	7620
ggcaaggctt gggccgctg gcacgctaaa tacagtaatg aattgaagta gttcacctc	7680
gcagacctga gtgacagggt ggcgcagacg ctgagggtgc aggaattaag tgagctaaag	7740
cacatttctt gcgccaggca ttgccagatc agcaaagttt gctgatctgg cagtttcaa	7800
aatttgggag aaagctgata tcaggaatac gggataaagg cagtgcacca taacgacggg	7860
gcgtgccatt cgtgatgaac gatattgcta ttgtgccgac ttctgttctt ggagtgttt	7920
attgtgattg tcgattttta tttcgatttt ttgagtccgt tctcttactt ggccaacct	7980
cgtttgtaaa agcttgccga agactatggc ttttccattc gttattaacg aatcgattg	8040
gcgcagatta aatagccat cggaaacggt ggtccatcta atcgcgacct gatagtcaag	8100
ctggactatt tgaagtaga ttgcaacgg tgggccgagc tttacgaaat accgttggt	8160
ttccagcta actacaacag ccgacggatg aatactgggc tttattactc gggagccatg	8220
gcacagactg gtgcctatgt gaatgtagta tttaatgcgg tttggggaga tggcatagct	8280
ccagatttgg aaagcttgcc tgctctggtg tctgaaaaac taggctggga tcgtagcgc	8340
ttcaggactt ttatcagcag cgatgccga acagagaggt atgacgagca gacacatgcc	8400
gcgatcgaac gcaaagtgtt cgggtgacca acgatgtttt tggcgatga aatgtggtg	8460
ggaaacgacc gtctatttat gctcgagaac gcagtgaggag gtgcgcctgt aatggagaa	8520
tagtcgctac ggagcgttg tgccggctaa atgccgatat aagtgttga cctgatcgtt	8580

-continued

---

```

atttgctcga tacagcgctt tcaaaatcag cggctactga agtcagataa aaatgcggga 8640
ctacttcagg catcctgtgc gacacaaagt tttacctgta attgtccacc tattccgagt 8700
ttggaatggt agctgactcg ctatgcgacc agcgatagcc taacaagaca tgcactactg 8760
gtaacggtagg ggtgtgaagc tcctgcaaca atgtagcccc ttgatgtgtg tatttgctgc 8820
gaggtgaagc acagatgctc ggagccgtac cggcttgtgg cgctaggctg gcaagtatga 8880
gcaacgtaag tgggggttgg ggcgcaatgg gaacccaaaa ccaacgcaag ccttaccagc 8940
gtcgttcggt gccttctccc catgcctccg cctcgataaa gcagctgcgc atatcggtct 9000
cctggctgat ctcggttagt aggtcatgca aggtcttgtc cagcgcctcg tcgctccgat 9060
acggaatggt cagctcgtaa tggccggtct ccgaccgctt catgccgtag ggctccaggc 9120
agtagcgctc gatgttctcc gtggcccgtc tccgaccgcg catgaacttg ctggtttca 9180
ccaccgccag gcgaggggtg acggtggcca cccgctcgac ggttgactct gccggtgacg 9240
cgatattgag cttttgacct cgcgcccagg cgctcttctg gtacgtcccg atctcgacgc 9300
cacggtggcg taggtagctg tacaggggtc tcttgagat gtgcaacttc tcgccgatgg 9360
cgctgacgct cagggcgccc tcgcggtaca gggctctccg ccgatggcg gtggcctcgg 9420
ccttgctggg cagggccttg ggacggcgac cgatccggcc tcgagtcctg gccgccgaca 9480
ggcccgcctg agtccgctcg cggatcagct cgcgctcgaa ctgaacaggt tgaacaccag 9540
gcatctttg gcgtgggtgc tgtcaatggg gtcgttcagg ctctgcaagc cgactttgag 9600
tgcagccagc tagccgacca actcaaccag gtgcttgagc gagcgaccga ggcgatccag 9660
cttcagatc accacggcat cccccgctcg aacatgggct agcaacttgt ccaactccgg 9720
ccgcgctctt tttgcgcccg tggcgatgct ttgatagatg cgttcgcacc cggcctggtt 9780
cagggcatcg acctggagggt cggcgttcta atccccgagt ctcaccgctg tataaccgat 9840
c 9841

```

&lt;210&gt; SEQ ID NO 4

&lt;211&gt; LENGTH: 2515

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

&lt;400&gt; SEQUENCE: 4

```

gaattcatca ggaagacatt caaatgaacg taaacaataa gggcagcgtc tgtatttgcg 60
gcagcgaat gctccctaaa ttcctcattt accccatctg aggattgctt tatgacagta 120
aagtggattg aagcagctgc tctttctgac atccttgaag gtgacgtcct cggcgtgact 180
gtcaggggca aggagctggc gctgtatgaa gttgaaggcg aaatctaagc tacogacaac 240
ctgtgcacgc atggttccgc ccgcatgagt gatggttata tcgagggtag agaaatcgaa 300
tgccccttgc atcaaggctg gtttgacggt tgcacaggca aagccctgtg cgcaccctg 360
acacagaaca tcaaaacata tccagtaagc attgagaacc tgcgctaat gattgatttg 420
agctaagaat ttaacagga ggcacccccg gccctagagc gtaatcacc ccatccatc 480
tttttaggt gaaaacatga attacaataa taaaatcttg gtaagtgaat ctggtctgag 540
ccaaaagcac ctgattcatg cggatgaaga acttttcaa catgaactga aaaccatttt 600
tgcgcggaac tggcttttcc tcaactcatg tagcctgatt cctgcccccg gcgactatgt 660

```

-continued

taccgcaaaa atggggattg acgaggtcat cgtctcccgg cagaacgacg gttcgattcg	720
tgcttttctg aacgtttgcc ggcacgtg caagacgctg gtgagcgtg aagccggcaa	780
tgccaaaggt tttgtttgca gctatcacgg ctggggcttc ggctccaacg gtgaactgca	840
gagcgttcca tttgaaaaag atctgtacgg cgagtcgctc aataaaaaat gtctgggggt	900
gaaagaagtc gctcgcgtgg agagcttcca tggcttcac tacggttgct tcgaccagga	960
ggcccctcct cttatggact atctgggtga cgctgcttg tacctggaac ctatgttcaa	1020
gcattccggc ggtttagaac tggctggctc tccaggaag gttgtgatca aggccaaactg	1080
gaaggcacc gcgaaaaact ttgtgggaga tgcataccac gtgggttga cgcacgcgtc	1140
ttcgcttcgc tcgggggagt ctatcttctc gtcgctcgct ggcaatgcgg cgtaccacc	1200
tgaaggcgca ggcttgcaaa tgacctcaa atacggcagc ggcatgggtg tgttgggga	1260
cgatattca ggtgtgcata gcgcagactt ggttccgaa ttgatggcat tcggaggcgc	1320
aaagcaggaa aggctgaaca aagaaattgg cgatgttcgc gctcggattt atcgacgcca	1380
cctcaactgc accgttttcc cgaacaacag catgctgacc tgctcgggtg ttttcaaagt	1440
atggaaccgg atcgacgcaa acaccaccga ggtctggacc tacgccattg tcgaaaaaga	1500
catgcctgag gatctcaagc gccgcttggc cgactctgtt cagcgaacgg tcgggcctgc	1560
tggcttctg gaaagcgacg acaatgacaa tatggaaaca gcttcgcaa acggcaagaa	1620
atatcaatca agagatagtg atctgcttcc aaaccttggg ttcgggtgagg acgtatacgg	1680
cgacgcggtc tatccaggcg tcgctggcaa atcggcgcac ggccagacca gttatcgtgg	1740
ttctaccgg gttaccagg cacacgtcag cagctccaac tgggctgagt tcgagcatgc	1800
ctctagtact tggcatactg aacttacgaa gactactgat cgctaacaga cgagtcgacc	1860
atgatgatca atattcaaga agacaagctg gtttccgcc acgacgccga agagattctt	1920
cgtttcttca attgccacga ctctgcttgg caacaagaag ccaactacgt gctgaccag	1980
gaagcgcatt tgttgacat tcaggcttac cgtgcttggg tagagcactg cgtgggggtca	2040
gaggtgcaat atcaggtcat ttcacgcgaa ctgcccgcag cttcagagcg tcgttataag	2100
ctcaatgaag ccatgaacgt ttacaacgaa aattttcagc aactgaaagt tcgagttgag	2160
catcaactgg atccgcaaaa ctggggcaac agcccgaagc tgcgctttac tcgctttatc	2220
accaacgtcc aggccgcaat ggacgtaaat gacaaagagc tacttcacat ccgctccaac	2280
gtcattctgc accgggcacg acgtggcaat caggtcgatg tcttctaagc cgcccgggaa	2340
gataaatgga aacgtggcga aggtggagta cgaatttgg tccagcgatt cgtcgattac	2400
ccagagcgca tacttcagac gcacaatctg atggtcttcc tgtgattcag tgaccatctt	2460
tacaaatggt cactgcaacc gcggtacca ttaatcaaag ggaatgtacg tgtat	2515

&lt;210&gt; SEQ ID NO 5

&lt;211&gt; LENGTH: 9706

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

&lt;400&gt; SEQUENCE: 5

gctgatttcg accaattatt ccacgccgtc tgcgccagca aggccgtaat cagttcgtaa	60
aggggagccc gcagtaacag cgaaccgacg ccggtagctg cgcgcgtgaa tcctgagatc	120
acaaattctt ggcgattatc gcatttcaat ttcacccaag cgcgcttctt tgcgctgctg	180

-continued

---

tagcggcggc catcacgctt ctccacgatt ccctccagct gcatccggca agcgttggcc	240
agcagctgca ctgggtaagc ttccagggtg tcgctgaagc gtacgcgctc caatgggcag	300
tgctcgagga gcgcctcaag tacctggcgg ctcaagtcaa cgccctctcc ccgcagatct	360
gcaccgtcga ggtagagcag gtcgaacgcc acgtacacaa atttgcggt acaccgtgcg	420
gcgaacgctg actgcagggc ttgaaatgct ggtcgaccgt cgtcatactg gaatacgacc	480
tcaccgtcga gccaggctga atggacggct aggcgtccca gctatttggc caggagtggc	540
atatgatcga tctagtcaaa cccgtttttg gtgaaaagct gcacctggtc accatcgatc	600
cgtgctaaca gacgatacca gtcgtacttg atctcgtatc gccatgctcc tgccgacgac	660
agtgtcagta gagtaaccag ttgtggcgcg atccaacacg ggtttgggtg cttgggcggt	720
ttcaactatcg ccacctcgct ataggaacat tccttcaggg tggagtgcgt aatcttctga	780
aaggggagcc aggttatgag tattcacatt ggtgataaac aacatcaact atgcgttatt	840
gacataaac gtcgtattca cgattattta ccatataagt cttataataa cgaagccata	900
ttatggaact cctcatacaa ccgaaaaatc gcataattcc cttcagtgcc ggtgccaacc	960
ttctggaagt gcttcgagag aacgggtgag ctatttccta cagttgcttg tctgggcggt	1020
gcggaacctg tcgctgccgg gttatagatg gcagtgtcat tgattctggg gcggaaatg	1080
ggcaatcaaa cctcaccgac aagcagtatg tgctcgctg tcagtcagta ctcaactggca	1140
attgcgctat cgaagtccca gaagccgacg aaattgtcac tcaccggcg cgaatcatca	1200
agggcacagt ggtcgcagtc gagtgcacca ctcaagatat ccgtcgctta cgcgtacgcc	1260
tctccaagcc cttcgagttc tcaccggac agtacgcgac actgcagttc agccctgagc	1320
atgcgcgtcc gtattcaatg gcaggtttg cagatgacca agaaatggag ttccacatac	1380
gcaaggtgcc ggggtggcgc gtcacggagt atgttttcga acacgtccgc gaaggtacaa	1440
gcatcaagtt gagcggccct cttggtacgg cttatctacg tcagaagcac accggaccga	1500
tgctgtgtgt aggtggcggg accggactcg caccggtgct gtcgattggt cgcggcgcgc	1560
tgaagtcggg tatgacgaac cccatcctcc tttatttcgg ggtgcgcagt cagcaagacc	1620
tctacgacgc agagcgattg cacaaactcg ccgctgacca ccctcaactg accgtacaca	1680
cggtgattgc aacgggcccg ataatgagc gtcagcgagc cggcctaatt accgatgtga	1740
tcgaaaaaga catcctttcg ctggctgggt ggagggccta cctgtgcggc gcaccagcga	1800
tggttgaagc gttgtgcacc gtcaccaagc atcttggaat atcaccgaa catatttatg	1860
ccgatgcctt ctatcccggg gggatctgaa tagttcccgg ccattgcaact ctgtccatcg	1920
agaattcatc aggaagacat tcaaatgaac gtaacaata agggcagcgt ctgtatttgc	1980
ggcagcgaag tgctccctaa attcctcatt taccctatct gaggattgct ttatgacagt	2040
aaagtggatt gaagcagtcg ctctttctga catccttga ggtgacgtcc tcggcgtgac	2100
tgctgagggc aaggagctgg cgctgtatga agttgaaggc gaaatctacg ctaccgacaa	2160
cctgtgcacg catggttccg cccgcatgag tgatggttat ctcgagggta gagaaatcga	2220
atgcccttg catcaaggtc ggtttgacgt ttgcacaggc aaagccctgt gcgcaccctg	2280
gacacagaac atcaaaaacat atccagctca gattgagaac ctgcgcgtaa tgattgattt	2340
gagctaagaa ttttaacagc aggcaccccg ggccttagag cgtaatcacc cccattccat	2400
cttttttagg tgaaaacatg aattacaata ataaaatctt ggtaagtga tctggtctga	2460
gccaaaagca cctgattcat ggcgatgaag aacttttcca acatgaactg aaaaccattt	2520

-continued

ttgcgcgaa ctggcttttt ctcaactcatg atagcctgat tcctgcccc ggcgactatg	2580
ttaccgcaaa aatggggatt gacgaggta tcgtctccc gcagaacgac ggttcgattc	2640
gtgcttttct gaacgtttgc cggcatcgtg gcaagacgct ggtgagcgtg gaagccggca	2700
atgcaaaag ttttgtttgc agctatcacg gctggggctt cggctccaac ggtgaactgc	2760
agagcgttcc atttgaaaa gatctgtacg gcgagtcgct caataaaaa tgtctggggt	2820
tgaagaagt cgctcgcgtg gagagcttcc atggcttcat ctacggttgc ttcgaccagg	2880
aggccccctc tcttatggac tatctgggtg acgctgcttg gtacctggaa cctatgttca	2940
agcattcccg cggtttagaa ctggtcggtc ctccaggcaa ggttgtgatc aaggccaact	3000
ggaaggcacc cgcgaaaac tttgtgggag atgcatacca cgtgggttg acgcacgcgt	3060
cttcgcttcg ctccggggag tctatcttct gctcgcctgc tggcaatgcg gcgctaccac	3120
ctgaaggcgc aggcttgcaa atgacctcca aatacggcag cggcatgggt gtgttgggg	3180
acggatattc aggtgtgcat agcgcagact tggttccgga attgatggca ttcggaggcg	3240
caaagcagga aaggctgaac aaagaaattg gcgatgttcg cgctcggatt tatcgagcc	3300
acctcaactg caccgttttc ccgaacaaca gcatgctgac ctgctcgggt gttttcaaag	3360
tatggaacc gatcgcgca aacaccaccg aggtctggac ctacgccatt gtcgaaaaag	3420
acatgcctga ggatctcaag cgcgcttg cgcactctgt tcacggaacg gtcgggcctg	3480
ctggcttctg gaaagcgac gacaatgaca atatgaaac agcttcgcaa aacggcaaga	3540
aatatcaatc aagagatagt gatctgcttt caaaccttg tttcgggtgag gacgtatacg	3600
gcgagcgggt ctatccaggc gtcgtcggca aatcggcgat cggcgagacc agttatcgtg	3660
gtttctaccg ggcttacag gcacacgtca gcagctcaa ctgggctgag ttcgagcatg	3720
cctctagtac ttggcatact gaacttacga agactactga tcgctaacag acgagtcgac	3780
catgatgatc aatattcaag aagacaagct ggtttccgcc cacgacgccg aagagattct	3840
tcgtttcttc aattgccag actctgcttt gcaacaagaa gccactacgc tgetgacca	3900
ggaagcgc atgttggtgaca ttcaggctta ccgtgcttg ttagagcact gcgtggggtc	3960
agaggtgcaa tatcaggtca tttcaocgca actgcgcgca gcttcagagc gtcgttataa	4020
gctcaatgaa gccatgaacg tttacaacga aaatcttcag caactgaaag ttcgagttga	4080
gcatcaactg gatccgcaaa actggggcaa cagcccgaag ctgcgcttta ctgcctttat	4140
caccaacgct caggccgcaa tggacgtaaa tgacaaagag ctacttcaca tccgctcaa	4200
cgtcattctg caccgggcac gacgtggcaa tcaggtcgat gtctttctac ccgcccggga	4260
agataaatgg aaacgtggcg aaggtggagt acgaaaattg gtcacgcgat tcgtcgatta	4320
cccagagcgc atacttcaga cgcacaatct gatggtcttt ctgtgattca gtagcattt	4380
ttacaaatgg tcaactgcaac cgcggtcacc ataatcaaa gggaatgtac gtgtatggc	4440
aatcaacaag tcgtttcgat aaccggtgca ggctcaggaa tcggtctcga actggttcgg	4500
tcctttaagt cggccggtta ttacgtatcc gctctctgac gaaacgagga gcaagaggcg	4560
cttctttgca aagagttcaa ggacgcactc gagattgtag tgggcatgt ccgggaccac	4620
gcaacaaatg agaagctgat aaagcaaa atcgtatgat tcggtcatct tgattgtttt	4680
attgcaaatg ccggtatctg ggattacatg ctgagcatcg aagagccttg ggagaaaata	4740
tcgagcagtt ttgacgaaat attcgacatt aatgtcaaga gctatttcag tggcatcagt	4800
gccgccctgc cggaaactgaa aaagactaac ggatcagtg tgatgaccgc ttcgggtgctg	4860
tcccacgctg tcggtggtg tggttcttgc tacatcgcca gcaagcatgc ggtgctcgg	4920

-continued

---

atggttaagc	ctttggccta	cgaattggcc	cccgaagttc	gcgtgaacgc	tgtttcgccg	4980
gggggcaccg	tgacgtctct	gtgcggttcc	gcgagcgcgc	gtttcgacaa	aatgcacatg	5040
aaagacatgc	ccggcatcga	cgatatgatc	aaaggtctca	cgctctctgg	gtttgcagcc	5100
aagcccgaag	acgtgggtgc	accctatttg	ttgctggctt	cgcgaaagca	aggaaaattc	5160
atcaccggca	ccgtgattag	cattgatggc	ggtatggcgc	tcggtcgcaa	gtgagcttgt	5220
agccgatcag	aagttataga	cacatttcag	gtgacgcccc	atgaagacaa	aactgtttat	5280
caataacgcc	tggatcgatt	ctagtgacca	gcagaccttc	gagcgcatac	accccgtcag	5340
cagcgatgtg	gtgactgaga	gcgcaaacgc	cacagtgcgc	gacgcgataa	aggcggcgca	5400
agcggccgag	gaggcgttca	agacctggaa	ggcggttgga	ccttcagagc	gtcgcgcgct	5460
tctcctaaa	gtcgcgatg	tcatggaaa	taaaacaccc	aagttcatcg	aagtgtggc	5520
catggaggtg	ggagcttccg	ccctttgggc	cggattcaac	gtccatgcgt	ctgccaatgt	5580
gttccgagag	gctgcctcgc	tggctaccca	aattcagggt	gaaaccatcc	caacggacaa	5640
agccgaaacg	ctctcaatga	cactacgtca	gccggtcggc	ccgatcctaa	gcatcgttcc	5700
atggaacggc	accgcagtgc	ttgcggcacg	agccatcgct	tatccgctgg	tctgtggcaa	5760
cactgtggtg	ttcaaaggct	ctgaatttag	tcccgcgacg	catgccctga	tcaccagtg	5820
cgtgcaggaa	gccgggctgc	ccgctggcgt	gctcaattac	ctcaactctt	cgctgaccg	5880
ttcgcggcag	atcgctgacg	cactgatctc	tgccaaggag	atccgccgca	tcaacttcac	5940
gggttccacc	cgcgtaggca	gcattatcgc	gcagaaagcc	gcgcaacacc	tcaagcgctg	6000
cctgctggag	ctcggcgcca	agtccccgct	tattgttctg	gatgatgcag	acatcgtatc	6060
ggcggccaag	gcagcgggtg	tcggtagctt	cctgttccaa	ggtcagatct	gcatgtccac	6120
tgagcgcttg	atcgttgatg	agaagatagc	cgacgaatth	gtcgcaaaat	ttgtcgaaaa	6180
aactaagcgc	ttgagcgcag	gcgacccgtg	cgtaactggc	gactgcatca	tcggcccgat	6240
ggtctcgcca	aattcgggtg	agcggatcaa	tggtttgttc	aaagacgcga	tcgacaaagg	6300
ggcaaaagtt	gtttgcggcg	gcttgcccga	aggtagcctc	atgccggcca	cgatcctgga	6360
tcacgtcaaa	tctgacatgc	ggatttacga	tgaggagacc	tttggctcca	tcaccgtggt	6420
aatccgttgt	aaaggccaag	cagaggccgt	ccgcattgcc	aacgacagcg	tctatggcct	6480
gtcgtcgggc	gtatttggcc	gcgacatcaa	ccgcgctcta	cgcgtaggta	tgtccatcga	6540
atatggttct	gtacacatca	acggttcgac	cgtccagaac	gaggcgcagc	ctccttacgg	6600
aggcaccga	aacaccggct	acgggogcct	cgacggccgt	gctgtaatcg	acgagttcac	6660
agagatcaag	tggctgacca	tcgaaccttt	cgagcagcaa	tatcccttct	gataagcact	6720
aactcccagc	aatcaaaacta	tgagtaagca	agctgcagtt	atcgagctcg	gatacatggg	6780
tatctcggtc	aaggaccctg	atgcgtggaa	atcatttgcc	acggatatgc	taggtctgca	6840
agttcttgat	gagggtgaga	aggaccgttt	ctatctgcgg	atggattact	ggcatcatcg	6900
gatcgtatgc	catcacaacg	gacaggacga	cttgaggtag	ctaggctggc	gtgtagccgg	6960
caagccggag	ttcgaagctc	tgggtcaaaa	gcttattgat	gccggttaca	agatccgcat	7020
ctgcgacaaa	gttgaggctc	aggagcgtat	ggtgttgggt	ctgatgaaga	cagaagatcc	7080
gggggcaaac	ccgaccgaga	tattctgggg	ccccggatc	gacatgagca	acccgttcca	7140
tcccggctgc	ccctgcacg	gaaagtttgt	gaccggtgac	caaggcttgg	gccattgcat	7200
cgttcgccaa	accgacgtcg	cagaagctca	taagttttat	agcctgctgg	gcttccgtgg	7260

-continued

ggacgtcgaa taccggattc cgttgcccaa cggcatgact gccgaactgt cgttcatgca	7320
ttgcaacgcc cgtgatcaact ccattgcttt tggtgccatg cccgctgcca aacgaactcaa	7380
tcacttgatg cttgagtaca cccatattgga agacttgga tacacgcacc aacagtttgt	7440
aaagaacgaa attgacattg ccttgacgct tggcattcac gccaacgaca aggcgttgac	7500
gttctatggt gcaacgcctt cgggctggct cattgagccc ggctggcgag gtgccacggc	7560
catagatgaa gcggagtatt acgtcggcga catcttcggc catggcgtgg aggccactgg	7620
atatggcctg gatgtaaaac tgagctaaag atgcgcgctc gttggcgag gctctagtcc	7680
agcatcttca tacgcaacca accttgacagg gcgatgagat caaaggacgt taaagcgaag	7740
gggaagtggg tggggccatg cgcataccga tccatgacat ttgtttcata gtatataggt	7800
agataggatg atcaagcgt tagtcaacta gtggacacat ctgttccatg aggcctatcta	7860
ctatctattc aaaacaagaa taataaatag gatgaaaata ataagataa aaagaacgat	7920
ttgtcttggt tatcctctat tctgtttggc aagccccaca tgggccgaag agtcgccttg	7980
gacgtaccgt attggtatga ctaatgtagc tttcgtgctc agcgcaaaag tataactaaa	8040
tggtcagcgg gtgccaggag gaagcgtgga tgcgagcgt aacaacgcgc ttacattcga	8100
cttcggctac gccatcaacg accagtgga tgtacgtgcg attgtcggta ttccgcctac	8160
aactaaagtg acgggcccag gcacacttcc tgggatccag ctggggaaaa taacttacgc	8220
tccaacagta ttaacgttga actataacct ccccgctttg ggtcccgttc gccctcacat	8280
aggtgcggga gtcaattaca cgcggatttt tgaaagtcgg gacgctaata taaaatcgtt	8340
cgatgccgac cacgcttggt cccccgcgt acatgttggt gccgatattg acgttaaccg	8400
tggttggttc gttagcattg atatccgaa gttatacctg aaaagcgacg catcagggta	8460
cttggggcca caggaggcta aagcacgggt aactcttgac ccattactaa cttcgatcgc	8520
gatcggacgc caattctgat gattctgttt aaagttcttt atctatctaa ccgcaaaggg	8580
tgtttccatg tcgaataaaa ttatgaaac gtcgcgtctt accgccgaag atatcaacgg	8640
cgcttgact ataatgccca caccctcgac gcctgatgct tctgattggc gcagcactgc	8700
cacgtggac ttagaagaga ctgccgcat agttgaagag ctgattgcag ctggtgtcaa	8760
cggtattcta agtatggga cttttggta gtgcgccacg ttgacctggg atgaaaaacg	8820
tgattatgtc tcgacgattg tcgagacat tcgtggctgc gtgccttatt tctgtggcac	8880
gacagcctta aatacccgag aagtcacccg ccagaccga gagcttatcg atattggcg	8940
caacgcgact atgctcgggg tgccgatgtg ggtgaagatg gacctgccta cagcggttca	9000
gttctatcgt gatgttcgag atgcggatc agaggctgcc attgcgattt acgccaaacc	9060
cgaagcattc aagttcgact tccctgccc attctgggca gagatgtcca aaattccgca	9120
ggtagtgact gcgaagtatc taggcacgga aatgcttgac ttggacctga gactggcacc	9180
caacatccgc ttcttcccc acgaagatga ctattacggc gccgcacgca tcaatccccga	9240
gcgataaacc gcgttctggt caagcggggc catgtgcggc ccgctaacc ccatcatggt	9300
gcgtgacgaa gtggtgcggg ccaagagcac cggtgactgg gccaaagcca aagccatctc	9360
cgatgatatg cgtgcagccg actcgacatt gtttccgct ggccactttt cggagttctc	9420
gaagtataat atcgggcttg aaaaggcacg gatggatgcg gctggttggc tcaaggctgg	9480
gccctgccgt ccgccctaca accttgcttc agaagactac ctgcctggtg cacagaaatc	9540
aggcaaggct tgggccgcgc tgcacgctaa atacagtaat gaattgaagt agttcacctc	9600
cgcagacctg agtgacaggg tggcgcagac gctgagggtg caggaaataa gtgagctaaa	9660

-continued

---

gcacatttct tgcgccaggc attgccagat cagcaaagtt tgctga 9706

<210> SEQ ID NO 6  
 <211> LENGTH: 2294  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (186)...(186)  
 <223> OTHER INFORMATION: n = a or t or g or c

<400> SEQUENCE: 6

agggcagcct ctgtatttgc ggcagcgaaa tgctccctaa attcctcatt taccatctt 60  
 gaggattgct ttatgacagt aaagtggatt gaagcagtcg ctctttctga catccttgaa 120  
 ggtgacgtcc tcggcggtgc tgcaggggc aaggagctgg cgctgtatga agttgaaggc 180  
 gaaatntacg ctaccgaaa cctgtgcacg catggttccg cccgcatgag tgatggttat 240  
 ctcgagggta gagaaatcga atgccccttg catcaaggtc ggtttgacgt ttgcacaggc 300  
 aaagccctgt gcgcaccctg gacacagaac atcaaaacat atccagtaa gattgagaac 360  
 ctgcccgtaa tgattgattt gagctaagaa ttttaacagg aggcaccccg ggccttagag 420  
 cgtaatcacc cccattccat ctttttttagg tgaaaacatg aattacaata ataaaatcctt 480  
 ggtaagttaa tttggtctga gccaaaagca cctgattcat ggcgatgaag aacttttcca 540  
 acatgaactg aaaaccattt ttgcccggaa ctggcttttt ctactcatg atagcctgat 600  
 tcctgcccc gcgactatg ttaccgaaa aatggggatt gacgaggtca tcgtctcccg 660  
 gcagaacgac ggttcgatcc gtgcttttct gaacgtttgc cggcatcgtg gcaagacgct 720  
 ggtgagcgtg gaagccggca atgcccagg ttttgtttgc agctatcacg gctggggctt 780  
 cggctccaac ggtgaactgc agagcgttcc atttgaaaa gatctgtacg gcgagtcgct 840  
 caataaaaaa tgtctggggt tgaaagaagt cgctcgcgtg gagagcttcc atggcttcat 900  
 ctacggttgc ttcgaccagg aggcctctcc tcttatggac tatctgggtg acgctgcttg 960  
 gtacctggaa cctatgttca agcattccgg cggtttagaa ctggctggtc ctccaggcaa 1020  
 ggttgtgatc aaggccaact ggaaggcacc cgcggaaaac tttgtgggag atgcatacca 1080  
 cgtgggttgg acgcacgctt ctctgcttgc ctccggggag tctatcttct cgtcgtcgc 1140  
 tggcaatgcg gcgctaccac ctgaaggcgc aggcttgcaa atgacctcca aatacggcag 1200  
 cggcatgggt gtgttgggg acggatattc aggtgtgcat agcgcagact tggttccgga 1260  
 attgatggca ttcggaggcg caaagcagga aaggctgaac aaagaaattg gcgatgttcg 1320  
 cgctcggatt tatcgcagcc acctcaactg caccgttttc ccgaacaaca gcatgctgac 1380  
 ctgctccggt gttttcaaa tatggaaccc gatcgcagca aacaccaccg aggtctggac 1440  
 ctacgccatt gtcgaaaaa acatgcttga ggatctcaag gcgcttgg ccgactctgt 1500  
 tcagcgaacg gtcgggcctg ctggcttctg ggaaagcgc gacaatgaca atatggaaac 1560  
 agcttcgcaa aacggcaaga aatatcaatc aagagatagt gatctgcttt caaaccttgg 1620  
 tttcgttgag gacgtatagc gcgacgggt ctatccaggc gtcgtcggca aatcggcgat 1680  
 cggcagagacc agttatcgtg gtttctaccg ggcttaccga gcacacgtca gcagctccaa 1740  
 ctgggctgag ttcgagcatg cctctagtac ttggcatact gaacttacga agactactga 1800  
 tcgtaaacag acgagtcgac catgatgatc aatattcaag aagacaagct ggtttccgcc 1860



-continued

---

```

cacgacgccg aagagattct tcgtttcttc aattgccacg actctgcttt gcaacaagaa 1920
gccactacgc tgctgaccca ggaagcgcac ttgttgaca ttcaggetta ccgtgcttgg 1980
ttagagcact gcgtggggtc agaggtgcaa tatcaggtca tttcacgcga actgcgcgca 2040
gcttcagagc gtcgttataa gctcaatgaa gccatgaacg tttacaacga aaatcttcag 2100
caactgaaag ttcgagttga gcatcaactg gatccgcaaa actggggcaa cagcccgaag 2160
ctgcgcttta ctgcctttat caccaacgtc caggccgcaa tggacgtaaa tgacaaagag 2220
ctacttcaca tccgctccaa cgtcattctg caccgggcac gacgtggcaa tcaggtcgat 2280
gtcttctacg ccgc 2294

```

&lt;210&gt; SEQ ID NO 7

&lt;211&gt; LENGTH: 4355

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

&lt;400&gt; SEQUENCE: 7

```

atcgataaaa ccatgagggt aataaataat gatgaaggag actatctaga attcgttctg 60
gagacggtgc cgggtggcata accgtagacc agcaggctga gcaaaatacc tcgggggtgat 120
aagccgcgct acccgcgtccg ccatatgcct gagtgagtgc gctaaggctc ggcgcctcaa 180
tggcttcgag aataaagcgg gccagggtgat cttctgtcaa tctcgcgaa tgggtggaag 240
cacatcaacc tgaccggcga ttacgtctgg cggcagagcc gcagactgga ggtcgggaag 300
ttccggccgt tacggcggcc ctgaaaacct tagtgtacga ttttttccgt cttctctatt 360
cggcctgcgt tgcgacgttc gatctgacta gggcgcagcg gcaacatcgg ctgagtacga 420
tccagcgcct ggatctgggt tatttcgtca accgacaaca ccagagcgtt atccggtggg 480
ttcaggtaaa gcccacaacc attgactacc tctcggcaaa atgagggtcg ttactaattt 540
tgaacgtctt caagcgatgg ggttttaggt cggaaactgc ccagacctgc ccaacctacc 600
acgtcgtgac ccgagcatat tcggcccgcg cggccaaaaa acacagaaat gagcgggtga 660
cccgatcgcc tttgatcgat tctccgcttt caaaatgggc gggggctgaa gtcagccaga 720
aatacatgac tacttcagac gattcgcagt attcacgctg gtgataaaca aattcaacta 780
tgctttattg acaataaaaa gcacgctcac catcatcgcg aatacaaatc ttataaaaat 840
taagccggat ttatggaact tctcatacag ccaaacaatc gcctcattag ctttagtccc 900
ggcgccaacc ttctggaagt gcttcgcgaa aacggtgtcg ctatttccta cagttgtatg 960
tctgggcggt gcggaacctg ccgctgtcgg gttacagatg gcagtgtaat tgattcgggg 1020
gcgggaaagc ggttaccaaa cctcgtggac gagcattatg tgctcgcctg tcagtcagta 1080
cttactcaca attgcgcatg cgaatccca gaaaccgacg aaatcgtcac ccaccggcg 1140
agaatcatca agggcactgt ggtcgcctgc gagtcgcca ctcacgatat ccgtcgccta 1200
cgcgtacgcc tcgctaagcc cttcagttc tcaccggac agtacgcgac attgcagttc 1260
agtctgagc atgcgcgtcc gtattcaatg gcaggtctgc cagatgacca agaaatggag 1320
ttccacatac gcaagggtgc ggggtggcgc gtaacggagt atgttttoga gcacgtccgc 1380
gaaggtacaa gcatcaagtt gagcgggcca cttggtacgg cttatttgcg tcagaaccac 1440
accgggcca tgctctgtgt gggcgggtgg accggactag caccggtgct gtcgattgtt 1500

```

-continued

---

cgcgcgcgcg	tgaagttggg	tatgacaaac	cccacccctcc	tttatttcgg	agtgcgcagt	1560
cagcaagacc	tctacgacgc	agagcgattg	cacaaactcg	ccgctgatca	ccctcaactg	1620
accgtacaca	cggtaatcgc	aatgggcccg	attaatgaga	gtcagcgagc	cggtctagtt	1680
accgatgtga	tcgaaaaaga	catcatttcg	ctggctgggt	ggagggccta	cctgtgcggc	1740
gcaccagcga	tggttgaagc	gctttgcacc	gttaccaagc	atcttgaat	atcaccgaa	1800
catatttatg	ccgatgcctt	ctatcccggg	ggaatctgaa	tagtcccttt	ccctgcacct	1860
ctgtccatcg	aggactcatc	aggaggatag	tcaaataagc	gcaataata	acagtcgctg	1920
cagtatttgc	ggcagcga	tggtttccct	ctccctcatt	taccccatct	gaggatagtt	1980
ttatgacaga	aaaatggatt	gaagcagtcg	ccctttctga	catcccagaa	ggtgatgtcc	2040
tcggcgtgac	tgctgagggc	aaggagctgg	cgttgtacga	agtggaaggc	gaaatctacg	2100
ctaccgacaa	cctgtgcacg	catggtgccc	cccgcgatgag	cgatggttat	ctcagggggc	2160
gagaaatcga	atgccctctg	catcaaggtc	ggtttgacgt	ttgtacaggc	agagccctct	2220
gccccccgtg	gacagagaac	atcaaacat	atgcagtcaa	gattgagaac	ctgcgcgtaa	2280
tgattgattt	gagcggagag	ttttaatag	aggtaccocg	gacctagcg	cgtaactacc	2340
ccaattccat	cttttttagg	tgaaaacatg	aattacaaaa	acaaaatatt	ggtgagtga	2400
tctgggctga	cccaaaagca	cctgattcat	ggcgatgaag	aacttttcca	gcacgaactg	2460
agaaccattt	ttgcgcgga	ctggcttttt	ctcactcatg	acagcctgat	tccatcccc	2520
ggcgactatg	ttaccgcaaa	aatgggtatt	gacgaggtca	tcgtctctcg	gcagagcgac	2580
ggttcgattc	gtgccttctc	gaacgtttgt	cgccaccgtg	gcaagacgct	ggttaacgcg	2640
gaagccggca	atgccaaagg	tttcgtttgc	agctatcacg	gctggggcct	cgctccaac	2700
ggtgaactgc	agagcgttcc	attcgaaaaa	gagctgtacg	gagctgcgct	caacaaaaaa	2760
tgctgggggt	tgaaagaagt	cgctcgcgtg	gagagcttcc	atgcttcat	ctatggttgc	2820
ttcgatcagg	aggccctccc	tcttatggac	tatctgggtg	acgctgcttg	gtacctagag	2880
cccatcttca	aacattcagg	cggtttagaa	ctggtcggtc	ctccaggcaa	ggttgtgatc	2940
aaggccaact	ggaagccacc	cgccgaaaac	tttgtggggg	atgcatacca	cggtgggttg	3000
acgcacgcgt	cttcgcttcg	ctcgggagag	tctatcttcg	cgctcctcgc	tggaacgca	3060
gtgctgcccc	ctgaaggtgc	aggcttgcaa	atgacctcca	aatacggcag	cgccatgggt	3120
gtgtgtggg	acgatattc	aggcgtgcat	agcgcagact	tggttccgga	ggtgatggca	3180
ttcggcggct	ctaagcagga	aaggctgaac	aaagaaattg	gcgatgttcg	cgcccggatt	3240
tatcgagacc	acctcaactg	caccgttttc	ccgaacaaca	gcgatgctgac	ctgctcgggt	3300
gttttcaaag	tatggaacc	gatcgacgca	aacaccaccg	aggtctggac	ctacgccatt	3360
gtcgaaaaag	acatgcccga	ggatctcaag	cgccgcttgg	ccgactcggg	tcagcgtacg	3420
ggtggccctg	ctggcttctg	ggaaagcgac	gacaatgaca	atatggaaac	agcgtcgcaa	3480
aacggcaaga	aatatcaatc	cagagatagt	gatctgcttt	caaaccttgg	tttcgtaag	3540
gacgtatacg	gcgacgcggg	ctatcctggc	gtcgtcggca	aatcggcgat	cgccgagacc	3600
agttatcgtg	gtttctaccg	ggccttaccg	gcacacgtca	gcagctcaa	ctgggctgag	3660
ttcaggatg	cctctagtag	ttggcatacc	gaactgacga	agactactga	tcgctaacag	3720
acgagtcgac	catgatgac	aatattcaag	aagacaagct	ggtctccgcc	cacgacgccc	3780
aagagtttct	tcgtttcttc	aattgccacg	acgcggcttt	gcaacaagaa	gccaccacgc	3840
tgctgaaccg	ggaagcgcac	ctggttgaca	ttcaggctta	ccgggcttgg	ttagagcact	3900

-continued

---

```

gcgtggggtc agaggttcaa tatcaggta tttcacgcga actgcgcgcc gcttccgagc 3960
gccgttataa gctcaatgaa gccatgaacg tttacaacga aaattttcag caactgaaag 4020
ttcgaatcga gcatcaactg gatccgcaaa actggagcaa cagcccgaag ctgcgcttta 4080
ctcgcttcat caccaatgtc caggccgcaa gggacgtaga tgacgaagag ctacttcaca 4140
tccgctccaa cgtcattctg caccggggcac gacgtggcaa tcaggtcgat gtcttctacg 4200
ccgcccggga agacaaatgg aaacgtggcg aaggtggagt gcgaaaattg gtccagcgat 4260
tcgtggatta cccagagcgc atacttcaga cgcacaatct gatggctttt ctgtgatcca 4320
gtgaccactt ttacaaatgg tgactgctac cgcggg 4355

```

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 2176

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

&lt;400&gt; SEQUENCE: 8

```

gtgatgtcct cggcgtgact gtcgagggta aggatctggc actgtacgaa gtggaaggcg 60
aaatctacgc taccgacgac ctgtgcacgc atggtgccgc ccgcatgagc gatggttatc 120
tcgagggggc agaaatcgaa tgccccttgc atcaaggtcg gtttgacgtt tgtacaggca 180
gagccctctg cgcgccctg acagagaaca tcaaacata tgcagtcaag attgagaacc 240
tgcgcgtaat gattgattha agctgagaat ttttaatagg aggcgccccg gaccatagag 300
cgtaattatc cccattccat ctttttttag gtgaaaacat gaattacaaa aacaaaatct 360
tggtaaatga gtctgggctg acccaaaagc acctgattca tggcgatgaa gaacttttcc 420
agcacgaact gagaaccatt tktgcgcgga actggctttt tctcactcat gacagcctga 480
ttccttcccc cggcgactat gttaccgcaa aaatggggat tgacgaggtc atcgtctctc 540
ggcaaagcga cggttcgatt cgtgccttcc tgaacgtttg ccggcaccgc ggcaagacac 600
tggtgaacgc ggaagccgac aatgctaaag gtttcgtttg cagttatcac ggcctgggct 660
tcggctccaa cggcgaactg cagagcgttc cattcgaaaa agagctgtac ggcgagtcgc 720
tcaacaaaaa atgtctgggg ttgaaagaag tcgctcgcgt agagagcttc catgggttca 780
tctatggttg cttcgatcag gaggccccct ctcttatgga ctatctcggg gacgctgctt 840
ggtaacctga acccatcttc aaacattcag gcggtttaga actggtaggt cctccaggta 900
aggttgtgat caaggccaac tggaaaggc acctcgaaaa ctttgtgggt gatgcatacc 960
acgtcggttg gacgcacgcg tcttcgcttc gcacaggcga atctatcttc tcgtcgcctc 1020
ctggcaacgc agtgctgccg cctgaagggt cgggcttgca aatgacctcc aaatacggca 1080
gcggtatggg tgtgttggg gacggatatt caggcgtgca tagcgcagac ttggttccgg 1140
aattgatggc attcggcggc gctaagcagg aaaggctgaa caaagaaatt ggcgatgttc 1200
ccgcccggat ttatcgcagc cacctcaact gcaccgtttt cccgaacaac agcgtgctga 1260
cctgctcggg tgttttcaaa gtatggaacc cgatcgacgc aaacaccacc gaggtctgga 1320
cctacgccat tctcgaaaaa gacatgcccg aggatctcaa gcgccgcttg gccgacggcg 1380
ttcagcgaac ggtcgggcct gctggcttct gggaaagcga cgacaatgac aatgatgaaa 1440
cagcatcgca aaacggcaaa aaatatcaat ccagagatag tgatctgatt tccaaccttg 1500

```

-continued

---

```

gtttcgggaa ggatgtatac ggcgacgcgg tctatcctgg cgtcgtcggg aaatcggcga 1560
tcggcgagac cagttatcgt ggtttctacc gggcttacca ggcacacgtc agcagctcca 1620
actgggctga gttcagagat gcctctagta cttggcatac cgaactgacg aagactactg 1680
atcgctaaca gacgagtcga ccatgatgat caatactcaa gaagacaagc tggatatccgc 1740
ccatgacgcc gaagagtttc ttcgtttctt caattgccac gactcggctt tgcaacaaga 1800
agccaccacg ctgctgaccc gggaaagcga tctgctggac attcaggctt accggacttg 1860
gtagagcac tgcgtggggc cagaggttca atatcaagtc atttcacgcg aactgcgccc 1920
cgcttccgag cgccttata agctcaatga agccatgaac gtttacaacg aaaatttcca 1980
gcaactgaaa gttcagtcg agcatcaact ggattcaca aactggagca acagcccga 2040
gtcgcgcttt actcgttca tcaccaatgt ccaggccgca atggacgtaa atgatgaaga 2100
tctgctcac gtccgctcca acgtcgttct gcaccgggca cgacgtggca atcaagtcga 2160
tgtcttctac gccgcc 2176

```

```

<210> SEQ ID NO 9
<211> LENGTH: 14462
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A modified DNA molecule encoding valine at the
position corresponding to the F352 amino acid in
NDO.

```

```

<400> SEQUENCE: 9
gtcgactccg gtggcacaat cgacgggagc acaagcgtta cagcatcggg gctatcggcc 60
tcaaccgctg agacgcattc acatacccaa aagcaatggc aagaagcgtc cgtggggaat 120
tccaacgatg cgggatcgtg cgtgcagcgc gctgtggaaa ctggcacttg agccggttgc 180
cgaaacgcgt gtagatccca actcctatgg atttcggccg cagcagatcca ctgccgatgc 240
aatcgcacat tgcttcaatg cactggcga aacgtggttc ggcactggg tactggaagg 300
tgacattcga ggctgtttcg acaatatcag tcacgattgg ctgctcacc aactgcccac 360
ggataagggt gttctgcgca aatggcttcg agcggggtat gtcgatcagg gagccttgtt 420
cgcaacggag gcaggaaccc cgcaaggggg aatcatctct ccggtacttg cgaattggac 480
gtgggatggc ctggaagatg tctgcatcgc aagcgtggct tcgacagcgc gcaagcgtaa 540
gccattcaag atacacgctg tacgatatgc cgtgacttc atcatcacag gggccacgca 600
agctgttctg caacatcag ttcgtcctgc aattgaggcg ttcctgaaac agcgtggact 660
ggaactctct gatgaagaga ctacagataa gcatatctca caaggcttcg attttctggg 720
ccagaacgta cgcaagtacg ccggcaagct actcatcact ccggttgca agagtgtgaa 780
ggcactgctg gataaggctg gggaaatcgc gaacgcaaac aaggcggcga ctcaagctaa 840
cttgatcttg accctgaacc cggtaatccg aggatgggcc atgtatcacc gccatgttgt 900
cgccgccaac gtttcgatg gatcgaccat cagatttggc aagtgttatg gcgctgggca 960
gttcgtcggc acgccaatga aatgcctat tgggtaaaac aacgctactt tctgtctgta 1020
ggtcaacggc actgggtttt cgccactcag gagaaagcgc gcggttgag tcaaccgct 1080
tggtgtatg ccgcccgag tgtttogac gtgcggcata tcaaaatatg cagtgcagcg 1140
aaccgcttcg atccggcatg gacgctttac cttgagcgtc gaagagcgc tcgtcaggtt 1200
gcccagctct actcagcgtg ctggaaggct tgagccgtat gaggggtgac tcccaggtac 1260
ggttcttagg ggagacaggg gtggtaacac cctgtttta ccgactgaa agcgcatac 1320

```

-continued

---

ggagccgacg cagaatcggg cctggtacat catgtccatg cacagccgcc aacgtggctg	1380
acgtgacgga agttgcccac ctgttgacag gtggcgagaa cgttgtctgt gcttgggggt	1440
acaccggcgt agagaaacgg cctgagcacg acggtcggca agtgatctgg cagatctcgc	1500
cgacgcagca cctacaagca tttgagcaaa cgcagtgcgc cgtacaaggc caggcgcaag	1560
atcgagaag ccaaagccca ggtacgtgcg aaggtcgaac atccgtttcg ggtgatcaag	1620
cgtcagttcg gttatgtgaa gaccgccttc cgtgtcctgg ccaagaatac ggcggaattg	1680
accacactgt tcgctgtgtc gaactctgtg gatggtgcgc cggcaattat tgctgctgc	1740
gggagaggtg cccccgtgag tgacagaaaa ccagggttt gcctcgggta tccaataaca	1800
cagcgactga aaatcgggca tttcggcatc cctaagccgc ccatttccga ctgatgagca	1860
acttgctcgc agtttcccta aagcacaagc gcaagccatc agaaaagagt gcctgagtgt	1920
gctccaagat agcccgaaac taaggccgga catggaaaag accaagatca cccatgtgaa	1980
tgatggactt gttttgtgg gccatcggat cttcgcgaag cgtagccgat acggagatat	2040
gcgtgtgatc acgacgatcc gagacaaaag cagaagattc gcagccctcac tgacggcgcct	2100
gctatcaggt aaccacagt aaagtaagat cgacatggtt gaatcagtca accgaaagct	2160
taaaggctgg gcggcgttta tcaattcgtt gattcaaaag caaagtattc agctatatcg	2220
atcgtgtcgt gttttggaaa ctggccatt ggctggctca aaaataccgc tcccaggttt	2280
gtcttgctg ttcctggccc gccgatgaac accacattct gcgcggtatc tgtgaactcc	2340
aggttgacc gtcacctatg ggcacaaaca atatctcgtg gccttgctg ggatacgcga	2400
ctaaccaaaa tcgctgactg gcgatgcag cttccatag ggagacgctg gaagcgtcgg	2460
aatagaccgt caatcagaag accttcttcg ctcccgtcga actgaaagcc tcaaccgagt	2520
cgaacgtcaa cgggaaagc gcgcaaagac ttgccttgct cacctcgtca cgagcgtaca	2580
aacgctgtga gctggctgta cgggtgcgct gcttagcgtt ggtttttccg ttctgtgagc	2640
caaccccgct atatcgtagt gcaggaccat gccgttaagg agggctgcct ggtcagcatt	2700
ttcagccagc gccggaagtt cctgcacttc ggccttgaac tggcgttcca atgcctggat	2760
atggccatag ggaggtacgc tttggcgtaa ggcgttgcat gcagcttggt gctgtcgagg	2820
ctgatggtgc ggagcttgag cagcttcatt tgcctgcca actccacgc ctgaaggaag	2880
ttcccggcca agtcacgag gaagcgtgc cggaaagctgg ccggggtgac tcttgccg	2940
aggtggcgaa aagcgagcga gtcgtaactg gcgcgctcaa tcctggagct gggaaacttg	3000
ccggtggcat aacctagac catcgggctg agcacaatgc ctccgggggtg ataagccgct	3060
accgctccg ccatatgcct gagtgagggc gctaaggtcg gcccgctcaa tggcttcgag	3120
aataaagcgg gccaggtgat cttctgccat ctctccgaa tgggtggaag cacatcaacc	3180
tgaccagcga ttacgtctgc gcagagccgc agactagagg tcgggaagtt ccggccgtta	3240
cggctgcccg gaaaacctca gtgtacgatt tttcagctc cctctattcg acctgcgttg	3300
cgacgttcga tctgactagg gcgcagcggc aacatcggct gactacgatc cagcgcctgg	3360
atgtgggta tttcgttaac cgacaacacc agagcgttat cctcggggt caggcagagc	3420
ccaaccacat gactacctct cggcaaaatg agggctgta ctaatttga acgtcttcaa	3480
gcgatggggt tttaggtcga aagctgccca ggcctgcgga acctaccaca tcgtaaccg	3540
agcatattcg gcccgccgcg gctaaaaaca cagaatgag cggggtgacc cgatcgcctt	3600
tgatcgattc tccgctttca aaagcggcag gggctgaagt cagccgaaa taccagacc	3660

-continued

---

aatcacaaca	ttcatgctgg	tgataaataa	attcaactat	gctttattga	caaataaaag	3720
cacactcacc	atcatcgca	atacaaatct	tataaaatta	agccggattt	atgaaacttc	3780
tcatacagcc	aaacaatcgc	ctcattagct	ttagtcccgg	cgccaacctt	ctggaagtgc	3840
ttcgcgagaa	cggtgctgct	atctcctaca	gttgatgctc	tgggcttgc	ggaacctgcc	3900
ggtgccgggt	tacagatggt	agtgaattg	attcggggac	gggaagcggg	ttaccacacc	3960
tcgtggacga	gcattatgtg	ctcgcctgct	ggcagtagct	tactaacaat	tgcgcgatcg	4020
aaatcccaga	agccgacgaa	atcgtcacc	acccggcgag	aatcatcaag	ggcactgtgg	4080
tcgctattga	gtcgcctact	cacgatatac	gtcgcctacg	cgtacgcctc	gccaagccct	4140
tcgagttctc	acccggacag	tacgcgacat	tgacagttcag	tcctgagcat	gcgctccctg	4200
attcaatggc	aggtctgcc	gatgaccaag	aatggagtt	ccacatacgc	aaggtgccgg	4260
gtgggcgcgt	aactgagtat	gtttctgagc	acgtccgcga	aggtacaagc	atcaaattga	4320
gcgggccact	tggtacggct	tatttacgct	agaaccacac	cgggccgatg	ctctgtgtgg	4380
gcggtggaac	cggactagca	ccggtgctgt	cgattattcg	cggcgctctg	aagttgggta	4440
tgacaaacc	catcctcctt	tattctggag	tgcgagtc	gcaagacctc	tacgacgag	4500
agcgattgca	taacctcgcg	gctgatcacc	ctcaactgac	cgtacacacg	gtaatcgcaa	4560
tgggcccgat	taatgagagt	cagcgagccg	gtctagttac	cgatgctgac	gaaaaagaca	4620
tcagttcgc	ggctgggtgg	agggcctatc	tgtgcggtgc	accagcgatg	ggtgaagcgc	4680
tttgaccctg	taccaaacat	cttggaaat	caccggaaca	tatttatgcc	gatgccttct	4740
atcccggtga	aatctgaatc	gtccctttcc	ctcacctcgg	tccattgagg	actcatcagg	4800
aggatactca	aatagcgca	aataataaca	gccgcgtcac	tatgtcggc	agcgaaatgg	4860
ttccctctc	cctcatttgc	cccatcggag	gatagtttta	tgacagaaaa	atggattgaa	4920
gcagtcgccc	tttgtagcat	tccagaaggt	gatgtcctcg	gcgtgactgt	cgagggtgaa	4980
gatctggcac	tgtacgaagt	ggaagcgcaa	atctacgcta	ccgacgacct	gtgcacgcat	5040
ggtgccgccc	gcatgagcga	tggttatctc	gagggcgag	aaatcgaatg	ccccttgcat	5100
caaggtcgg	ttgacgtttg	tacaagcaga	gccctctcgc	ccccctgac	agagaacatc	5160
aaaacataty	cagtcaagat	tgagaacctg	cgcgtaatga	ttgatttaag	ctgagaattt	5220
ttaataggcg	gcccccgga	ccatagagcg	tgattatccc	cattccatct	tttttaggt	5280
gaaaacatga	attacaaaa	caaatcttg	gtaagtgagt	ctgggctgac	ccaaaagcac	5340
ctgattcatg	gcggtgaag	gcttttccag	cacgaactga	gagccgtttt	tgcgcggaac	5400
tggctttttc	tactcatga	cagcctgatt	ccttcccccg	gcgactatgt	taccgcaaaa	5460
atggggattg	acgaggtcat	cgtctctcgg	caaagcgacg	gttcgattcg	tgctctctg	5520
aacgtttgcc	ggcaccgcgg	caagacactg	gtgaacgcgg	aagccggcaa	tgctaaaggt	5580
ttcgtttgca	gttatcacgg	ctggggcttc	ggctccaacg	gcgaactgca	gagcgttcca	5640
ttcgaaaaag	agctgtacgg	cgagtgcctc	aacaaaaaat	gtctgggggt	gaaagaagtc	5700
gctcgcgtag	agagcttcca	tgggttccatc	tatgcctgca	tcgatcagga	ggccccctct	5760
cttatggact	atctcgggtga	cgctgcttgg	tacctggaac	ccatcttcaa	acattcaggc	5820
ggtttagaac	tggtagggcc	tccaggtaag	gttgatgaca	aggccaactg	gaaggcacct	5880
gcggaaaact	ttgtgggtga	tgcataccac	gtcggttgga	cgcacgcgct	ttcgtctgct	5940
acagggcagt	ctatcttctc	gtcgtctgct	ggcaacgacg	tgctgccgct	tgaaggtgct	6000
ggcttgcaaa	tgacctcaa	atacggcagc	ggtatgggtg	tgttggtgga	cggatattca	6060

-continued

---

ggcgtgcata	gcgcagactt	ggttcgga	ttgatggcat	tcggcgcg	taagcaggaa	6120
aggctgaaca	aagaaattgg	cgatgttcgc	gcccggattt	atcgagcca	cctcaactgc	6180
accgttttcc	cgaacaacag	cgctgtgacc	tgctcgggtg	ttttcaaagt	atggaaccgg	6240
atcgacgcaa	acaccaccga	ggtctggacc	tacgccattg	tcgaaaaaga	catgcccgag	6300
gatctcaagc	gccgcttggc	cgacgcggtt	cagcgaacgg	tcgggcctgc	tggttcttgg	6360
gaaagcgacg	acaatgacaa	tatggaaaca	gcatcgcaa	acggcaaaaa	atatcaatcc	6420
agagatagtg	atctgatctc	caaccttgg	ttcgggaagg	atgtatacgg	cgacgcggtc	6480
tatcctggcg	tcgtcggaaa	atcggcgatc	ggcgagacca	gttatcgtgg	tttctaccgg	6540
gcttaccagg	cacacgtcag	cagctccaac	tgggctgagt	tcgaggatgc	ctctagtact	6600
tggcataccg	aactgacgaa	gactactgat	cgtaaacaga	cgagtcgacc	atgatgatca	6660
atactcaaga	agacaagctg	gtatcggccc	atgacgccga	agagtttctt	cgtttcttca	6720
attgccacga	ctcggctttg	caacaagaag	ccaccacgct	gctgaccggg	gaagcgcatc	6780
tgctggacat	tcaggcttac	cggacttgg	tagagcactg	cgtgggttca	gaggttcaat	6840
atcaagtcat	ttcacgcgaa	ctgcgcgccc	cttccgagcg	acgttataag	ctcaatgaag	6900
ccatgaacgt	ttgcgacgaa	aatttccagc	aactgaaagt	tcgagtcgag	catcaactgg	6960
attcacaaaa	ctggagcaac	agcccgaagc	tgcgctttac	tcgcttcac	accaatgtcc	7020
aggccgcaat	cgagctaaat	gatgaagatc	tgcttcacgt	ccgctccaac	gtcgttctgc	7080
accgggcacg	acgtggcaat	caagtogatg	tcttctacgc	cgcccgggaa	gacaaatgga	7140
aactgtggca	aggtggatg	cgaaaattgg	tgcagcgatt	cgtggattac	ccagagcgca	7200
tacttcagac	gcacaatctg	atggcttttc	tgatgaccgg	tgaccacttt	tacaaatggt	7260
gactgtctacc	gcggtcacca	ttaatcaaaa	gggaatgtac	gtgtatgggc	aatcaacaag	7320
tcgtttcaat	aaccgggtgc	ggctcaggaa	tcggtctcga	actggttcga	tccttcaagt	7380
cgcccggtta	ttgcgtatcc	gctctcgtac	gaaacgagga	gcaagaggcg	cttctttgca	7440
atgaattcaa	ggacgcactc	gagatcgttg	tgggcgatgt	ccgagatcac	gcaataaatg	7500
agaagctgat	caagcagaca	atcgctagat	tcggtcatct	cgattgtttc	atcgcaaatg	7560
ccggtatttg	ggattacatg	ctgagcatcg	aagagccttg	ggagaaaaatc	tccagcagtt	7620
ttgacgaaat	attcgacatc	aatgtaaaga	gctatctcag	tggcatcagt	gcagctctgc	7680
cggaaactgaa	aaagcgaac	ggatcgggtg	tgatgaccgc	ttcgggtctg	tccatgagg	7740
tcggtggtgg	tggttcttgc	tacatcgcca	gcaagcatgc	ggtgttaggt	atggtcaagg	7800
ctttggccta	cgaattggct	cccgaattc	gcgtgaacgc	tgtctcggcg	ggcggcaccg	7860
tgacgtctct	gtcggctcct	gcaagcgccg	gtttcgacaa	aatgcacatg	aaagacatgc	7920
ccggcatcga	cgatatgatc	aaaggcctca	ctcctcttgg	gtttgcagcc	aagcccgaag	7980
acgtggtgga	gccctatctg	ttgctggctt	cgcgaaagca	gggaaaattc	atcaccggca	8040
ccgtgattag	cattgatggc	ggtatggcgc	tcggtcgcaa	gtgagcttgc	agccgatcaa	8100
aggttataga	aacattttta	ggtgacgccc	catgaagaca	aaactgttta	tcaacaacgc	8160
ctggatcgat	tccagtgacc	agcagacctt	cgagcgcaag	caccccgtca	acagcgaggt	8220
gatgactgag	agcgcacacg	ccacgggtgac	ggacgcgata	aaggcggcgc	aagtggccga	8280
ggagcattc	aagacctgga	aggacgttgg	accttcggag	cgtcgccgcc	ttctcctgaa	8340
ggtcgccgat	gtcatggaaa	gtaaaacacc	caagtttatc	gaagtgatgg	ccatggaggt	8400

-continued

---

gggagcttcc gctctttggg ccggattcaa cgtccatgcg tctgccaatg tgttccggga	8460
ggctgcctcg ctggccactc aaattcaggg cgaaaccatc ccaacggaca aagccgaaac	8520
gctctcaatg aactacgctc agccggctcg cccgatcctg agcatcgtcc catggaacgg	8580
caccgcagtg ctggcggcac gagccatcgc gtatccgctg gtctgtggca acacggtggt	8640
gttcaaaggc tctgaattta gtcccgcgac gcatgccctg atcaccagtg gcgtccagga	8700
agccgggctg ccgctggcg tgctcaacta tctcaactcc tcgcctgacc gttcgcccga	8760
gatcgccgac gactgatct ccgcgaagga gatccgccgc atcaacttca cgggttcaac	8820
ccgctggggc agcattatcg cgcagaaggc cgcgcaacac ctcaagcgtc gcctactgga	8880
gctcggcggc aagtcgccgc ttattgttct ggatgacgca aacattgacg cggcggtcaa	8940
ggcagcggtg ttcggtagct tcctgttcca aggtcagatc tgcattgcca ctgagcgtt	9000
ggtggtgat gagaagattg ccgacgaatt tgcgccaag tttgtcga aaactaagcg	9060
cttgagcgtg ggcgaccctg gcgtaactgg cgactgcatc atcggcccaa tggctcggc	9120
aaattcgggc gagcggatca atggtttgtt caaggacgcg atcgataaag gggccaaagt	9180
tgtttcggc gccatggccc aggtgctggt catgccggcc acgatcctgg atcacgtgaa	9240
atctgacatg ccgatctacg atgaggagac ctttggctcc atcacagtgg tgatccgtt	9300
caaaggggaa gcagaggcca tccgcattgc caacgacagc gtttatggtc tgcctcggg	9360
cgtgtttggc cgcgacatca accgtgctct cgcagtgggt atgtcgtcgc aatattggtt	9420
cgtaacatc aacggctcga ccgtccgaaa cgaggcgcag gctccttacg gaggtaccaa	9480
gaacaccggc tacgggcgct tcgacggccg tgcctggtgc gacgagtca cagagctcaa	9540
gtggctgacc attgagccat tcgagcagca atatccctt tgaaagcact aactccaagg	9600
aatcaaacga tgagtaagca agctgcagtt atcgagctcg gatacatggg catctcagtc	9660
aaggatcctg atgctgtaa atcgtttgcc atgaatatgc tgggtctgca agtactcgt	9720
gaggtgaga agaccgttt ctatctgcgg atggattact ggcaccatcg tatcgtagtt	9780
catcacggcg gagagacga cttggaatat ctaggctggc gtgtagccgg caagccggag	9840
ttcgaagctt tggggcaaaa gctcattgat gccggttaca agatccgtgt ctgcgacaaa	9900
ggtgaggtc aggagcgtat ggtgttggc ctgatgaaga cagaagatcc aggcggcaac	9960
ccgaccgaga tattctgggg gcccggatc gacatgagca atccgttcca tcccggccgc	10020
ccctgcacg gcaagttgt gaccggtgac cagggcttag gtcattgcat cgttcgcca	10080
accgacgtcg ctgcggccca taaattctac agcctgctgg gcttccgtgg ggacgtcga	10140
taccgattc cattgcccga ccgcatgact gccgaactgt cattcatgca ttgcaacgcc	10200
cgtgatcact ccattgctt tgggtccatg cctgctgcca agcggctcaa tcaactgat	10260
cttgagtaca cccatatgga agacttggga tatacgcac aacagttcgt gaagaacgaa	10320
attgacatcg ccttgagct tggcattcac gccaacgaca aggcgttgac gttctacggc	10380
gcaacgcctt cggcgtgct tatcagccc ggctggcgag gtgctacggc catagacgaa	10440
gcggagtatt acgtcggcga catcttcgac catggcgtcg aggcacctgg atatggcctg	10500
gatgtaaaac tgagttaaaa gcgattatgc gtacatcggg tttctgacgt tttctgctt	10560
ctatacagc caataacaat aacaactaag tgggaatatt aataatgata aaaaaaacgt	10620
ttctttacat gcctcgtctt acttgttcac tcagcaccgc atgggcccga gaatcacctt	10680
ggacataccg catcggcatg agtaaatatg cttttgatc aagcggccaa gtgtacttgg	10740
gagccagcg tgtccggga ggaagcgtg acgcgagcaa taacaacgcg ctacattcg	10800



-continued

---

acttcggcta tgccatcaac gaccaatgga atgcacgttt gattgtcggg attccaccta 10860  
caactaaagt taagggcgca ggcacacttc cgggcattca gctgggaaaa ataacttatg 10920  
ctccaacatt actgacgtta aactataacc tcccagcttt tgggcccggt cgtcctcaca 10980  
tcggtgcagg agtcaattac acgcgaatth tggaaagcaa ggacgctaatt ctaaaatcat 11040  
tcgatgccga ccacgcttgg tcccccgcg tgcattgttg tgcgatatt gacgtgagtc 11100  
gcaactggtt cgtcagcatt gatattcgga agttatacct gaaaaccgac gcatcaggtt 11160  
acttagggcc acaggaggct aaagcaaaag taactcttga cccattgata acatcgatcg 11220  
caatcggagc ccaattttga tgcctcttt taaggctctc tatctatcta actgcaaagg 11280  
gtatthttat gttgaataaa attagtaaaa ccgctgctct taccgctgaa gatatcaatg 11340  
gtgctgggac tataatgccc acaccgtcga cgcctgatgc ttctgattgg cgcacgacta 11400  
acactgtgga cttagacgag actgcccga tagttgaaga gctgattgct gctggtgtca 11460  
acggtattht gagtatgggt acctttggtg agtgcgccac gttgacctgg gaggagaaac 11520  
gtgattatgt ttcgacggtt gtcgagacca ttcgctgctg tgtaccttat ttctgctgca 11580  
cgacggccct gaataccgga gaagtcattc ggcagaccgg agagcttacc gatattggcg 11640  
ctaaccggac catgctagge gtgctgatgt gggtaagat ggacctgccc acagcgttcc 11700  
agttctatcg tgatgttga ggcgcggtac cggaggtgct cattgctgatt tacgccaacc 11760  
ccgaagcatt caaattcgac ttcctctgcc catthtgggc agagatgtct aaaattctct 11820  
aggtagtgac tgccaagtat ctaggcatcg gaatgcttga cttggacctg aaattggcgc 11880  
ctaaccatccg cttccttcca cacgaggagc actattacgc ggcgcgacgc atcaatcccg 11940  
agcgcattac tgcgttctgg tcaagcgggg ccatgtgctg cccgctacc gctatcgggt 12000  
tgcgtgatga agtgagcgg gccaaagata ccggtgactg gatcaaggcc aaagccatct 12060  
ccgatgatat gcgtgacgc gattcgacat tgtttccgcg tggcgactth tcggagttct 12120  
cgaagataa tatcgggctt gaaaaggcac ggatggacgc ggcgtggttg ctcaaggctg 12180  
gtcctgcccg tcctccttac aatctgttc cagaagatta cctcgttggg gcacagaaat 12240  
caggcaagtc gtggcccgcg ctgcacgcta aatacagtaa agaattaaag tagttcacct 12300  
ccgatgcct gagcgcgagg ggtgaogtaa acgccgagcg gtgcgggaag taagtgagtt 12360  
agagttcatt tcttgtgcca ggcactgcta gatcagcaa gttagctgat ctacgagctt 12420  
cgaaaattht ggcgaaagct gatcttagga atgcccggata aaggcagtac accgtaacga 12480  
tcggggtgtg ccgttcatgt tgaacgacac cgctattgcg ccgacttctc ttcttcggag 12540  
tgtttgattg tgattgtcga tttctatttc gattthttga gtccgttctc ttacttggcc 12600  
aatcagcgtt tgtcaagct tgcgcaagat catggcctta ccacgtgtha taacgcgac 12660  
gatttggcgc gggcaaaat agcagatcgt aacgttggc catctaactg cgacttggaa 12720  
gtaaaattgg actatthtga agtagatttg caacggtggg cccagcttha cggaaatccg 12780  
ctggtattht cagctaaact caacagcaga cggatgaata ctgggcttha ttactcggag 12840  
gccgaggtgc agcccgctgc ctatgtgaat gtagtattta atgctgattg gggagaaggc 12900  
atagcaccag atthtgaaa cttgcctgcc ctggtatctg aaaagctagg ctgggatcgt 12960  
agtgccttc agcgtttht cagcagcaac gcccaacag agaggatga cgagcagaca 13020  
catttcgcca tcgagcga ggtgttcggt gtgccaacga tgtthttggg cgatgaaatg 13080  
tggtggggga acgacctct gtttatgctc gagagcga tggggcgtt gtgccgaaa 13140

-continued

---

```

aatgccgatt taagtagttg atctgatcgt tatttgctcg atgagtcgct tcaagatca 13200
gCGgatactg aagtcagcta aatgcgggac tacttcaggc catgcttcag gggcggtcag 13260
ggcggactgg cgtgtgcacg gtagttgttg cgtgaggcat gtttttaaga tactattttc 13320
agtgcctgct gctctctctg ggttgagtgt gagggcgccg atagtctcaa atctcgcggt 13380
gtacctgacc agagatacgg gtgtttatga tggcatcgct ggtacagcgc atgacgccat 13440
gctgcttcac ttcgagtgta ttcacgacct cgacgctagc aatctcaacg agccagatga 13500
tcgcagacca gggcgaagc tagtcgtgat tcgggttttc tacgttgtag ccgaatgcaa 13560
tcctggtcctt aacgggccac gccttaaacg tggaatgcca aatctgcgat gtcgacattg 13620
gccccataaa tgttttggtt ctctctagtg cagaaatcag taagggtgtg atggtgataa 13680
ctggtcaagc cgggaatcag cggaatcgct gcgctggcgc cactggcgat caaacagcgg 13740
tcaaatacta ccattgaact ggcctaagag ggtgtggaca aaataaagta aacttcttgc 13800
ctcctttcta tgcagcattg agccatgcct aaaactggac gccaccgta atcgctacgc 13860
accattacc tctgctgacc aggctcgctc atacgcagcc ttattccagt caagccgaac 13920
tggcgcaaga ttccatgcag aaacgggcat caccgcgcat ccgacacct ttgcaaaagc 13980
gctgagactg gccgggatcg ttcgagtaaa ggagcgtgcc aaaggtagct tccagcctcc 14040
cgagcctcgt aagtcttatg gctataccga ggcacaccgg cgtcagttgc cggagcaacg 14100
ctatcccagt tgctgactg atgcagaatg gacgttggtc gctgatttat ttgaagtctc 14160
gggaggctgc gccgtaccgc tcgccactcc cgacgcactc ttttgaagc ctgctgttat 14220
gtcgtgcgca cagggtgctc ctggcgaatg ctgcttcgcg agtttcccta ttgggacaat 14280
gtctataaaa cctttcggcg ctggagcgtc agggcaagtt tgagcaaatg cacgaccggc 14340
tccgtgccca atggcgagag cgggtggatc gtgatgaacg gccgtcagcc gctgttctgg 14400
attccaatc aacgcgcacg tctccccaag gcggtgaaag cggttacgac gcaggcaaaa 14460
ag                                                                                   14462

```

&lt;210&gt; SEQ ID NO 10

&lt;211&gt; LENGTH: 12808

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

&lt;400&gt; SEQUENCE: 10

```

gtcgacgcat gatgcaggac tgggcgacg gctcagacct ctteagcag aaccaggtcg 60
aggcggccag catgccgctc accgtgcatc tggaaaggtgt gcccgattc ccgagtgagc 120
aaaccgcaag cgcgccctct acgccggttg ccgcttcgcc aagcctgctc gtgacgaagc 180
cgggtgacgc catgccgttg gttttctcgg ccgcacatcg gctgccggca gtgccgcccc 240
agcgatcggc cgcgccgctg gtgccttcgg acattcagcg cgagagaatg gatttgttcg 300
atgtcttcga agcgcgcgac aaccttcccg tcgctgcggt tgccaagatg gcgggcaaat 360
ctcgcaggtg gatcagctac gagatccagg cgggcaactt gctggcggtt aacgtgggca 420
accgcgccca gcgcgtgccg gactggcacc togacccgct caagcacgag ctgatccagt 480
ctgtcctgaa gctgaccagg ggtgcggacc cttggcagat ctaccatgca ctgctgcagc 540
cgcgctcgat gctgcggggg cgctcggcac tggagggcgt gactgccagc aatctcgaca 600
agctcgtcat gcccgtagc acagcgggtga aggaaagcga atggaccccg ctgogggtcg 660

```

-continued

---

gtggtcgtgt agtcaaaaca cgggcccgta agggatggcc tggacattat tcatattagt	720
gatactaata ttcatttatg gtttattgac tattagaata cagtcaatga tcatggaacc	780
ataaagcata taaataaaga agctagatct atggaacttc tcgtactacc gaacaatcgc	840
cgcttgccctt ttgattcccg tgccaacctt ttggaagtgc tccgtgagca ccggtgggg	900
atttcctaca gctgtatgtc tggacgatgc ggtacttgcc gctgccgagt tatagatggc	960
agcgtcatta gttcggcggc gaaaagcggg gactcaaadc gcatcgaaga gcattatgta	1020
ctcgcctgtc agtcagtgct caccagcaat tgcgcaattg agatcataga ctacagcgc	1080
atagtcactc acccggcggc aatcatcaaa ggcatggttg tgcgccgca gtcgccccact	1140
cacgatattc gccgcatccg cattcgcctc gccaaagcct tcgagttctc acccggacag	1200
tacgcgatgc tacagttcag tcccgaacat gtgcgtccat attcaatggc tggctgcca	1260
gatgaccaag aaatggagtt ccatatccgc aaagtcccgg gcgggctgtg cacggagtat	1320
attttcgagc acgtccgcga aggtacaagc attaagttga gtgggcctct tggtagggc	1380
tatctcgcgc aggtccacac cgggcccgatg ctgtgtgtgg gcggcgggac cggactcgca	1440
ccggtgctgt cgattgttcg cggcgcgctg aagtcgggaa tgacgaacc caccacctt	1500
tatttcgggg tgcgcagtca gcaagacctt tacgacgcag accgattgaa ccaactcgcg	1560
gctatccacc ctcaactgac tgtccataca gtgatcgcga cgggcccgat taatgagggc	1620
cagcgggccc gcctaattac cgatttgatt gaaaaagaca tcccctcgtc ggctgggtgg	1680
agagcctacc tgtgcggcgc accagcagtg gttgacgctc tatgcaccgt cgcctaaagat	1740
cttggaaatc cccccgagca tatttatgcc gacgccttct atcccagcgg ggtctgaatt	1800
gccccgacc ttcacctctg tacatcgaga attcatcagg aagacactta aatgagcatc	1860
actaacaaca gccgcgtctg aatatttagg acagctggat gatctctaac tccatcatta	1920
ccccatttga agatagcttt atgacagaaa aatggattga cgcagtcgct ctttatgaaa	1980
tcccgaagg tgacgtcctc ggcgtgacag tcgaaggtaa ggaactagcg ctgtatgaag	2040
tggaaggcga aatctacgct accgacaacc tgtgcacaca tgggtgctgcc cgcgatgagtg	2100
atggctttct agaaggcaga gaaattgaat gtcctttgca tcaaggtaga tttgatgttt	2160
gcacaggcag ggcttctgtc gcccctgta cacagaacat caaaacatac ccggtgaaga	2220
ttgagggcca gcgtgtgatg attgatttga gctgagaatt ttaataggag gcaccccgga	2280
ccctagagcg taatcccccc cattcgatct cttgaggtga aaatatgaat tacaaaaata	2340
aaaacttggg gagtgaatct gggctgaccc aaaaacacct gattcatggc gacgaagaac	2400
ttttccagcg cgaactggaa accatttttg ctcggaactg gcttttctc actcatgaca	2460
gcctgattcc gtcccctggc gactatgtta cggcaaaaat gggggttgat gaggttatcg	2520
tctccaggca gaacgacggt tcgattcgtg cttttctgaa cgtttgtcgt cacogtggca	2580
agacgctggt acacgcagaa gcaggtaatg ctaaaggttt cgtttgacg tatcacggct	2640
ggggcttcgg cgctaaccgt gaactgcaga gcgtcccgtt tgaaaaagaa ctgtatggcg	2700
aggcgtcga caagaaatgt atgggattga aagaagtcgc tcgtgtagag agcttccatg	2760
gcttcatcta tggttgcttc gatgaggaag ccccttctct caaagactac atgggggacg	2820
ctggctggta cctggagcct atgtttaagc attccggagg gctagaactg atcggctctc	2880
caggaaaggt cataatcaag gctaactgga aagcggccgc gaaaaacttt acgggggatg	2940
cgtaccacgt gggttggacg catgcgtctt cgcttcgctc agggcagtcg gtcttctcgt	3000

-continued

cgttagctgg caacgcagct ttgccccag aaggtgcagg tctgcaaatg acctccaaat	3060
acggcagcgg catgggtgtg ttgtgggacg gatattcagg cgtgcacagc gcagacctgg	3120
ttccggaatt gatggccttc ggcggtgcta agcaggaacg gctgaacaaa gaaattggcg	3180
aggttcgcgc acgaatctat cgcagccacc tcaactgcac cgttttcccg aacaacagtt	3240
ttctgacctg ctcggtgtc ttcaaggtat ggcacccgat cgacgcaaat accactgagg	3300
tatggacctc cgccatggtc gaaaaagaca tgcccagga tctcaagcgc cgcttggtcg	3360
acgcggttca gagaacggtt gggcctgctg gcttctggga aagcgacgac aacgacaata	3420
tgaaacggt atcgcaaac gccaaagaat atcagtccag agatggcgat ctggtttcca	3480
acctgggttt cggcggggac gtatacggcg acgaggttta tcctggcctc gtcggcaaat	3540
cggcgattgg cgagaccagt tatcgtggct tctatcgggc ttacggcgcg cacatcagca	3600
gctctagctg ggctgaattc gaggatgtct ctaaaaattg gcataccgaa ctggcaaaga	3660
ctactgatcg ctaacagagc agagggacca tgatgattaa tattcaggaa gacaagcttg	3720
tctccgcca cgacgcgaa gagtttctc gtttcttcaa tccggcgac gaggcttgc	3780
aacaagaagc taccacgttg ctaaccggg aagcgcctct tttagacatt caggcttacc	3840
gcgcctgggt agagcactgc gtggactcag aggtgaaata tcagattatc tcacgcgaac	3900
tgcgctcagc ttccgagcgc cgttaccagc tcaatgaaac catgaacatt ttcaacgaga	3960
attatgaaca actggaagtt cgcgtagcgc atcaactgga tccgcaaac tggggcaata	4020
gtccaaaggt gcgctttact cgtttcatca caaatatcca ggctgcaatg gacgaaaatg	4080
aagatttgc tcaattcgc tccaacctaa ttgttcaccg agcagcagc ggcaatcaag	4140
tcgatgtctt ctatgccact cgggaggata aatggaagcg cggcgaagat ggagcgcgta	4200
agttggtcca acgattgatt gattatccag agcgcacatt ccagacgcac aatgtgatga	4260
tctttatgtg acccaataat cgcctttaca aatggtgact gctacaagcg gtcccattgt	4320
tcaaaaggaa atttatgtgt atgagcaatc aacaagtcgt ttcgataacc ggtgctggct	4380
caggaattgg tctcgaactg gttcgtatcct ttaagtccgc cggttattgc gtatccgctc	4440
tcgtacaaaa cgaggagcaa aaggcgagcc tttgcaatga gttcaaggac gcaactcgaga	4500
tcgctgtggg cgatgtccgg gaccacgcaa caaatgagaa gctgataaag caaacaaccg	4560
atagattcgg ccatctcgat tgtttcattg caaatgccgg tatttgggat tacatgcttg	4620
gcatcgaaga gccttgggag aaaatatcga gcagttttga tgagatattc aacatcaatg	4680
tcaagagcta tttcagcggc atcagggccg ccctgcagga actgaaaaag actagcggat	4740
cagtggatg gaccgcttca gtgtcgtccc atgcggtcgg tgctggtggg tcttgctaca	4800
tcgcagcaaa gcatgcggtc ctgggcatga tgaaagcttt ggcttacgaa ttggctcccc	4860
acattcgcgt caacgcgta gcaccggcg gcaactgtgac gcctctgagc ggtcccga	4920
gcgcggcctt cgacaaaact cacatggaaa acatgcccg tctcagggac atgatcaagg	4980
gtctaaccgc tcttgaatt tcagccaagg cogaagacgt agtggcaacc tatttgttgt	5040
tgcgctcgcg agatcaaggg aaattcatta ccgggactgt cattaatata gatggaggga	5100
tgcgctcgcg tcgcaagtag gtttgcgcc tatcttga taataactaa atttctggta	5160
aaaccgcatg aatacaaat tgtttatcaa caatgtctgg atcaattcca gtgaccaaca	5220
gacctcagc cgaaagcacc ccgtcagtg tgaggtgatg acggagtgtg caaactccac	5280
ggtgatggat gcgttaaagg ccgcgcaagc tgcccagag gctttccaga cctggaagac	5340
tgttgacct tcggagcgtc gccgccttct gctgaggtc gctgaggtta tggaaagtaa	5400

-continued

---

aacacccgag	tttatcgaag	tgatggccaa	ggaggtggga	gcctccgctc	tttgggccgg	5460
cttcaatgtc	cagatgtcag	ccaatgtggt	ccgtgaagcg	gcacgcctgg	ctacacaaat	5520
tcagggggaa	actattccga	cagacaagtc	tgacacgctc	tcaatgacgc	tacgtcagcc	5580
ggtcggtcgg	atcctgagca	tcgtgccctg	gaacggcacc	gcagtgctgg	cggcacgagc	5640
catcgcttat	ccgctggtct	gcggcaacgc	ggtggtattc	aaaggttctg	agtttagtcc	5700
cgcgacgcat	gocctgatca	cccagtgctg	gcaggaagcc	gggctgcctg	ctggcgtgct	5760
caactatctc	aactctctgc	ctgaccgttc	gcccagagtc	gccgacgcac	tgatctcagc	5820
caaggagatc	cgacgcatca	acttcacggg	ctccaccgcc	gtgggcagta	ttatcgcgca	5880
gaaggccggc	caacacctca	agcgtgcctc	gctggagctc	ggtggcaagt	ccccacttat	5940
tgttctggat	gatgcagaca	tcgatgcggc	ggtcaaggca	gcggtgttcg	gtagcttccct	6000
gttccaaggt	cagatctgca	tgtccactga	gcgcttgatc	gttgatgaga	agatagccga	6060
cgaatttgtc	gcaaaatttg	tcgaaaaaac	taagcgcttg	agcgcaggcg	accctgctgt	6120
aactggcgac	tgcatcatcg	gcccgatggt	ctcgccaaat	tcgggtgagc	ggatcaatgg	6180
tttgttcaaa	gacgcgatcg	acaaaggggc	aaaagttggt	tcggcgggct	tggcccaagg	6240
tgcgctcatg	ccggccacga	tcctggatca	cgtcaaatct	gacatgcgga	tttacgatga	6300
ggagaccttt	ggtcccatca	ccgtggtaat	ccgttgtaaa	ggcgaagcag	aggccgtccg	6360
catcgccaac	gacagcgtct	atggcctgtc	gtcgggcgta	tttgggcggc	acatcaaccg	6420
cgctctacgc	gtgggtatgt	ccatcgaata	tggttctgta	cacatcaacg	gttcgaccgt	6480
ccagaacgag	gcgcaggctc	cttacggagg	caccaagaac	accggctacg	ggcgcttcga	6540
cggccgtgct	gtaatcgacg	agttcacaga	gatcaagtgg	ctgaccatcg	aacctttcga	6600
gcagcaatat	cccttctgat	aagcactaac	tcccaggaat	caaactatga	gtaagcaagc	6660
tgagttatc	gagctcggat	acatgggtat	ctcggtaag	gacctgatg	cgtggaaatc	6720
atttgccacg	gatatgctag	gtctgcaagt	tcttgatgag	ggtgagaagg	accgtttcta	6780
tctgcggatg	gattactggc	atcatcggat	cgtagtccat	cacaacggac	aggacgactt	6840
ggagtaacct	ggctggcctg	tagccggcaa	gccggagtcc	gaagctctgg	gtcaaaagct	6900
tattgatgcc	ggttacaaga	tcgcgatctg	cgacaaagt	gaggctcagg	agcgtatggt	6960
gttgggtctg	atgaagacag	aagatccggg	cggcaaccgg	accgagatat	tctggggccc	7020
ccggatcgac	atgagcaacc	cgttccatcc	cggtcgcccc	ctgcacggaa	agttttgtac	7080
cggtgaccaa	ggcttgggcc	attgcatcgt	tcgccaaacc	gacgtcgag	aagctcataa	7140
gttttatagc	ctgctgggct	tccgtgggga	cgtcgaatac	cggattccgt	tgcccaacgg	7200
catgactgcc	gaactgtcgt	tcatgcattg	caacgcccgt	gatcaactca	ttgcttttgg	7260
tgccatgccc	gctgccaaac	gactcaatca	cttgatgctt	gagtacaacc	atatggaaga	7320
cttgggatac	acgcaccaac	agtttgtaaa	gaacgaaatt	gacattgcct	tgacgcttgg	7380
cattcacgcc	aacgacaagg	cgttgacggt	ctatggtgca	acgccttcgg	gctggctcat	7440
tgagcccgcc	tggcgagggt	ccacggccat	agatgaagcg	gagtattacg	tcggcgacat	7500
cttcggccat	ggcgtggagg	ccactggata	tggcctggat	gtaaaactga	gctaaagatg	7560
cgcgctcgtt	ggcgagggtc	ctagtccagc	atcttcatac	gcaaccaacc	ttgcagggcg	7620
atgagatcaa	aggacgttaa	agcgaagggg	aagtggttcg	ggccatgcgc	ataccgatcc	7680
atgacatttg	tttcatagta	tataggtaga	taggtgaatc	aagcgcttag	tcaactagtg	7740

-continued

gacacatctg ttccatgagg ctatctacta tctattcaaa acaagaatga taaataggat	7800
gaaaataata atgataaaaa gaacgatttg tcttgtgtat cctctattct gtttgcaag	7860
ccccacatgg gccgaagagt cgccttggac gtaccgtatt ggtatgacta atgtagcttt	7920
cgatgctagc gcaaaagtat acttaaatgg tcagcgggtg ccaggaggaa gcgctgatgc	7980
gagcgataac aacgcgctta cattcgactt cggctacgcc atcaacgacc agtggaatgt	8040
acgtgcgatt gtcggtattc cgcctacaac taaagtgacg ggcgcaggca cacttctctg	8100
tatccagctg gggaaaaataa cttacgctcc aacagtatta acgttgaact ataacctccc	8160
cgctttgggt cccgttcgcc ctcacatagg tgcgggagtc aattacacgc ggatttttga	8220
aagtcgggac gctaattctaa aatcgttcga tgcggaccac gcttgggtccc ccgctgaca	8280
tgttggtgcc gatattgacg ttaacctggt ttggttcgtt agcattgata tccggaagtt	8340
atacctgaaa accgacgcat cagggtaactt ggggccacag gaggctaaag cacgggtaac	8400
tcttgaccca ttactaactt cgatcgcgat cggacgcaa ttctgatgat tctgtttaa	8460
gttctttatc tatctaaccg caaaggtgtt ttccatgtcg aataaaatta tgaanaacgtc	8520
gcgtcttacc gccgaagata tcaacggcgc ctggactata atgcccacac cctcgacgcc	8580
tgatgcttct gattggcgca gcaactgccac cgtggactta gaagagactg cccgcatagt	8640
tgaagagctg attgcagctg gtgtcaacgg tatttctaagt atgggtactt ttggtgagtg	8700
cgccacgttg acctgggatg aaaaacgtga ttatgtctcg acgattgtcg agaccattcg	8760
tggtcgcgtg cttattttct gtggcacgac agccttaaat acccgagaag tcatccgcca	8820
gaccgagag cttatcgata ttggcgcaa cggcactatg ctcgggtgct cgatgtgggt	8880
gaagatggac ctgcctacag cggttcagtt ctatcgtgat gttgcagatg cggtaaccaga	8940
ggctgccatt gcgatttacg ccaaccccga agcattcaag ttcgacttcc ctcgcccatt	9000
ctgggcagag atgtccaaaa ttccgcaggt agtgactgcg aagtatctag gcatcggaat	9060
gcttgacttg gacctgagac tggcacccaa catccgcttc cttcccacg aagatgacta	9120
ttacgcggcc gcacgcatca atcccagcgc cataaccgcg ttctggtcaa gcggggccat	9180
gtgogggccc gctaccgcca tcatgttgcg tgacgaagtg gtgcgggcca agagcaccgg	9240
tgactgggcc aaggccaaaag ccattctccga tgatatgctg gcagccgact cgacattggt	9300
tccgctggc gacttttctg agttctcgaa gtataaatc gggcttgaag aggcacggat	9360
ggatgcggct ggttggtcga aggctgggcc ctgccgtccg ccctacaacc ttgttccaga	9420
agactacctc gctggtgcac agaaatcagg caaggcttgg gccgcgctgc acgctaaata	9480
cagtaatgaa ttgaagtagt tcacctccgc agacctgagt gacaggggtg cgcagacgct	9540
gaggtgcag gaattaagtg agctaaagca ctttcttgc gccaggcatt gccagatcag	9600
caaagtgtgc tgatctggca gtttcaaaaa tttggcgcaa agctgatatc aggaatacgg	9660
gataaaggca gtgcaccata acgacggggg cgtgccattc gtgatgaacg attttctat	9720
tggtccgact tctgttcttg gagtgtttga ttgtgattgt cgatttttat ttcgattttt	9780
tgagtccgtt ctcttacttg gccaacctac gtttgcataa gcttgcgcaa gactatggct	9840
tttccattcg ttattacgca atcgatttgg cgcgagttaa aatagccatc ggaacggtg	9900
gtccatctaa tcgcgacctg atagtcaagc tggactatct gaaagtagat ttgcaacggt	9960
gggcccagct ttacgaaata ccggttggat tcccagctaa ctacaacagc cgacggatga	10020
atactgggct ttattactcg ggagccatgg cacagactgg tgcctatgtg aatgtagtat	10080
ttaatgcggt ttggggagat ggcatagctc cagatttggg aagcttgctt gctctgggtat	10140

-continued

---

ctgaaaaact aggctgggat cgtagcgcct tcgaggactt tatcagcagc gatgccgcaa 10200  
cagagaggta tgacgagcag acacatgccg cgatcgaacg caaagtgttc ggtgtgccaa 10260  
cgatgttttt gggcgatgaa atgtggtggg gaaacgaccg tctatztatg ctcgagaacg 10320  
cagtgggagg tgcgcctgta aatggagaat agtcgctacg gagcgcttgt gccggctaaa 10380  
tgccgatata agtggttgac ctgatcgtta tttgctcgat acagcgcttt caaaatcagc 10440  
ggctactgaa gtcagataaa aatgcgggac tacttcaggc atcctgtgcg acacaaagtt 10500  
ttacctgtaa ttgtccacct attccagatt tggaaatgta gctgactcgc tatgcgacca 10560  
gcgatagcct aacaagacat gcatcactgg taacgggtggg gtgtgaagct cctgcaacaa 10620  
tgtagccctt tgatgtgtgt atttgctgcg aggtgaagca cagatgctcg gagccgtacc 10680  
ggcttgtggc gctagcctgg caagtatgag caacgtaagt gggggtggg gcgcaatggg 10740  
aaccaaaaac caacgcaagc cttaccagcg tcgttcggtg ccttcctccc atgctcctgc 10800  
ctcgataaag cagctgcgca tatcggcttc ctggctgac tcggttagta ggtcatgcaa 10860  
ggtcttgtcc agcgcctcgt cgctccgata cggaatggtc agctcgtaat ggcggtctc 10920  
cgaccgcttc atgccgtagg gctccaggca gtacgctcg atgttctccg tggcccgtt 10980  
ccgaccgcbc atgaacttgc tgttgttcac caccgccagg cgcagggatga cggtgccac 11040  
ccgctcgacg gttgactctg ccggtgacgc gatattgcbc ttttgacctc gcgccagggc 11100  
gctcttctg tacgtcccga tctcgacgcc acggtggcgt aggtagctgt acagggtgct 11160  
cttgagatg tgcaacttct cgccgatggc gctgacgctc aggcggccct cgcggtacag 11220  
ggtctccgcc gccatggcgg tggcctcgcc cttggctggc aggcccttgg gacggcgacc 11280  
gatccggcct cgagtccgtg ccgccgacag gccccctga gtcgctcgc ggatcagctc 11340  
gcgctcgaac tgaacagggt gaacaccagg cgatcttggg cgtgggtgct gtcaatgggg 11400  
tcgttcaggc tctgcaagcc gactttcgt gcagccagct agccgaccaa ctcaaccagg 11460  
tgcttgagcg agcagaccgag gcgatccagc ttccagatca ccacggcatc gcccgctcga 11520  
acatgggcta gcaacttgtc caactccgpc cgcgcgcttt ttgcgcccgt ggcgatgtct 11580  
tgatagatgc gttcgacacc gccctgttc agggcatcga cctggaggtc ggcgttctaa 11640  
tcccagatgc tcaccgcgt ataaccgatc ttcataaaaa gtaccgttta cttgactgca 11700  
ttagtaatag ttgaactttg attaagctta ccagttatth gaaccctagc gcagggtgaa 11760  
gcgtccagcc gccccacctc tactcagctt gatgaaccga ggggcagtag ttcataatc 11820  
cggctgttag gaaaactctg aagaagactt cctgattttg gcaaaatgcc cggatttcac 11880  
ccgccgagtt ttccaatgaa gcagatgacc ttcctcgacg ccgagtatgc cggtaagcgc 11940  
aaacagacc gcaaaagact gttcctgatc gagatggatc ggggtgggccc gtggaagggt 12000  
ttgattgcct tgatcgatcc gcattacccc aagggtgagg gtggcccgcc agcctatcca 12060  
ctgacggcaa tgctgcgggt tcatctgatg cataagtggg tcggctacag cgaccggcg 12120  
atggaggag cgctgtacga gacgaaccac ctgcccagc ttgccgggtt gagcctggag 12180  
cgcatcccg actaaaccac catcccacac ttcgccggc tgctggagaa acacgaacta 12240  
cctaccggca tcatgtttgc tgaatthtc cctttggctt tgagtgcggc attcaaccga 12300  
tacagggtgt gcatgacacg ccaaagaaat caaccttggc ggctagaaca cttgtcgatg 12360  
aagogaacaa tccgcaaacg ttaaggctac caggaaaaac ccaggatgcg gttagccgata 12420  
gcccgcgcbc gcattgtct ccttcctcc aagagtgtca aaggatattg gactaatgca 12480

-continued

---

```

gcatgcctcg accacatggc cgtgggtccgt tcatctgttg gccatacgtc tatcgaatcg 12540
gacgcgggcyg gcgacgacct cgggttgttg gcgttcggcc cagtcgatga gctcagtcag 12600
ggacggcatc agcgaagtcc cgagcggggt gagcccgtag cgcacagatg ggggtgtcga 12660
gggggttacc tcgcccaga tgagtccgtc gcgttcgagg tgacgcagcg tctcggtcag 12720
catccggcgc gaaatgtcgg gcacggcgcg ggccagcga ttgaatcgtt gcggaccctg 12780
cgacaaggty accaggatca gcgtcgac 12808

```

&lt;210&gt; SEQ ID NO 11

&lt;211&gt; LENGTH: 15024

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.

&lt;400&gt; SEQUENCE: 11

```

atcgtcctta agcggccgac gcagccgttt aagtgaattg ctgacggcag gctgcgtcag 60
ccccagtttt tcgcccggccg tcgatacgtc ccggtcgcagc agtagctggt tgaagaccac 120
cagcagattc aagtcgatgt cgcgcagatc catgatgcct caccattatt catgctggtg 180
attttaacta tcagacttga tctatagcgc tataccgacg gacgcgccag aatcgcagcc 240
attcggagac aactgaaaaa agagcttgca tggaaactggt agtagaacc ccaatttgc 300
atctgaacgc ggagaccggc agcaccctgc ttgacgtgct caggccaac gaggtcccca 360
tttcttatag ctgcattgctg gcccgctgcg gcaactgccc ttgccgtgtg attgccggcc 420
atcttcgcga taacggcccc gagacagggc gcccgcaggc aggaaagga acctacgttc 480
tggcctgtca ggcggttctg accgaagact gcacgatcga gattcctgaa tctgacgaga 540
tcgtggttca cccggcgcgc atcgtcaagg ggacggtcac agcgatagac gaagccacc 600
atgacatccg gcgcctgcgc atcaactgg ccaaaccgct tgagttcagc cctggccagt 660
acgcaacggt gcagttcacg cccgaatcgc tccgccata ttcgatggcc gggctgccta 720
gcgatcggga aatggagttt cagattcgcg cggttccggg cgggcatgct agcaactacg 780
ttttcaatga actgtccgta ggcgcttcg tgcggatcag cggccccctc ggaacggctt 840
atctgcggcg cacgcacacc ggccccatgc tttgtgtggg ggggtggaaca ggtctggcgc 900
ccgtcctttc gatcgttcga ggcgcactgg aaagcgggat gagcaacccc atccatctgt 960
acttcggtgt gcggagcgag caggacatct atgacgagga acgccttcac gcattggctg 1020
caaggtttcc gaatctcaag gtgaatgtcg ttggtgcaac aggccctgcc ggcctggtc 1080
gtcgatccgg cctggtcacc gatctgatcg gccgtgactt gcccaatttg gcgggatggc 1140
gcgcctacct gtgtggcgct ccggccatgg tcgaggccct gaacctgctc gttgctcgcc 1200
taggcatagt acccgggac atccatgcg atgcgttcta tcccagcggc gtctgagcga 1260
aggcaccatg cgaacccaat tcaacccaag gataccaagc catgagtga ccccaacgat 1320
taaaacccgt gtttcccaa gatccgaaat ggccgggcca aggtagcagc cgcgttcct 1380
tctgggccta caccgcgaa gacctgtaca agcgcgaatt ggagcgcctg ttctatgcaa 1440
accactgggt ctatgtaggc ctggaagccg agattccgaa tccagcgcac ttcaagcga 1500
cggtgatcgg tgagcgtcgc gtcacatcgg tgcgtgatcc ggatggcggc atcaacgtgg 1560
tggaagacgt ctgcccacc cgtggcatgc gcttttgccg cgagcgcacc ggcaacgcca 1620
aggacttctt ctgccctac caccagtgga actacagcct caagggtgac ctgcagggcg 1680

```



-continued

---

tgcccttccg	ccgtggcgtc	aagcaggacg	gcaaggtcaa	cgccggcatg	cccaaggact	1740
tcaaactcga	agaacacggc	ctgaccaagc	tcaaggtggc	cgcccagggc	ggtgcagtgt	1800
ttgcctcttt	tgaccacgat	gtcgagccct	tcgaggagtt	cctgggcccc	accatcctgc	1860
attacttcga	ccgcgtcttc	aacggccgca	agctcaagat	cctgggctac	cgccgccagc	1920
gcatcccggg	caactggaag	ctgatgcagg	agaacatcaa	ggacccttac	caccggggcc	1980
tgctgcacac	ctggttctcg	accttcgggc	tctggcgcgc	cgacaacaag	tcggaactga	2040
agatggacgc	caagtccgcg	cacgcccga	tgatctccac	gcgcggtcag	ggcggcaaga	2100
acgaggaggt	cgtgtccggc	gtggacagct	tcaaggaaca	gatgaagggtg	aacgaccgcc	2160
gcctgctcga	catcgtgccc	gagccctggt	ggggcggfcc	gactgcggtg	atgaccacga	2220
tcttccccag	cgtgatcctc	cagcagcagg	tcaacagcgt	atcgaccgcc	cacatccagc	2280
ccaacggcca	cggtctcttc	gatttctgtc	ggaccactt	cggtctcgag	gacgacaacg	2340
aggagtggac	ccagcggccc	ctgatccagg	ccaacctggt	cgggccggcg	ggcttctgtg	2400
cgcccgatga	cggcgagggt	atcgagtgtg	cgcaggaagg	ctttgagcaa	aaaccgacgc	2460
accgcaccgt	gatcgagatg	ggcggtcacg	aaatcggcga	cacggaccac	atggtcaccg	2520
agacgctgat	ccgcggcatg	tacgactact	ggcgaagggt	gatgggggaa	taaactggtg	2580
cgacttcaaa	acctatttgc	aactgctgaa	cctgtacagc	gactacgcca	tggtgtgcga	2640
ctccgccaat	tgggagaagt	ggcctgattt	cttcatcgag	accggcacct	accgcctgca	2700
gccgcgcgag	aactttgagc	agggcctgcc	gctgtgcctg	ctggcgtggg	agagcaaggc	2760
aatgatccgc	gaccgggtgt	acggcgtcaa	ggaacctatg	taccacgacc	cctactacca	2820
gcccacacac	gtgggcacgc	cgccgctgct	gtcagtggag	cgtgacgcgg	atggcgagcg	2880
catcaccgcc	gaagccagct	atgccgtgat	tcgcaccaag	tacgacggcg	attccacgat	2940
tttcaacgcc	ggctattacc	gagacgtgat	cgtgcgcacg	cccgagggcc	tcaagctgaa	3000
gtcgcgcctg	tgcgtttacg	acagcgaaat	gatccccaac	tctgtgatct	atccaatctg	3060
aggcgacgca	catgactcag	aactggattg	atgcagcttg	tcttgacgac	atccctgaag	3120
gcgatgtggt	cggcgtcaaa	gttaacggca	aggaaattgc	gctctacgag	gtcgaggggg	3180
agatttatgc	caccgataac	ctgtgcacgc	acggcgtgct	gcgcatgagc	gatggctttc	3240
tcgaaggccg	gaaattgaa	tgccctctgc	accaaggtcg	atgtgatgtc	tgacacaggca	3300
aagccttggt	cacccccctg	acaaaggaca	tcaaaaccta	cccgtcaaa	attgaaaaca	3360
tgccgctgat	gctcaaaatg	gagtaagact	gctttcaatc	aggaggctga	attcggacca	3420
atcaaccaaa	ccatccaatc	caccatttag	ccaaaaaacg	gagacattaa	tcatgattta	3480
tgaaaatttg	gtgagtgaag	cagggctgac	gcaaaagcac	ctgattcatg	gcgacaaaga	3540
acttttccag	cacgaattga	agaccatctt	cgccgaaaac	tggttttttc	tgaccatga	3600
cagcttgatt	ccctcccccg	gcgactatgt	cacagccaaa	atgggtgtcg	atgaagtcac	3660
cgtctccgcg	cagaacgatg	gctcggctgc	agcctttttg	aatgtttggc	gtcaccgggg	3720
caagacacta	gttcacgctg	aagccggaaa	tgcgaaaggc	tttgtgtgca	gttaccacgg	3780
ctggggcttt	ggctccaacg	gcgaactgca	aagcgttccc	tttgaaaaag	agttgtacgg	3840
cgatcacgatc	aaaaagaagt	gcctgggctt	gaaagaagtc	cccgcacatg	aaagctttca	3900
tggttctcatt	tacggttggt	ttgatgcaga	ggccccacg	cttgtcgatt	atctgggtga	3960
tgacgcctgg	tacttagaac	ccatcttcaa	gcactctggt	ggcctggaac	ttgtaggccc	4020

-continued

---

ccccggcaaa	gtggtgatca	aggccaactg	gaaggctcct	gcgaaaaact	ttgtgggtga	4080
cgcgtaaccac	gttggttgga	cgcacgcatac	gtctttgcgc	tcaggtcagt	cgatatttac	4140
ccctcttgcg	ggcaacgcta	tgcttccacc	cgaaggcgcg	ggcttacaaa	tgaccagcaa	4200
gtatggcagt	ggaatggcg	tattgtggga	cggctactcc	ggtgtccaca	gtgctgacct	4260
ggttcccga	atgatggcat	tcggcggcg	aaaacaggaa	aaactcgcca	aggaaatcgg	4320
cgatgtccgg	gcacggat	accgcagcca	tctaaactgc	acggttttcc	cgaacaacag	4380
cattttgacc	tgctccgggt	tcttcaaggt	ctggaacccg	atcgatgaaa	acacgaccga	4440
ggtttggacg	tatgccatcg	tagaaaaaga	catgcctgag	gacttaaagc	gtcgcctggc	4500
tgacgcggtt	cagcgcactg	tcggaccacg	aggattctgg	gaaagcgacg	acaacgacaa	4560
catggagacg	gagtcgcaaa	atgccaaaga	ataccaatcc	agcaacagtg	atctgattgc	4620
caatttggtt	ttcggcaagg	acgtctacgg	cgacgaatgc	tatccggggc	tcgttgccaa	4680
atcggcaatc	ggcgaacca	gctatcgcgg	attctaccgt	gcctaccagg	ctcacatcag	4740
cagctccaat	tgggcccag	tcgaaaaac	ctcccgaat	tggcacaccg	aactcaccaa	4800
gacgactgat	cgtaatacca	ggagccaacc	atgatgatca	ataccagga	agacaagctg	4860
gtctccgcgc	acgaccccga	agaatttcat	cgtttcttcg	tcgggcacga	cagcgatctg	4920
cagcaagaag	tcaccacact	cctgaaccga	gaagcacatc	tggtggacat	tcaggcctac	4980
aacgcctggc	ttgaacactg	cgttgcccc	gagatcaaat	accaagtgat	ctcgcgagaa	5040
ttcgggtcca	cttccgagcg	tcgatacca	ctgaatgatg	cgggtgaacat	ctacaacgag	5100
aaactatcagc	acctgaaagt	tcgagttgag	catcagatgg	accgcagaaa	ctgggccaac	5160
agcccgaaga	tcggtttcac	ccgcttcgtc	accaatgtca	cagcggccaa	ggacaagatc	5220
gtaccggatc	tgctgcatgt	gcgttccaac	ctcattctcc	accgcgccag	acgcggcaat	5280
caagttgacg	tcttctatgc	aacgcgggaa	gacaaatgga	aacgcacgca	aggtggtggc	5340
atccaactgg	tggaactgct	tgtggactac	ccggagcgca	ttctccagac	ccacaatctg	5400
atgaccttcc	tgtgaacctt	gggatgcct	gccttgatgg	cggtcacoc	tgattgtttt	5460
aaacagaaat	ttattgccat	gaacatacag	caagttattg	ccattactgg	cgcoggttca	5520
ggcatcgggc	tggaactggt	tcgatccttc	aaagcagctg	gctattgctg	gtccgcactt	5580
ggttcgaacg	aggaacaaga	ggcgggcctt	cgcagtgaat	tcaaatgatc	cattgagatc	5640
gtagcgggcg	atgtttgta	tcacgccacc	aatgaaaagc	tggtcaacaa	ggcggtcgcc	5700
aggttcggac	acctcgactg	cttcatcgga	aatgccggga	tatgggatta	catgctgggc	5760
gtcgcagagc	catgggagaa	attatccg	agtttcgagg	agatatttga	tatcaacgtc	5820
aaaagctatt	tcagcggcat	cagcgcggcc	tgcccggaac	tcaaaaaaac	gaacggatcg	5880
gtcgtagtga	cggcttccgt	ttcttctat	gcggccggcg	gcggcggtc	ttgctacatt	5940
gccagcaagc	atgcagtgtc	gggtatggtc	aaggcgttgg	cctacgaatt	ggccccgac	6000
atccgggtca	atggcgttgc	gccaggtggt	acggtcactt	ctttggctgg	gccggcaagc	6060
gccggtttcg	acaaaaccaa	aatgaaagac	atgcccgga	tcgatgacat	gatcaagggc	6120
ctgacccctt	tggggttcgc	agcaaggccc	gaggacgtgg	tggcaccgta	tcttttgctg	6180
gcctcccggg	aacaagggaa	gttcatcact	ggcaccgtaa	tcggcattga	tgogggcatg	6240
gcgctcggtc	gaaagtgaat	tttcaatcaa	atcagatttt	tcaaccccat	tcccaggaga	6300
caaccatga	agacgaaatt	gttcatcaac	aacacctgga	gcgcttcgag	tgacaaaaag	6360
tcattcgcac	gcaagcacc	tgtcagtg	gaggtcgtga	ccaatgcgc	gaacgccacc	6420

-continued

---

gtggacgatg	cggatcaatgc	ggctcgagcc	gctcaagagg	cgttcaagtc	ctggaaggcc	6480
gtcggaccct	cggagcggcg	gcgccttctt	ttgaagggtg	cagacgtcat	ggagagcaaa	6540
acgcccagat	tcacgaagt	gatggccaag	gaagtgggag	cctccgcgct	gtgggcgggg	6600
ttcaacgtgc	acctgtcggc	caatgtattc	cgggaagccg	cctcactggc	cacccaatt	6660
caaggcga	ccattccgac	ggacaagcct	gacaccctgt	caatgacgct	gcgtcacgct	6720
gtcggcccca	tcttgagcat	cgttcctctg	aacggcaccg	ccgtgctcgc	ggcgcgggcc	6780
atcgcttate	cgctggtctg	cggcaatacc	gttgtgttca	aaggctccga	gttcagcccc	6840
ggtagcagc	ctttgatcac	caagtgcctg	caggaggccg	acctgcctgc	tggcgtgctc	6900
aactatctga	actcctcccc	ggaccggtcg	cccgatattg	cagatgcgct	gatttcgtct	6960
aaagagattc	gtcgcataca	cttcacaggc	tccactcgcg	tggggcgcac	catcgcgccag	7020
aaatcgccc	agcatctcaa	gcgctgcttg	ctggagttgg	gtgaaaagtc	cccgctgac	7080
gttctggacg	acgtgacat	cgacgcggca	gtcaaggccg	cgggtgttcg	cagcttctctg	7140
ttccaaggcc	agatctgcat	gtccaccgaa	cgctggttgg	tcgacgaaaa	gatcgcggac	7200
gaatttctgc	cgaagtctgt	cgagaaaacc	aagcagttga	gcgcaggcga	tccatgcgtc	7260
acaggggact	gcatcatcgg	cccgatggtg	tcgccaact	cgggtgaccg	aatcaatggt	7320
ctgttcaaa	atgccatcag	caaggcgccc	aaggtcgtgt	gcggcggcat	cgccgagggt	7380
gcggtcatgc	ccgccagat	cttgaccac	gtgacagccg	acatgcagat	ctacgatgag	7440
gaaaccttcg	gtccatcac	tgtggttate	cggtgcaaga	gcgaagcggg	cgccatccgc	7500
attgccaatg	acagcccta	cggcctgtca	tcgggcgtgt	ttggccggga	cgtgaaccgg	7560
gctctgcgcg	tgggcatggc	gatcgaatac	ggctcggctc	atatcaacgg	ctccaccgta	7620
cagaacgagg	ctcagcgccc	ttatggcggg	acaaaggcca	ccggttatgg	ccgcttcgac	7680
ggacgcgcg	tgatcagcga	gttcacggaa	ctcaagtggc	tgaccattga	accattcgag	7740
cagcagatc	ccttctaagc	tgaagcaaca	aaggagttaa	accatgaaca	agccagcaac	7800
tgctattgaa	ttggggtaca	tgggcatttc	ggtcaaggat	cccgcagcgt	ggaatcctt	7860
tgccgaaaac	atgctgggac	ttcaagtcct	cgatgagggt	gacaaggatc	gcttctatct	7920
gcgaatggac	aattggcacc	atcggatcgt	ggttcacac	aacggtcaag	atgaccttga	7980
atacctgggc	tggcgtgtcg	ccggtcaacc	ggaattcgag	gcattgggtc	aaaagctcgt	8040
ggacgcaggc	tacaaagtcc	gcgtgtgcga	caaagccgaa	gcacaagaac	ggatggtgct	8100
gggctgatg	aagacagaag	atccgggggg	caaccgacc	gagattttct	ggggacccc	8160
gattgacctg	aacaaccctt	tccatcccgg	tcgtcccttg	cacgggaaat	ttctaaccgg	8220
tgatcagggc	ctgggccact	gcacgtgtcg	tcagaacgat	gttgaagcgg	cacgtaagtt	8280
ctatagcttg	ctgggatttc	gtggagatgt	cgagtaccgc	cttcctttgc	ccaacggcat	8340
gacggctgag	ttgacgttca	tgcattgcaa	tgctcgcgat	cattccatcg	ctttcgtgtc	8400
aatgcctgcg	gccaagcgcc	tcaatcatct	gatgattgaa	tacactcata	tcgaagattt	8460
gggttgca	caccagcttt	tcacgaagga	aaagattgac	attgccttgc	aattgggcat	8520
ccattccaac	gataaggcgc	tgacgttcta	cggggcaaca	ccttcggct	ggctgataga	8580
acctgggtgg	cgaggcggcc	cgccattgc	tgaatcgaa	tattacgtcg	gcgacatttt	8640
cggccacacc	atcagggcca	ccggttatgg	attggacgtc	aaactgagct	agccatgtaa	8700
cagatgcgaa	atcagtcgca	tctgttttcc	ccattcagtt	ccatataaaa	aaaaggagac	8760

-continued

---

aatgatgac	aaagaagcca	tttcctcgc	aggacttggg	atgctgatgc	tcagcaccgc	8820
atatgccag	gattcccgtt	ggtcatatcg	catcggcgcc	accaacgtag	ccttcgatgc	8880
gagcgccaaa	gtttcgattg	acggaacaag	ggtgccgggt	ggaagcgtg	acgccagtga	8940
caacaacgct	ttgacatttg	acttcggtta	catcattaac	gataactgga	acgcgcgatt	9000
aattgttggc	attccaccca	ccacaaaagt	gacggggcga	ggcacgctgc	ctccgatttt	9060
gctgggccgt	gtccaatatg	ctcctgcagt	tttgtcggcg	acctacaacc	tgccacagat	9120
gggattggtt	cgcccgtacg	tggggcgggg	gatcaactac	actcgaattc	tgaaaagcaa	9180
agatgccaat	ctgacctcat	tcgatgcaga	tcatgcgtgg	gcacttgtgc	tcacatcgg	9240
tgagaagcg	aacatcaacc	gcgactggtt	cgtcagcttt	gatatccgaa	aactttatct	9300
aaaaacagat	gcatcggggt	ttcttgggcc	tcaagttgct	acagcccgcg	taacgttgaa	9360
tccgctgctg	acgtcgattg	cgattggccg	gagatttga	tcggtccaca	ttgattccaa	9420
aattctgttt	gcatcaccat	tttcaaagga	aatttgaatg	acaagaaaga	cgagcaaagc	9480
ggtgcgcctg	accgcccgcg	atattcaag	cgcatgggtc	atcatgccga	ccccgtccac	9540
gccggatgcc	tcggactggc	gcagcacgca	cacggctgat	ctcgacgaga	cgccccgat	9600
tgtcagggag	ttgattgcgg	ccggcgtcaa	tggcattctg	agccacggca	cctttggcga	9660
atgcgcgacg	ctgacgtggg	aggagaagcg	ggattttggt	tcaacggctg	tggaaaccgc	9720
gcgcggtcga	gtgccctact	tctgcggcac	aacggccttg	aataccctg	aagtcatacg	9780
ccagaccgcg	gaattgatcg	acattggcgc	ccaaggaaca	atgctcggcg	tgccgatgtg	9840
ggtgaagatg	gatctgccta	ctgccgtgca	attttatcgc	gatgtggcgg	aagcagtgcc	9900
agatgcagcc	atcgctgtct	acgccaacc	ggaggctttc	aaatttgatt	ttcctcgc	9960
gttttgggcc	gaaatgtcca	aaatcccga	ggttgcaca	gccaaact	tgggcatcgg	10020
gatgctggac	ttggatctga	aattggcccc	aaatattcgc	ttccttccgc	atgaggatga	10080
ctactacgct	gcggcccgga	tcaatcccga	gcgcatgact	gctttctggt	ctagcggttc	10140
catgtgcggc	ccagcgaccg	cccttgtgct	gcgcgatgag	gtggtaaagg	ccaaaatac	10200
aggtgatttg	gccaaagcca	aggetatttc	agatgacatg	cgcgagccg	atgccacact	10260
gtttccacgc	ggcgatttct	cggaattctc	aaaatacaac	attggcctcg	aaaaagcacg	10320
aatggacgag	gcccgtggc	tcaaggcggg	gccgtgcgg	ccaccctata	cgtggttcc	10380
cgacgaatac	cttgacggtg	ccgaaaatc	aggcaaggcc	tggccgcac	tgcataccaa	10440
gtatgccaa	gaattgagga	aaacaaaac	ggcaaccaac	tcgaaaaga	agtaagtcca	10500
ggcctgag	cagacatctc	cgatcagcac	aacctgctga	tctggagggt	ttctggatta	10560
gtgcagtcgg	cgagttaaaa	atatgccagt	acagagtgga	agcgcacaa	gcgcaggg	10620
caccgatcgc	cctgaagcaa	tctcacacta	ttgccatctt	ctctttgttg	ggagtgcatt	10680
atcgtgatgg	tcgattttta	tttcgatttt	ttgagcccat	tttcgtatct	ggccaaccac	10740
cgtttgcgg	tgctcgcggg	gcggttatgga	ttctccatcc	agtatcagc	cattgatttg	10800
gcgcgagcaa	aaacggccat	tggcaacatc	gggcatcca	atcgggacct	caaggtcaag	10860
cttgactact	taaagggtgga	tttgacgca	tgggcccgatc	tctataggat	tccgttgggt	10920
ttcccccta	acttcaacag	ccgcccgggtg	aatgccggac	tgtattaacc	ggcagccagg	10980
gagcgagccg	ctgaatatgt	tcgccttgtt	ttcgattcgg	cttgggggaa	aggggtggca	11040
ctggatgctg	atagcttctg	ggctgaggtg	tgcgacaagc	taaactggga	tctcgtgtaa	11100
tttgaagatt	ttttgaacag	cgaaaatgcc	gccaaggcat	acgacgaaga	gacgcagggc	11160

-continued

---

gccattgacc gaaaggtttt cggggttccc accgtgtttt gggatgatca aatgtggtgg 11220  
 ggaaatgacc gccttttcat gcttgagagc aggttgcaaa aggaaacgca accataaatt 11280  
 ctcagtgcac cgatTTTTct gatTTTTcaa ccacgccttg attttaagga gtctcatgaa 11340  
 gctttattac agccccggcg catgttcacg gtcgcctcac atcatccttc gtgaaggtgg 11400  
 atttgacttt cagctagaaa aggttgatct cggcaccaag gtgactgaga ctggtgttga 11460  
 ttacaagacc gtcaatcccc tgggcagtgt ccccgctttg caaatggatg atgggcaggt 11520  
 gctcaccgaa gggccggcca tcgttcaata cctcgctgac cgtgtgccag aaaaatgcct 11580  
 ggcaccggca gctggtctgc tggagcgtta ccgactgatg gaatggctga atttcatctc 11640  
 caccgaattg cataaaagct tcggagcgtc gttcagcccc gtgtttccac aggatgccaa 11700  
 gccagtcatc aaggcccaat tggaaagccg tcttgcccat accgagcaga tgctcgggtga 11760  
 caaggtttgg gccatgggga acgacttttc cgtggtggac gcctacttgt ttactgtgct 11820  
 tggctggggg gcttacgtga atgtggacct ttcgccttgg cccggcctgc aaggctacct 11880  
 caaccgcgtg gctgaacgtc cagcagtcgc ggccacattg tcggctgaag gtttgatctg 11940  
 atTTTTtag agaaataaat aaagcatggc cagcctccat gagcggccag ccatgccgcg 12000  
 gggcagccgt gggcagcgcg ctcgatcaaa tttcgatgca cacagattac gagccccctt 12060  
 ttccgactgc ggtcggattc agaaattgcc gatacttgct ttggtctgat cgaagcgtga 12120  
 gggatatacg cttccccat ccacatgctt gatgaagagg agcgtatcac catgagtcac 12180  
 gaacttggcc gactggaaga cctgcgcgag gactaccgag acgaactcaa acaacttaac 12240  
 ctggtgccgc tatggcccag cctacgcgcg gtgctgccgc ccaatgtccc gaccgccag 12300  
 acgcagccga cttactggtc ctaccagacg ctcaagccgc tgctgtcaa ggcgggtgag 12360  
 ctgaccccca ttgagaaggc cgagcgcgcg gtgctggtgc tggccaaccc cggccacggc 12420  
 ctggagaaga tgcaagccag cgcgccata tacctgggca tgcagttgct gctgcccggc 12480  
 gagtggggcg ccagccaccg ccacaccccc aacgcggtgc gcatgatcgt ggagggcgag 12540  
 gggcctaca ccaccgtgga tggcgagaag tgccccatga gccggggtga cctcactctc 12600  
 acgccaccg gcctgtggca cgagcacggc cacgacggca acgagcccgt ggtgtggtc 12660  
 gatgtgctgg acctgcccgt ggtgtactac atggaggcca gctaccacat cgaocggcgag 12720  
 cgccagcagc tcgacccccg cggggcgac tgcgcctgga cccgtgcggg cgtggtgcca 12780  
 acccccgtgt tccagcgcg cgacaagcgc tatcctctct tgcgctaacc ttgggccgac 12840  
 accogtgccc ccctgctgtc gctggogccc gaccagcctg agcaggaatg cgtgcaggtc 12900  
 acctacgtca accccgaaac gggtgacgac gccgagaaca tcctgggctt ctacgcctc 12960  
 atgtcaagc ccggccagac cctgcgcctg cccgtgcgtt cgcgcccgct ggtgttccac 13020  
 cagatcgaag gccgcagcga ggcgcgcatc gccgagtcca ccttcgcctt gaggaagcc 13080  
 gatacctgct gcgccccgg ctacaccgag gtgacgctga aaaacctctc agccgaccag 13140  
 ccgtccttca tcttcatggc cgacgaatcg cccctgcacc gcaagctggg cgtctttgaa 13200  
 aaccgcggtc gagccggcgc gaagcaccac acaacaggaa agcaagtgag caactactc 13260  
 tggaaacccg ctcctgtcca gtctctgccc gttcgtggca agaccgagcg cttcccctc 13320  
 aaccgcatct tctgctcggc ccgcaactac cacgcccacg cggtggaat gggccgtccg 13380  
 gtcgacaaaa gcgtcgaaca agcgttctac ttcacaaat cgcacaaac cctggtgaa 13440  
 agtggcgca ccgtggccta cccgcgcgcg accagcaact accactacga gatggagctg 13500

-continued

---

```

gtgtggcgca tcggcaagcc cggcttccgc gtcagcgaag accaggcgca cgagttgatt 13560
tacggctacg ccgccggcct ggacatgacc cggcgcgacc tgcaactggt ggcacgcgac 13620
aagggccgcc cctgggacac cggcaaggac atcgaggaag gctcggctctg ctccgagatc 13680
gtgccgatgc aaggcgtggt ggtggagcag ggcgcgatcg ccctggaagt caacggccag 13740
accaaacagt cgtccaacgt ggacaagctg atctggaacg tccgcgagat cattgcccac 13800
ctctccacct actaccactt gcaaccgggc gacctgattt acaccggcac gcccgaaaggc 13860
gtgggcgccc tgggtggcggg tgacaagatc atcggccgtg tggaaaggcat tgccgagatc 13920
agcctgaccg tcggcccggc cgagttagcc tgcacgcgat gaagctgtac aacttctggc 13980
gcagcggcac gtcacaccgg ctgcgcatcg cgctcaacct caaggcgtg ccctacgagt 14040
acctggccgt gcacctgggc aaggaagagc acctaaagga cgccttcaag gcgctgaacc 14100
cacagcagtt ggtgcccgcg ctggacacgg gcgcgcaagt gctgatccag tcgccggcca 14160
tcacgaatg gctggaggaa cagtacccca cgcccgcgct gctgccggcc gacgccgacg 14220
gccccaacg ggtgcgcgcg ctggccgcca tcgtgggctg cgacatccac cccatcaaca 14280
accgccgat tctggagtag ctgcaaga cgctcggcgc cgacgaggcc gccatcaacg 14340
cctggtgtgg cacctggatc agcgcgggtt tcgatgccta cgaagcactg ctggcggctg 14400
acctgaagcg cggccgctac agctttggcg acacaccac gctggccgac tgctacctgg 14460
tgccgcaggt gaaagcgccc cgcgccttc aggtggacct gacgccctac cccctgatcc 14520
gcgcagtgga cgcggcctgc ggcgagttgg acgcatttcg gcgcgccg cgagctgctc 14580
aacctgattc ggcttgacga aaaatacgcc gccttcgccc taataaacag ttcgtagccc 14640
tgcccagtga caagtatcaa tgagcaatag tgaaaatgta aggggaaaga ttatgaaaca 14700
tattctgacc cgacgagcag ccctgagcac tttgggctcc cttggaatcg ggggccttc 14760
ggcagatgag ttggcgaat ccggccctgg cgtggccacg atcgtgattg gactcggcgc 14820
aggcggagcg accgatatgg ctgcccgccg gttgtctgag ggaatgcgcg gtgcctatgc 14880
ttccagtgct ctcgtcgaca accgcacggg ggcgggtggt cgaattgcga tccagcatgt 14940
taaggccgcg gcaccaaagc gcgcgacct tctgctgacg cctgcatcca tgatgacgct 15000
ataccctcac acgtacaaaag atct 15024

```

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 4912

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

```

<223> OTHER INFORMATION: A modified DNA molecule encoding valine at the
position corresponding to the F352 amino acid in
NDO.

```

&lt;400&gt; SEQUENCE: 12

```

gagctcgttg cgcaagcgct tccatcagtg ggggcatgaa gtacatctcg ccgatgtcgg 60
tcattgccaa gttgaagggt gcgctgctgg caaatgggtc gaaagagtca cgggtcgtca 120
gtgccgtctg cagcgtggtg agcgcataga ccacgggctc cgcaagatgc agtgcatatc 180
gtgtcggctc catgcctttt gaggtgcgca agaacaaatc gtccttttagc gccgcacgca 240
gccgtttaag tgaattgctg acggcaggct gogtcagccc cagtttttcg ccggccgctg 300
atacgctccg gtcgagcagt agctggttga agaccaccag cagattcaag tcgatgtcgc 360
gcagatccat gatgcctcac cattattcat gctggtgatt ttaactatca gacttgatct 420
atagcgctat accgatcgac gcgccagtat cgcagccatt cggagacaac tgaaaaaaga 480

```

-continued

---

gcttgcatgg aactggtagt agaaccctc aatttgcac tgaacgcgga gaccggcagc	540
acctgcttg acgtgctcag gtccaacgag gtccccattt cttatagctg catgtcgggc	600
cgctgcggca cttgccgttg ccgtgtgatt gccggccatc ttcgcgataa cgctccgag	660
acagggcgcc cgcaggcagg aaagggggcc tatgtcctgg cctgtcaggc ggttctgacc	720
gaagactgca cgatcgagat tcctgaatct gacgagatcg tggttcacc gccgcgcac	780
gtcaagggga cggtcacagc gatagacgaa gccaccatg acatccggcg cctgcgcac	840
aaactggcca aaccgcttga gttcagccct ggccagtac caacggtgca gttcaccgcc	900
gaatgcgtcc gccctattc gatggccggg ctgcctagcg atgcggaat ggagtttcag	960
attcgcgcgg ttccggcgcg gcatgtcagc aactacgttt tcaatgaact gtcctagggc	1020
gcttcggtgc ggatcagcgg cccctcggg acggcctatc tgcggcgcac gcacaccggc	1080
ccatgcttt gtgtgggggg tggaacaggt ctggcggccg tcctttcgat cgttcgaggc	1140
gcactggaaa gcgggatgag caaccctac catctgtact tcggtgtgcg gagcgagcag	1200
gacatctatg acgaggaacg ccttcacgca ttggctgcaa ggtttccgaa tctcaagggtg	1260
aatgtcgttg ttgcaacagg ccctgccggc cctggtcac gatccggcct ggtcaccgat	1320
ctgatcggcc gtgacttgcc caatttgcg ggatggcgcg cctacctgtg tggcgctccg	1380
gccatggtcg aggcctgaa cctgtcgtt gctcgcctag gcatagtacc cgggcacatc	1440
catgccgatg cgttctatcc cagcggcgtc tgagcgaagg caccatgcca acccaattca	1500
acccaaggat accaagccat gagtgaaccc caacgattaa aaccctgtgt tcccaagat	1560
ccgaaatggc cgggcgaagg tagcagccgc gttcccttct gggcctacac ccgcgaagac	1620
ctgtacaagc gcgaattgga gcgcctgttc tatgcaaacc actggtgcta tgtaggcctg	1680
gaagccgaga ttccgaatcc aggcgacttc aagcgaacgg tgatcgggtg gcgctcggtc	1740
atcatggtgc gtgatccgga tggcggcac aacgtggtgg agaacgtctg cgcccactgt	1800
gggatcgcct tttgccgca gcgccacggc aacgccaagg acttctctg cccctaccac	1860
cagtggaact acagcctcaa gggtagcctg cagggcgtgc ccttccgcc aggcgtcaag	1920
caggacggca aggtcaacgg cggcatgccc aaggacttca aactcgaaga acacggcctg	1980
accaagctca aggtggccgc ccgagggcgt gcagtgtttg cctctttoga ccaogatgtc	2040
gagcctttcg aggactgtgc gtgtacgaca gcgagatgat ccccaactcc ctcatctacc	2100
ccatttgagg ttgcagaaca tgtccgagaa ctggattgat gccatcgac gggacgctgt	2160
gcctgagggc gatgtggtcg gagtcatcgt ggcaggcaaa gacattgctt tctatgaggt	2220
ggaaggtgag gtcttcgcca ccgacaactt gtgtaccac ggggctgccc gcttgagcga	2280
cggctttctc gaaggccggg aaattgaatg tcctttgcat caaggccgat tcgatgtttg	2340
cacgggtaaa gccttgtgca caccctgac acaggacatc aaaacctacc ccgtaaaaat	2400
cgaaaacatg cgcgtgatgc tcaagctgga ctaaaactct ttgcaggagg aaagccaaat	2460
ccggaaatca cccaccctca cccaatcact acccgtttcc aaacaagagg agataagcaa	2520
ttatgagtta ccaaaactta gtgagtgaag cagggctgac gcaaaagctc ctgattcatg	2580
gcgacaaaga acttttccag cacgaattga agaccatctt cgcgcggaac tggcttttcc	2640
tgacctatga cagtctgatt cctccccgc gcgactatgt cacagccaaa atgggcgtcg	2700
atgaagtcat cgtctccccg cagaacgatg gctcgggtcg agcctttttg aatgtttgcc	2760
gtcaccgggg caagacacta gttcacactg aagccgaaa tgcgaaaggc tttgtgtgcg	2820

-continued

gctaccacgg ctggggctac ggttccaacg gcgaactgca aagcgttccc ttgaaaaag	2880
agttgtacgg agatgcgac aaaaagaaat gcctgggctt gaaagaagtc ccccgcatcg	2940
aaagctttca tggctttatc tatggctgtt ttgatgcaga agtcccccg ctcatcgatt	3000
atctgggtga tgcagcctgg tacctggaac ccaccttcaa gactctggt ggcctggaac	3060
ttgtaggccc ccccgcaaa gtggtggta aggccaactg gaagcctttt gcggaaaact	3120
ttgtagggtga catctaccac gttggttga cgcacgcagc ggctttgcgc gcagggcagt	3180
cggatattag ttctcttgcg ggcaacgcta agcttccacc cgaaggcgcg ggcttgcaaa	3240
tgaccagcaa gtatggcagt ggaatgggct taacgtggga ctactactcc ggtaacttca	3300
gcgctgatat ggttcccgat ctgatggcat tcggcgcgcg aaaacaggaa aaactcgcca	3360
aggaaatcgg cgatgtccgg gcacggattt accgcagcat tctgaacggc acggttttcc	3420
cgaacaacag ctttttgacc ggctcogeta ccttcaaggc ctggaacccg atcgatgaaa	3480
acacgaccga ggtttggagc tatgccttcg tagaaaaaga catgcctgag gacttaagc	3540
gtcgttggc tgacgcggct cagcgcagtg tcggaccagc aggattctgg gaaagcgcg	3600
acaacgaaaa catggagacg ttgtcgcaaa atgccaagaa ataccaatcc agcaacagt	3660
atcagattgc cagtttgggt ttcggcaagg acgtctacgg cgacgaatgc tatccggcg	3720
tcgttggcaa atcggcaatc ggcgaaacca gctatcgcgg attctaccgt gcctaccagg	3780
ctcacatcag cagctccaat tgggccgagt tcgaaaatgc ctcccgaat tggcacaccg	3840
aaactaccaa gacaactgat cgctaatacca ggagccaacc atgatgatca ataccagga	3900
agacaagctg gtctccgcgc acgacgccga agaatttcac cgtttcttca tcgtacaaga	3960
tgatgacta ctgcaagaag tcaacacgct cctgaccgcg gaagcgcacc tgctggacat	4020
tcaggcctac aaagcctggc ttgaacactg cgttgcccc gagatcaaat accaagtgat	4080
ctcgcgagaa cttcgtctca cttccgagcg tcgataccaa ctgaatgatg cgtggaatct	4140
ctacaacgag aactatcaac agctgaaagt tcgagttgaa caccagatgg atcctcagaa	4200
ctgggccaac aaccggaaga tccgcttcac ccgcttcgtc accaatgtca cggcggccaa	4260
ggacaagagc gcaccgaaa tgctgcatgt ggggtccaac ctattctcc atcgcgccag	4320
acgagaaaa caagttgacg tcttctatgc aacgcgtgaa gacaaatgga aacgcacga	4380
agggtgtgt atcaaatgg tcgaacgctt tgtggactac ccggagcga ttccccagac	4440
ccacaacctg ttggtcttcc tgtgaacct ggggatgcct gcctggatgg cggcattcg	4500
tgattatatt taacagaaat ttattgccat gaacacacag caagttgttg ccatcactgg	4560
cgccgctcg ggcattggtt tcgagttggt tcgctctttt aaggcagccg gttatcgcgt	4620
atctgcactc gttcgcacg aggagcaaga ggcgggtcct cgcagtgaat tcaaagacga	4680
cattgagatc gtggcgggag atgtccgtga tcacgccacc aatgagaagc tggtaaaca	4740
gacggttgc aagttcgggc gcctggattg cttcatcgga aatgccggga tatgggatta	4800
catgctgagc atcagatgat cttggggaaa attctcgggc agtttcgacg agatatttga	4860
catcaacgtc aaaagctatt tcagcggcat cagcgcggcc ttgcccggagc tc	4912

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 6779

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: A modified DNA molecule encoding valine at the position corresponding to the F352 amino acid in NDO.



-continued

&lt;400&gt; SEQUENCE: 13

atgcatacgt agcggtaggc aaagagggcg cgctggaaga atccggctctg tagctctggc	60
agaagaccga aggcgagatc aaccgcaccg gactccatat cctccttcag attgccagca	120
ttcgggcatga gctgctgat ctggatgtga ggagctcgtt gcgcaagcgc ttccatcagt	180
ggggcatga agtacatctc gccgatgtcg gtcattgccca agttgaaggt gcgcgtgctg	240
gcaaatgggt cgaagagatc acgggtcgtc agtgccgtct gcagcgtggt gagcgcatag	300
atcacgggct ccgcaagatg cagtgcatac ggtgtcggct ccatgccttt tgagggtgcgc	360
aaagaacaaat cgtcgttcag cgctgtacgc agccgtttaa gtgaattact gacggcaggc	420
tgctgcagcc ccagtttttc gccggccgtc gatacgtcc ggtcgagcag tagctggttg	480
aagaccacca gcagattcaa gtcgatgtcg gcgagatcca tgacctacc ctcaccatta	540
ttcatgctgg tgattttaac tatcagactt gatctatagc gctataccga tcgacgcgct	600
agaatcgcag ccattcggag acaactgaaa aaagagcttg catggaactg gtagtagaac	660
ccctcaattt gcatctgaac gcggagaccg gcagcacctt gcttgacgtg ctcagggtcca	720
acgaggtccc catttcttat agctgcattg cgggccgctg cggcacttgc cgttgccgtg	780
tgattgccgg ccatcttcgc gataacggcc ccgagacagg gcgccgcag gcaggaaagg	840
ggccctatgt cctggcctgt caggcggttc tgaccgaaga ctgcacgac gagattcctg	900
aatctgacga gatcgtggtt caccggcgc gcacgtcaa ggggacggtc acagcgatag	960
acgaagccac ccatgacatc cggcgcctgc gcacaaaact ggccaaaccg cttgagttca	1020
gccctggcca gtacgcaacg gtgcagttca gcgccgaatg cgtccgccc tattcgatgg	1080
ccgggctgcc tagcgatgcg gaaatggagt ttcagattcg gcgggtccg ggcgggcatg	1140
tcagcaacta cgttttcaat gaactgtccg taggcgcttc ggtgcggatc agcggcccc	1200
tcggaacggc ctatctgcgg gcacgcaca ccggcccat gctttgtgtg gggggtgaa	1260
caggctctgc gccctcctt tcgatcgttc gaggcgcact ggaagcggg atgagctacc	1320
ccatccatct gtacttcggt gtgcggagcg agcaggacat ctatgacgag gaacgccttc	1380
acgcattggc tgcaaggttt ccgaatctca aggtgaatgt cgttgttga acaggcctg	1440
ccggccctgg tcacgcatcc ggccgtgca ccgatctgat cggccgtgac ttgcccaatt	1500
tggggggatg gcgactgcat cctgtgtggc gctccggcca tggtcgaggc cctgaacctg	1560
ctcgttgctc gcctaggcat agtacccgg cacatccatg ccgatgcgtt ctatcccagc	1620
ggcgtctgag cgaagccacc atgcgaacc aattcaacc aaggatacca agccatgagt	1680
gaacccaac gattaaaacc cgtgtttccc caagatccga aatggccggg cgaaggtagc	1740
agccgcgttc cttctgggc ctacaccgc gaagacctgt acaagcgcga attggagcgc	1800
ctgttctatg caaacctg gtgctatgta ggcctggaag ccgagattcc gaatccaggc	1860
gacttaagc gaacggtgat cggtagcgc tcggtcatca tggtagctga tccggatggc	1920
ggcatcaacg tggtaggaa cgtctgcgc caccgtggca tgcgcttttg ccgcgagcgc	1980
cacggcaacg ccaaggactt cttctgccc taccaccagt ggaactacag cctcaagggt	2040
gacctgcagg gcgtgcctt ccggcgtggc gtcaagcagg acggcaagg caacggcggc	2100
atgccaagc acttcaaac cgaagaacac ggcctgacca agctcaagggt ggcgcgccg	2160
aggcgtgca gtgtttgct ctttcgacca cgatgtcgag ctttcgagg acttctggg	2220
ccaacctacc tgcactact cgatcgcgtc ttcaatggc gcaagctcaa gatcctggg	2280

-continued

taccgccgcc agcgcacccc gggcaactgg aagctgatgc aggagaacat caaggacccc	2340
taccacccgg gcctgctgca cacctggttc tcgaccttcg ggctctggcg cgcgcacaac	2400
aagtcggaac tgaagatgga cgccaagttc cgccacgccg caatgatctc cagcgcgggt	2460
cagggcggca agaacgagga ggtcgtgtcc ggcgtggaca gcttcaagga acagatgaag	2520
gtgaacgacc cgcgcctgct cgacatcgtg cccgagccct ggtggggcgg tccgactgcg	2580
gtgatgacca cgatcttccc cagcgtgatc atccagcagc aggtcaacag cgtatcgacc	2640
cgccacatcc agcccaacgg tcacggctcc ttcgatttcg tctggaccca ctteggcttc	2700
gaggacgaca acgaggagtg gaccacggcg cgcctgatcc aggccaaacct gttcgggccg	2760
gcgggcttcg tctcggccga tgacggcgag gtgatcgagt ggtcgcagga aggccttgag	2820
caaaaaccga cgcaccgcac cgtgatcgag atggggcgtc acgaaatcgg cgacacggac	2880
cacatggtca ccgagacgct gatccgcggc atgtacgact actggcga ggtgatggg	2940
gaataaacat ggtagacttc aaaacctatt tcgaactgct gaacctgtac agcgactacg	3000
ccatggtgtg cgactccgcc aattgggaga agtggcctga tttcttcac gagaccggca	3060
cctaccgcct gcaaccgcgc gaaaacttcg agcaggactt gccgctgtgt ctgctggcgc	3120
tggagagcaa ggccatgatt cgtgaccgag tgtacggtgt caaggaaacc atgtaccacg	3180
atccctacta ccagcggcac atcgtaggca cgccgcgcgt gctgtcagtg gagcgtgatg	3240
cggacggcga gcgcacacc gccgaagcca gctatgccgt gattcgcacc aagtacgacg	3300
gcgattccac gattttcaac gccggctatt accgagacgt gatcgtgcgc acgcccagg	3360
gcctcaagct gaagtgcgcg ctgtgcgtgt acgacagcga aatgattccc aactccatca	3420
tctaccctat ctgagaagga atccaatgag cgagaactgg atcgacgccg ccgcccgcga	3480
cgaggtgcc aagggcgac gtgatcggca tcaatatcgt cggcaaggag attgcctcta	3540
cgaggtggcg ggcgagatct acgccaccga caacacctgc actcacggcg ccgcccgat	3600
gagcgtggc tttctcgaag gccgggaaat tgaatgtcct ttgcatcaag gccgattcga	3660
tgtttgcacg ggtaaagcct tgtgcacacc cctgacacag gacatcaaaa cctaccctgt	3720
aaaaatcgaa aacatgcgcg tgatgctcaa gctggactaa atgctcaagc tggactaaaa	3780
ctctttgcag gaggaaagcc aaatccgaa atcacccac ccaaccaat cactaccctgt	3840
ttcaaacaa gatgagacaa gcaattatga gttaccaaaa cttagttagt gaagcagggc	3900
tgacgaaaa gcacctgatt tatggogaca aagaactttt ccagcacgaa ttgaagacca	3960
tcttcgcgcg gaactggctt tttctgacct atgacagtct gattccctcc ccgggcgact	4020
atgtcaaagc caaaatgggc gtcgatgaag tcacgtctc ccgccagaac gatggctcgg	4080
tgcgagcctt tttgaatgtt tgccgtcacc ggggcaagac aatagttgac gctgaagccg	4140
gaaatgcgaa aggctttgtg tgcggttacc acggctgggg ctatggctcc aacggcgaac	4200
tgcaaagcgt tccctttgaa aaagagttgt acggagatgc gatcaaaaag aaatgcctgg	4260
gcttgaaga agtccccgc atcgaagct ttcattggctt tatctatggc tgttttgatg	4320
cagaagctcc ccgctcact gattatctgg gtgatgtagc ctggtacctg gaaccacct	4380
tcaagcactc tgggtggcctg gaactttagt gccccccgc caaagtggtg gttaaaggca	4440
actggaaggt ttttgcgaa aacttttagt gtgacatcta ccacattggt tggacgcacg	4500
catctatttt gcgcgcaggg cagggcatat ttgctcctct tgcgggcaac gctatgcttc	4560
caccgcaag cagggcttg caagcgacca ccaagtatgg cagtggaatt ggcgtatcgt	4620
tggacgccta ctccggtgtc cagagocgtg atctggttcc cgaatgatg gcattcggcg	4680

-continued

---

```

gcgcaaaaca ggaaaagctc gccaaagaaa tcggcgatgt ccgggcgcgg atttaccgca 4740
gccaaagtga cggcacgggt ttcccgaaca actgcttttt gaccggcgcc ggtgtcttca 4800
aggtctttaa cccgatcgat gaaaacacga ccgaggcttg gacgtatgcc atcgtagaaa 4860
aagacatgcc tgaggactta aagcgtcgct tggctgacgc ggctcagcgc tctgtcggac 4920
cagcaggata ctgggaaagc gacgacaacg acaacatggt gttgtcgcaa aatgccaaaga 4980
aataccaatc cagcaacagt gatctgattg ccgatttggg tttcggcaag gacgtctacg 5040
gcgacgaatg ctatccgggc gtcgtagca aatcggcatt cagcgaacc aaccatcgcg 5100
gattctaccg tgctaccag gctcacatca gcagctcaa ttgggcccag ttcgaaaaa 5160
cctcccgaat ttggcacacc gaactcacca agacgactga tcgctaacc aggagccaat 5220
catgatgatc aatacccagg aagacaagct ggtctccgcg cagcagccg aagaatttca 5280
ccgtttcttc gtcgggcacg acagcgatct gcagcaagaa gtcaccacac tctgacccg 5340
cgaagccgac ctgctggaca ttcaggccta caaagcctgg cttgaacact gcgttgcccc 5400
cgagatcaaa taccaagtga tctcgcgaga acttcgctcc acttccgagc gtcgatacca 5460
actgaatgat gcggtgaata tctacaacga gaactatcaa cagctgaaag ttcgagttga 5520
acaccagatg gatcctcaga actggtacaa cagcccgaag atccgcttca cccgctcgt 5580
caccaatgtc acggcggcca aggacaagag cgcaccgaa atgctgcatg tgcggtccaa 5640
cctcatttct catcgcgcca gacgaggaaa ccaagttgac gtcctctatg caacgcgaga 5700
agacaaatgg aaacgcatcg aaggtggtgg catcaaattg gtcgaacgct ttgtgacta 5760
cccggagcgc agtccccaaa cccacaacct gatgatcttc ctgtgagccc tggggatgcc 5820
tgcttgatg gcgggcatc gtgattatth ttaacagggc ggattcaaaa gtgaagtga 5880
acaccctgga tttcagtga tgagagtgga gtgctgctgg ctattcaca gcagttcgcg 5940
gtagaccgcc agcggatgac gtaactccag ccctttcctt ggccggttgt tgatttcatc 6000
ggcaatcgca tcgagctgct cctggctgta gatgctcaga tccgtccctt tgggcaggta 6060
ctggcgcacc aggcattca tgttctcgtt ggagcctctt tgccaagggc tgtgcgggtc 6120
gcagaagtac acggctatgc cggtttgcct actgagcttc ttgtgcatgg acatctcccg 6180
gccctggtcg tacgtcatgc tcaacogcat cggctgcgca atgccagca gcttgtccgt 6240
gaagccctgc aagacgttg cagcactggc cggcttgaac tcaggcagct tgaccagcat 6300
caccagccgg ctggtgctgt ccaccaaggt cccgactgcg ctggcattgc cttctcctt 6360
gatgagatca cttcccagc gcccggaata ctggcgtct tcgatctcgg gcgggcgtac 6420
atggatgctc agcatgctcg gaatctggcc tctgcggtcc ttgcccttc tgcgcggcag 6480
ccgcttggtg tggcgtgac gcagggtgac gatcagctct ttgcgcagct ctcccaggg 6540
catggcatag atgcagttgt agatggttct gtgtgacacg cggatttcat ggcccaggg 6600
atacaaacgt gccagtgtca gggcaatctg ctcgggcgac cagcgcagcc gcagcagatg 6660
gatcaccagg caggacaaga tcgactcggg atgcagcttg atagctggtc tgccacagcg 6720
tctgcgctgc agggactggc actgggcatg tgcgctgcca tagccagatg aagatgcat 6779

```

&lt;210&gt; SEQ ID NO 14

&lt;211&gt; LENGTH: 449

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:3.

-continued

&lt;400&gt; SEQUENCE: 14

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln  
 1 5 10 15  
 Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys  
 20 25 30  
 Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45  
 Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
 50 55 60  
 Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80  
 Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala  
 85 90 95  
 Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
 100 105 110  
 Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu  
 115 120 125  
 Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140  
 His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145 150 155 160  
 Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175  
 Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190  
 Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205  
 Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220  
 Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240  
 Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270  
 Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300  
 Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320  
 Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335  
 Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Val  
 340 345 350  
 Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365  
 Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380  
 Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415

-continued

Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430

Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 15

<211> LENGTH: 449

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:4.

<400> SEQUENCE: 15

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln  
 1 5 10 15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys  
 20 25 30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45

Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
 50 55 60

Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80

Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala  
 85 90 95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
 100 105 110

Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu  
 115 120 125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140

His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145 150 155 160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205

Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220

Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300

Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320

-continued

---

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Val  
 340 345 350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365

Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380

Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400

Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415

Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430

Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 16  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:5.

<400> SEQUENCE: 16

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln  
 1 5 10 15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys  
 20 25 30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45

Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
 50 55 60

Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80

Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala  
 85 90 95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
 100 105 110

Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu  
 115 120 125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140

His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145 150 155 160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205

Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220

Cys Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu

-continued

---

225                                    230                                    235                                    240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
   245                                    250                                    255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
   260                                    265                                    270

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
   275                                    280                                    285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
   290                                    295                                    300

Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
305                                    310                                    315

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
   325                                    330                                    335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Val  
   340                                    345                                    350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
   355                                    360                                    365

Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
   370                                    375                                    380

Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
385                                    390                                    395                                    400

Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
   405                                    410                                    415

Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
   420                                    425                                    430

Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
   435                                    440                                    445

Arg

<210> SEQ ID NO 17  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:6.

<400> SEQUENCE: 17

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Phe Gly Leu Ser Gln  
1                                    5                                    10                                    15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys  
   20                                    25                                    30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
   35                                    40                                    45

Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
   50                                    55                                    60

Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
65                                    70                                    75                                    80

Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala  
   85                                    90                                    95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
   100                                    105                                    110

Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu  
   115                                    120                                    125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
130                                    135                                    140

-continued

His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145 150 155 160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205

Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220

Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300

Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Val  
 340 345 350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365

Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380

Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400

Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415

Tyr Arg Ala Tyr Arg Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430

Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 18  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:7.

<400> SEQUENCE: 18

Met Asn Tyr Lys Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Thr Gln  
 1 5 10 15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Arg  
 20 25 30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45



-continued

---

Pro Ser Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
     50                                    55                                    60  
 Ile Val Ser Arg Gln Ser Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65                                    70                                    75                                    80  
 Cys Arg His Arg Gly Lys Thr Leu Val Asn Ala Glu Ala Gly Asn Ala  
                                     85                                    90                                    95  
 Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
                                     100                                    105                                    110  
 Glu Leu Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly Glu Ser Leu  
                                     115                                    120                                    125  
 Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
                                     130                                    135                                    140  
 His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145                                    150                                    155                                    160  
 Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Ile Phe Lys His  
                                     165                                    170                                    175  
 Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
                                     180                                    185                                    190  
 Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
                                     195                                    200                                    205  
 Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
                                     210                                    215                                    220  
 Ala Ser Leu Ala Gly Asn Ala Val Leu Pro Pro Glu Gly Ala Gly Leu  
 225                                    230                                    235                                    240  
 Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
                                     245                                    250                                    255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
                                     260                                    265                                    270  
 Gly Gly Ser Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
                                     275                                    280                                    285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
                                     290                                    295                                    300  
 Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305                                    310                                    315                                    320  
 Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
                                     325                                    330                                    335  
 Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Val  
                                     340                                    345                                    350  
 Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
                                     355                                    360                                    365  
 Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
                                     370                                    375                                    380  
 Ser Asn Leu Gly Phe Gly Lys Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385                                    390                                    395                                    400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
                                     405                                    410                                    415  
 Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
                                     420                                    425                                    430  
 Glu Asp Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
                                     435                                    440                                    445  
 Arg

-continued

---

```

<211> LENGTH: 449
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:8.
<221> NAME/KEY: SITE
<222> LOCATION: (35)...(35)
<223> OTHER INFORMATION: Xaa = any amino acid.

<400> SEQUENCE: 19

Met Asn Tyr Lys Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Thr Gln
 1                5                10                15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Arg
 20                25                30

Thr Ile Xaa Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile
 35                40                45

Pro Ser Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val
 50                55                60

Ile Val Ser Arg Gln Ser Asp Gly Ser Ile Arg Ala Phe Leu Asn Val
 65                70                75                80

Cys Arg His Arg Gly Lys Thr Leu Val Asn Ala Glu Ala Gly Asn Ala
 85                90                95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly
 100               105               110

Glu Leu Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly Glu Ser Leu
 115               120               125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe
 130               135               140

His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Ser Leu Met
 145               150               155               160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Ile Phe Lys His
 165               170               175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys
 180               185               190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His
 195               200               205

Val Gly Trp Thr His Ala Ser Ser Leu Arg Thr Gly Glu Ser Ile Phe
 210               215               220

Ser Ser Leu Ala Gly Asn Ala Val Leu Pro Pro Glu Gly Ala Gly Leu
 225               230               235               240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly
 245               250               255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe
 260               265               270

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Pro
 275               280               285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn
 290               295               300

Ser Val Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp
 305               310               315               320

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met
 325               330               335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ala Val Gln Arg Thr Val
 340               345               350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr
 355               360               365

```

-continued

---

Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Ile  
 370 375 380

Ser Asn Leu Gly Phe Gly Lys Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400

Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415

Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430

Glu Asp Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 20  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:9.

<400> SEQUENCE: 20

Met Asn Tyr Lys Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Thr Gln  
 1 5 10 15

Lys His Leu Ile His Gly Gly Glu Gly Leu Phe Gln His Glu Leu Arg  
 20 25 30

Ala Val Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45

Pro Ser Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
 50 55 60

Ile Val Ser Arg Gln Ser Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80

Cys Arg His Arg Gly Lys Thr Leu Val Asn Ala Glu Ala Gly Asn Ala  
 85 90 95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
 100 105 110

Glu Leu Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly Glu Ser Leu  
 115 120 125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140

His Gly Phe Ile Tyr Ala Cys Ile Asp Gln Glu Ala Pro Ser Leu Met  
 145 150 155 160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Ile Phe Lys His  
 165 170 175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205

Val Gly Trp Thr His Ala Ser Ser Leu Cys Thr Gly Glu Ser Ile Phe  
 210 215 220

Ser Ser Leu Ala Gly Asn Ala Val Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270

-continued

---

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300

Ser Val Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ala Val Gln Arg Thr Val  
 340 345 350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365

Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Ile  
 370 375 380

Ser Asn Leu Gly Phe Gly Lys Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400

Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415

Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430

Glu Asp Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 21  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:10.

&lt;400&gt; SEQUENCE: 21

Met Asn Tyr Lys Asn Lys Asn Leu Val Ser Glu Ser Gly Leu Thr Gln  
 1 5 10 15

Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln Arg Glu Leu Glu  
 20 25 30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45

Pro Ser Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Val Asp Glu Val  
 50 55 60

Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80

Cys Arg His Arg Gly Lys Thr Leu Val His Ala Glu Ala Gly Asn Ala  
 85 90 95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ala Asn Gly  
 100 105 110

Glu Leu Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly Glu Ala Leu  
 115 120 125

Asp Lys Lys Cys Met Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140

His Gly Phe Ile Tyr Gly Cys Phe Asp Glu Glu Ala Pro Ser Leu Lys  
 145 150 155 160

Asp Tyr Met Gly Asp Ala Gly Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175

Ser Gly Gly Leu Glu Leu Ile Gly Pro Pro Gly Lys Val Ile Ile Lys



-continued

---

Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly Glu Leu  
 100 105 110  
 Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly Asp Thr Ile Lys Lys  
 115 120 125  
 Lys Cys Leu Gly Leu Lys Glu Val Pro Arg Ile Glu Ser Phe His Gly  
 130 135 140  
 Phe Ile Tyr Gly Cys Phe Asp Ala Glu Ala Pro Thr Leu Val Asp Tyr  
 145 150 155 160  
 Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Ile Phe Lys His Ser Gly  
 165 170 175  
 Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys Ala Asn  
 180 185 190  
 Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His Val Gly  
 195 200 205  
 Trp Thr His Ala Ser Ser Leu Arg Ser Gly Gln Ser Ile Phe Thr Pro  
 210 215 220  
 Leu Ala Gly Asn Ala Met Leu Pro Pro Glu Gly Ala Gly Leu Gln Met  
 225 230 235 240  
 Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly Tyr Ser  
 245 250 255  
 Gly Val His Ser Ala Asp Leu Val Pro Glu Met Met Ala Phe Gly Gly  
 260 265 270  
 Ala Lys Gln Glu Lys Leu Ala Lys Glu Ile Gly Asp Val Arg Ala Arg  
 275 280 285  
 Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn Ser Ile  
 290 295 300  
 Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp Glu Asn  
 305 310 315 320  
 Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met Pro Glu  
 325 330 335  
 Asp Leu Lys Arg Arg Leu Ala Asp Ala Val Gln Arg Thr Val Gly Pro  
 340 345 350  
 Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr Glu Ser  
 355 360 365  
 Gln Asn Ala Lys Lys Tyr Gln Ser Ser Asn Ser Asp Leu Ile Ala Asn  
 370 375 380  
 Leu Gly Phe Gly Lys Asp Val Tyr Gly Asp Glu Cys Tyr Pro Gly Val  
 385 390 395 400  
 Val Ala Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe Tyr Arg  
 405 410 415  
 Ala Tyr Gln Ala His Ile Ser Ser Ser Asn Trp Ala Glu Phe Glu Asn  
 420 425 430  
 Thr Ser Arg Asn Trp His Thr Glu Leu Thr Lys Thr Thr Asp Arg  
 435 440 445

<210> SEQ ID NO 23  
 <211> LENGTH: 447  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:12.

<400> SEQUENCE: 23

Met Ser Tyr Gln Asn Leu Val Ser Glu Ala Gly Leu Thr Gln Lys Leu  
 1 5 10 15

-continued

---

Leu Ile His Gly Asp Lys Glu Leu Phe Gln His Glu Leu Lys Thr Ile  
 20 25 30  
 Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile Pro Ser  
 35 40 45  
 Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Val Asp Glu Val Ile Val  
 50 55 60  
 Ser Arg Gln Asn Asp Gly Ser Val Arg Ala Phe Leu Asn Val Cys Arg  
 65 70 75 80  
 His Arg Gly Lys Thr Leu Val His Thr Glu Ala Gly Asn Ala Lys Gly  
 85 90 95  
 Phe Val Cys Gly Tyr His Gly Trp Gly Tyr Gly Ser Asn Gly Glu Leu  
 100 105 110  
 Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly Asp Ala Ile Lys Lys  
 115 120 125  
 Lys Cys Leu Gly Leu Lys Glu Val Pro Arg Ile Glu Ser Phe His Gly  
 130 135 140  
 Phe Ile Tyr Gly Cys Phe Asp Ala Glu Ala Pro Leu Ile Asp Tyr  
 145 150 155 160  
 Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Thr Phe Lys His Ser Gly  
 165 170 175  
 Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Val Lys Ala Asn  
 180 185 190  
 Trp Lys Pro Phe Ala Glu Asn Phe Val Gly Asp Ile Tyr His Val Gly  
 195 200 205  
 Trp Thr His Ala Ala Ala Leu Arg Ala Gly Gln Ser Val Phe Ser Ser  
 210 215 220  
 Leu Ala Gly Asn Ala Lys Leu Pro Pro Glu Gly Ala Gly Leu Gln Met  
 225 230 235 240  
 Thr Ser Lys Tyr Gly Ser Gly Met Gly Leu Thr Trp Asp Tyr Tyr Ser  
 245 250 255  
 Gly Asn Phe Ser Ala Asp Met Val Pro Asp Leu Met Ala Phe Gly Ala  
 260 265 270  
 Ala Lys Gln Glu Lys Leu Ala Lys Glu Ile Gly Asp Val Arg Ala Arg  
 275 280 285  
 Ile Tyr Arg Ser Ile Leu Asn Gly Thr Val Phe Pro Asn Asn Ser Phe  
 290 295 300  
 Leu Thr Gly Ser Ala Thr Phe Lys Val Trp Asn Pro Ile Asp Glu Asn  
 305 310 315 320  
 Thr Thr Glu Val Trp Thr Tyr Ala Phe Val Glu Lys Asp Met Pro Glu  
 325 330 335  
 Asp Leu Lys Arg Arg Leu Ala Asp Ala Ala Gln Arg Ser Val Gly Pro  
 340 345 350  
 Ala Gly Phe Trp Glu Ser Asp Asp Asn Glu Asn Met Glu Thr Leu Ser  
 355 360 365  
 Gln Asn Ala Lys Lys Tyr Gln Ser Ser Asn Ser Asp Gln Ile Ala Ser  
 370 375 380  
 Leu Gly Phe Gly Lys Asp Val Tyr Gly Asp Glu Cys Tyr Pro Gly Val  
 385 390 395 400  
 Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe Tyr Arg  
 405 410 415  
 Ala Tyr Gln Ala His Ile Ser Ser Ser Asn Trp Ala Glu Phe Glu Asn  
 420 425 430

-continued

---

Ala Ser Arg Asn Trp His Thr Glu Leu Thr Lys Thr Thr Asp Arg  
 435 440 445

<210> SEQ ID NO 24  
 <211> LENGTH: 451  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:13.

<400> SEQUENCE: 24

Met Arg Gln Ala Ile Met Ser Tyr Gln Asn Leu Val Ser Glu Ala Gly  
 1 5 10 15  
 Leu Thr Gln Lys His Leu Ile Tyr Gly Asp Lys Glu Leu Phe Gln His  
 20 25 30  
 Glu Leu Lys Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp  
 35 40 45  
 Ser Leu Ile Pro Ser Pro Gly Asp Tyr Val Lys Ala Lys Met Gly Val  
 50 55 60  
 Asp Glu Val Ile Val Ser Arg Gln Asn Asp Gly Ser Val Arg Ala Phe  
 65 70 75 80  
 Leu Asn Val Cys Arg His Arg Gly Lys Thr Ile Val Asp Ala Glu Ala  
 85 90 95  
 Gly Asn Ala Lys Gly Phe Val Cys Gly Tyr His Gly Trp Gly Tyr Gly  
 100 105 110  
 Ser Asn Gly Glu Leu Gln Ser Val Pro Phe Glu Lys Glu Leu Tyr Gly  
 115 120 125  
 Asp Ala Ile Lys Lys Lys Cys Leu Gly Leu Lys Glu Val Pro Arg Ile  
 130 135 140  
 Glu Ser Phe His Gly Phe Ile Tyr Gly Cys Phe Asp Ala Glu Ala Pro  
 145 150 155 160  
 Pro Leu Ile Asp Tyr Leu Gly Asp Val Ala Trp Tyr Leu Glu Pro Thr  
 165 170 175  
 Phe Lys His Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Ala Lys Val  
 180 185 190  
 Val Val Lys Gly Asn Trp Lys Val Phe Ala Glu Asn Phe Val Gly Asp  
 195 200 205  
 Ile Tyr His Ile Gly Trp Thr His Ala Ser Ile Leu Arg Ala Gly Gln  
 210 215 220  
 Ala Ile Phe Ala Pro Leu Ala Gly Asn Ala Met Leu Pro Pro Glu Gly  
 225 230 235 240  
 Thr Gly Leu Gln Ala Thr Thr Lys Tyr Gly Ser Gly Ile Gly Val Ser  
 245 250 255  
 Leu Asp Ala Tyr Ser Gly Val Gln Ser Ala Asp Leu Val Pro Glu Met  
 260 265 270  
 Met Ala Phe Gly Gly Ala Lys Gln Glu Lys Leu Ala Lys Glu Ile Gly  
 275 280 285  
 Asp Val Arg Ala Arg Ile Tyr Arg Ser Gln Val Asn Gly Thr Val Phe  
 290 295 300  
 Pro Asn Asn Cys Phe Leu Thr Gly Ala Gly Val Phe Lys Val Phe Asn  
 305 310 315 320  
 Pro Ile Asp Glu Asn Thr Thr Glu Ala Trp Thr Tyr Ala Ile Val Glu  
 325 330 335  
 Lys Asp Met Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ala Ala Gln  
 340 345 350



-continued

---

Arg Ser Val Gly Pro Ala Gly Tyr Trp Glu Ser Asp Asp Asn Asp Asn  
 355 360 365

Met Val Leu Ser Gln Asn Ala Lys Lys Tyr Gln Ser Ser Asn Ser Asp  
 370 375 380

Leu Ile Ala Asp Leu Gly Phe Gly Lys Asp Val Tyr Gly Asp Glu Cys  
 385 390 395 400

Tyr Pro Gly Val Val Ser Lys Ser Ala Phe Ser Glu Thr Asn His Arg  
 405 410 415

Gly Phe Tyr Arg Ala Tyr Gln Ala His Ile Ser Ser Ser Asn Trp Ala  
 420 425 430

Glu Phe Glu Asn Thr Ser Arg Asn Trp His Thr Glu Leu Thr Lys Thr  
 435 440 445

Thr Asp Arg  
 450

<210> SEQ ID NO 25  
 <211> LENGTH: 2265  
 <212> TYPE: DNA  
 <213> ORGANISM: Pseudomonas sp.

<400> SEQUENCE: 25

gagggtagag aaatcgaatg ccccttgcac caaggtcggg ttgacgtttg cacaggcaaa 60  
 gcctctgtgc caccctgtgc acagaacatc aaaacatcag cagtcgaagat tgagaacctg 120  
 cgcgtaataa ttgatttgag ctaagaatct taacaggagg caccctgggc cctagagcgt 180  
 aatcaccccc attccatcct ttttagtgta aaacatgaat tacaataata aaatcttggt 240  
 aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac tttccaaca 300  
 tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattcc 360  
 tgccccggc gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctccccgca 420  
 gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt 480  
 gagcgtggaa gccggcaatg ccaaagggtt tgtttgacgc taccacggct ggggcttcgg 540  
 ctccaacggt gaactgcaga gcgttcatt tgaaaaagat ctgtacggcg agtcgctcaa 600  
 taataaatgt ctggggttga aagaagtcgc tcgctgggag agcttccatg gcttcatcta 660  
 cggttgcttc gaccaggagg cccctcctc tatggactat ctgggtgacg ctgcttggtg 720  
 cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctcctc caggcaagg 780  
 tgtgatcaag gccaaactga aggcacccgc ggaaaacttt gtgggagatg cataccacgt 840  
 ggggtggacg cagcgtctct cgtctcctc gggggagtct atcttctcgt cgtcgtctgg 900  
 caatgcggcg ctaccacctg aagcgcgagg cttgcaaatg acctccaaat acggcagcgg 960  
 catgggtgtg ttgtgggagc gatattcagg tgtgcatagc gcagacttgg ttccggaatt 1020  
 gatggcattc ggaggcgaag agcaggaaa gctgaacaaa gaaattggcg atgttcgccc 1080  
 tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tgctgacctg 1140  
 ctccgggtgt ttcaaatgat ggaacccgat cgacgcaaac accaccgagg tctggacctg 1200  
 cgccattgtc gaaaaagaca tgctgagga tctcaagcgc cgcttgcccg actctgttca 1260  
 gcgaacgttc gggcctgctg gcttctggga aagcgcgac aatgacaata tggaaacagc 1320  
 ttcgcaaac ggcaagaaat atcaatcaag agatagtgat ctgctttcaa accttggttt 1380  
 cggtgaggac gtatacggcg acgcggtcta tccaggcgtc gtcggcaaat cggcgatcgg 1440  
 cgagaccagt tatcgtggtt tctaccggcg ttaccaggca cacgtcagca gctccaactg 1500

-continued

---

```

ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg 1560
ctaacagacg agtcgacccat gatgatcaat attcaagaag acaagctggt tccgcccac 1620
gagcgcgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc 1680
actacgctgc tgaccagga agcgcatttg ttggacattc aggcttaccg tgcttggtta 1740
gagcaactgc tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgcgcagct 1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaaa ttttcagcaa 1860
ctgaaagttc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg 1920
cgctttactc gctttatcac caacgtccag gccgcaatgg acgtaaatga caaagagcta 1980
cttcacatcc gctccaacgt cattctgcac cgggcacgac gtggcaatca ggtcgatgtc 2040
ttctacgccg cccgggaaga taaatgaaa cgtggcgaag gtggagtacg aaaattggtc 2100
cagcgattcg tcgattaccg agagcgcata cttcagacgc acaatctgat ggtcttctg 2160
tgattcagtg accattttta caaatggtca ctgcaaccgc ggtcaccatt aatcaaaggg 2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg 2265

```

&lt;210&gt; SEQ ID NO 26

&lt;211&gt; LENGTH: 449

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Pseudomonas sp.

&lt;400&gt; SEQUENCE: 26

```

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln
 1           5           10          15
Lys His Leu Ile His Gly Asp Glu Leu Phe Gln His Glu Leu Lys
 20          25          30
Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile
 35          40          45
Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val
 50          55          60
Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val
 65          70          75          80
Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala
 85          90          95
Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly
100         105         110
Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu
115         120         125
Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe
130         135         140
His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met
145         150         155         160
Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His
165         170         175
Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys
180         185         190
Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His
195         200         205
Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe
210         215         220
Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu
225         230         235         240

```

-continued

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270  
 Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300  
 Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320  
 Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335  
 Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Phe  
 340 345 350  
 Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365  
 Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380  
 Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415  
 Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430  
 Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 27  
 <211> LENGTH: 2265  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A sequence encoding an NDO mutant.

<400> SEQUENCE: 27

gagggtagag aaatcgaatg ccccttgcac caaggtcggg ttgacgtttg cacaggcaaa 60  
 gccctgtgag caccctgtgac acagaacatc aaaacatata cagtcaagat tgagaacctg 120  
 cgcgtaatga ttgatttgag ctaagaatth taacaggagg caccctgggc cctagagcgt 180  
 aatcaccccc attccatctt ttttagtgga aaacatgaat tacaataata aaatcttggg 240  
 aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac ttttccaaca 300  
 tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattcc 360  
 tgccccgggc gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctcccggca 420  
 gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt 480  
 gagcgtggaa gccggcaatg ccaaaggtht tgtttgagc taccacggct ggggcttcgg 540  
 ctccaacggt gaactgcaga gcgttcatt tgaaaaagat ctgtacggcg agtcgctcaa 600  
 taaaaaatgt ctggggttga aagaagtcgc tcgcgtggag agcttccatg gcttcatcta 660  
 cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggtg 720  
 cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctctc caggcaaggt 780  
 tgtgatcaag gcccaactgga aggcaccgcg ggaaaacttt gtgggagatg cataccacgt 840

-continued

---

```

gggttgagc cacgcgtctt cgcttcgctc gggggagtct atcttctcgt cgctcgctgg 900
caatgcggcg ctaccacctg aaggcgacag cttgcaaatg acctccaaat acggcagcgg 960
catgggtgtg ttgtgggacg gatattcagg tgtgcatagc gcagacttgg ttccggaatt 1020
gatggcattc ggaggcgcaa agcaggaaaag gctgaacaaa gaaattggcg atgttcgcgc 1080
tcggatttat cgagccacc tcaactgcac cgttttcccg aacaacagca tgctgacctg 1140
ctcgggtggt ttcaaagtat ggaacccgat cgacgcaaac accaccgagg tctggaccta 1200
cgccattgtc gaaaaagaca tgccctgagga tctcaagcgc cgcttggccg actctgttca 1260
gcgaacgggc gggcctgctg gcttctggga aagcgacgac aatgacaata tggaacagc 1320
ttcgcaaac ggcaagaaat atcaatcaag agatagtgat ctgctttcaa accttggttt 1380
cggtagagac gtatacggcg acgcggtcta tccagcgtc gtcggcaaat cggcgatcgg 1440
cgagaccagt tctcgtggtt tctacgggc ttaccaggca cacgtcagca gctccaactg 1500
ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg 1560
ctaacagacg agtcgacct gatgatcaat attcaagaag acaagctggt ttccgcccac 1620
gacgccgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc 1680
actacgctgc tgaccaggga agcgcatttg ttggacattc aggttaccg tgcttggtta 1740
gagcactcgc tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgcgcagct 1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaa tttcagcaa 1860
ctgaaagtgc gagtttagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg 1920
cgctttactc gctttatcac caactgccag gccgcaatgg acgtaaatga caaagagcta 1980
cttcacatcc gctccaactc cattctgcac cgggcacgac gtggcaatca ggtcgatgct 2040
ttctacgccg cccgggaaga taaatggaaa cgtggcgaag gtggagtacg aaaattggtc 2100
cagcgattcg tcgattaccg agagcgcata cttcagacgc acaatctgat ggtctttctg 2160
tgattcagtg accattttta caaatggta ctgcaaccgc ggtcaccatt aatcaaaggg 2220
aatgtacgtg tatgggcaat caacaagtgc tttcgataac cggtg 2265

```

&lt;210&gt; SEQ ID NO 28

&lt;211&gt; LENGTH: 2265

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A sequence encoding an NDO mutant.

&lt;400&gt; SEQUENCE: 28

```

gaggtagag aaatcgaatg ccccttgcac caaggtcggg ttgacgtttg cacaggcaaa 60
gccctgtgcg caccctgtac acagaacatc aaaacatata cagtcaagat tgagaacctg 120
cgcgtaatga ttgatttgag ctaagaattt taacaggagg caccocgggc cctagagcgt 180
aatcaccccc attccatctt ttttaggtga aaacatgaat tacaataata aaatcttggg 240
aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac tttccaaca 300
tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattcc 360
tgccccggcg gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctcccggca 420
gaacgacggt tcgattcgtg cttttctgaa cgtttgcccg catcgtggca agaocgtggt 480
gagcgtggaa gccggcaatg ccaaagggtt tgtttgacgc tatcacggct ggggcttcgg 540
ctccaacggt gaactgcaga gcgttccatt tgaaaaagat ctgtacggcg agtcgctcaa 600
taaaaaatgt ctggggttga aagaagtcgc tcgcgtggag agcttccatg gcttcatcta 660

```

-continued

---

```

cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggtgta 720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctctc caggcaaggt 780
tgtgatcaag gcccaactgga aggcaccgcg gaaaaacttt gtgggagatg cataccacgt 840
gggttgagcg cacgcgtctt cgtctcgctc gggggagtct atcttctcgt cgctcgctgg 900
caatgcggcg ctaccacctg aaggcgagc cttgcaaatg acctccaaat acggcagcgg 960
catgggtgtg ttgtgggacg gatattcagg tgtgcatagc gcagacttgg tccggaatt 1020
gatggcattc ggaggcgcaa agcaggaaa gctgaacaaa gaaattggcg atgttcgcgc 1080
tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tegtgcactg 1140
ctcgggtggt tcaaaagtat ggaaccgat cgacgcaaac accaccgagg tctggacctg 1200
cgccattgtc gaaaaagaca tgcctgagga tctcaagcgc cgcttgccg actctgttca 1260
gcgacggcc gggcctgctg gcttctggga aagcgacgac aatgacaata tggaaacagc 1320
ttcgcaaaac ggcaagaaat atcaatcaag agatagtgat ctgctttcaa acctgggtt 1380
cggtgaggac gtatacggcg acgcggtcta tccaggcgtc gtcggcaaat cggcgatcgg 1440
cgagaccagt tatcgtggtt tctacgggca ttaccaggca cacgtcagca gctccaactg 1500
ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg 1560
ctaacagacg agtcgacct gatgatcaat attcaagaag acaagctggt tccgccccac 1620
gagcggcaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc 1680
actacgctgc tgaccagga agcgcatttg ttggacattc aggcctaccg tgcttggtta 1740
gagcactgcg tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgcgcagct 1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaaa ttttcagcaa 1860
ctgaaagttc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg 1920
cgctttactc gctttatcac caacgtccag gccgcaatgg acgtaaata caaagagcta 1980
cttcacatcc gctccaactg cttctgcac cgggcacgac gtggcaatca ggtcgatgct 2040
ttctacgccg cccgggaaga taaatgaaa cgtggcgaag gtggagtacg aaaattggtc 2100
cagcgattcg tcgattaccg agagcgcata cttcagacgc acaatctgat ggtctttctg 2160
tgattcagtg accattttta caaatggtca ctgcaaccgc ggtcaccatt aatcaaaggg 2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg 2265

```

&lt;210&gt; SEQ ID NO 29

&lt;211&gt; LENGTH: 2265

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A sequence encoding an NDO mutant.

&lt;400&gt; SEQUENCE: 29

```

gagggtagag aaatcgaatg ccccttgcat caaggtcggg ttgacgtttg cacaggcaaa 60
gccctgtgcg caccctgac acagaacatc aaaacatc cagtcaagat tgagaacctg 120
cgcgtaatga ttgatttgag ctaagaatth taacaggagg caccctgggc cctagagcgt 180
aatcaccctt attccatctt ttttagtgta aaacatgaat tacaataata aaatcttggg 240
aagtgaatct ggtctgagcc aaaagcact gattcatggc gatgaagaac ttttccaaca 300
tgaactgaaa accatttttg cgcggaaact gctttttctc actcatgata gcctgattcc 360
tgccccgcg gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctcccggca 420

```

-continued

gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt	480
gagcgtggaa gccggcaatg ccaaaggttt tgtttgcagc tatcacggct ggggcttcgg	540
ctccaacggt gaactgcaga gcgttcatt tgaaaaagat ctgtacggcg agtcgctcaa	600
taaaaaatgt ctggggttga aagaagtcgc tcgctggag agcttccatg gcttcatcta	660
cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggtg	720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctctc caggcaaggt	780
tgtgatcaag gccaaactga aggcaccgc ggaaaacttt gtgggagatg cataccacgt	840
gggttgacg cacgcgtcct cgcttcgctc gggggagtct atcttctcgt cgctcgtcg	900
caatgcggcg ctaccacctg aaggcgagg cttgcaaag acctccaaat acggcagcgg	960
catgggtgtg ttgtgggacg gatattcagg tgtgcatagc gcagacttg ttccggaatt	1020
gatggcattc ggaggcgcaa agcaggaaa gctgaacaaa gaaattggcg atgttcgctc	1080
tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tctgacctg	1140
ctcgggtgtt ttcaaagtat ggaaccgat cgacgcaaac accaccgagg tctggacctg	1200
cgccattgtc gaaaaagaca tgcctgagga tctcaagcgc cgcttgccg actctgttca	1260
gcgaacgacc gggcctgctg gcttctggga aagcgacgac aatgacaata tggaaacagc	1320
ttcgcaaac ggcaagaat atcaatcaag agatagtgat ctgcttcaa accttggttt	1380
cggtgaggac gtatacggcg acgcggtcta tccaggcgtc gtcggcaaat cggcgatcgg	1440
cgagaccagt tatcgtggtt tctaccgggc ttaccaggca cacgtcagca gctccaactg	1500
ggctgagttc gagcatgct ctagtacttg gcatactgaa cttacgaaga ctactgatcg	1560
ctaacagacg agtcgacct gatgatcaat attcaagaag acaagctggt ttccgcccac	1620
gacgccgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc	1680
actacgctgc tgaccaggga agcgcatttg ttggacattc aggttaccg tgcttggtta	1740
gagcactgcg tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgcgacgt	1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaa ttttcagcaa	1860
ctgaaagttc gagttgagca tcaactggat cgcgaaaact ggggcaacag cccgaagctg	1920
cgctttactc gctttatcac caacgtccag gccgcaatgg acgtaaatga caaagagcta	1980
cttcacatcc gctccaactg cttctgcac cgggcacgac gtggcaatca ggtcogatgc	2040
ttctacgccg cccgggaaga taaatgaaa cgtggcgaag gtggagtacg aaaattggtc	2100
cagcgattcg tcgattacc agagcgcata cttcagcgc acaatctgat ggtcttctg	2160
tgattcagtg accattttta caaatggtca ctgcaaccgc ggtcaccatt aatcaaagg	2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cggtg	2265

&lt;210&gt; SEQ ID NO 30

&lt;211&gt; LENGTH: 2265

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A sequence encoding an NDO mutant.

&lt;400&gt; SEQUENCE: 30

gagggtagag aaatcgaatg ccccttgcac caaggtcggg ttgacgtttg cacaggcaaa	60
gccctgtgcy caccctgac acagaacatc aaaacatc cagtcaagat tgagaacctg	120
cgcgtaatga ttgatttgag ctaagaatct taacaggagg caccctgggc cctagagcgt	180
aatcaccccc attccatctt ttttagtgta aaacatgaat tacaataata aaatcttgg	240

-continued

---

```

aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac tttccaaca 300
tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattec 360
tgcccccggc gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctccccgca 420
gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt 480
gagcgtggaa gccggcaatg ccaaaggttt tgtttgcagc tatcacggct ggggcttcgg 540
ctccaacggt gaactgcaga gcgttcatt tgaaaaagat ctgtacggcg agtcgctcaa 600
taaaaaatgt ctggggttga aagaagtcgc tcgctggag agcttccatg gcttcatcta 660
cggttgcttc gaccaggagc cccctctctc tatggactat ctgggtgacg ctgcttggtg 720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggtcctc caggcaaggt 780
tgtgatcaag gccaactgga aggcacccgc ggaaaacttt gtgggagatg cataccacgt 840
gggttgagc caccgctctt cgcttcgctc gggggagtct atcttctcgt cgctcgtctg 900
caatgcggcg ctaccacctg aagcgcagc cttgcaaatg acctccaaat acggcagcgg 960
catgggtgtg ttgtgggagc gatattcagg tgtgcatagc gcagacttg ttccggaatt 1020
gatggcattc ggaggcga aagcaggaaag gctgaacaaa gaaattggcg atgttcgccc 1080
tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tctgacctg 1140
ctcgggtgtt ttcaaagtat ggaacccgat cgacgcaaac accaccgagg tctggacctg 1200
cgccattgtc gaaaaagaca tgctgagga tctcaagcgc cgcttgcccg actctgttca 1260
gcgaacgctc gggcctgctg gcttctggga aagcgcagc aatgacaata tggaaacagc 1320
ttcgcaaac ggcaagaaat atcaatcaag agatagtgat ctgcttcaa accttggttt 1380
cggtaggac gtatacggcg acgcggtcta tccagcgtc gtcggcaaat cggcgatcgg 1440
cgagaccagt tatcgtggtt tctaccggcg ttaccaggca cacgtcagca gctccaactg 1500
ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg 1560
ctaacagacg agtcgaccat gatgatcaat attcaagaag acaagctggt ttccgcccac 1620
gacgccgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc 1680
actacgctgc tgaccaggga agcgcatttg ttggacattc aggttaccg tcttgggtta 1740
gagcactcgc tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgocgact 1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaa tttcagcaa 1860
ctgaaagtgc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg 1920
cgctttactc gctttatcac caactccag gccgcaatgg acgtaaatga caaagagcta 1980
cttcacatcc gctccaactg cattctgcac cgggcacgac gtggcaatca ggtcogatgc 2040
ttctacgccg cccgggaaga taaatggaaa cgtggcgaag gtggagtacg aaaattggtc 2100
cagcgattcg tcgattacc agagcgcata cttcagacgc acaatctgat ggtctttctg 2160
tgattcagtg accattttta caaatggta ctgcaaccgc ggtcaccatt aatcaaagg 2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg 2265

```

&lt;210&gt; SEQ ID NO 31

&lt;211&gt; LENGTH: 2265

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: A sequence encoding an NDO mutant.

&lt;400&gt; SEQUENCE: 31

-continued

gagggtagag aaatcgaatg ccccttgcat caaggtcggg ttgacgtttg cacaggcaaa	60
gccctgtgcg caccctgtgac acagaacatc aaaacatata cagcaagat tgagaacctg	120
cgcgtaatga ttgatttgag ctaagaatth taacaggagg caccocgggc cctagagcgt	180
aatcaccccc attccatctt ttttaggtga aaacatgaat tacaataata aaatcttggg	240
aagtgaatct ggtctgagcc aaaagcact gattcatggc gatgaagaac tttccaaca	300
tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattcc	360
tgccccggc gactatgta ccgcaaaaat ggggattgac gaggtcatcg tctcccggca	420
gaacgacggg tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggg	480
gagcgtgtaa gccggcaatg ccaaaggtht tgtttgcagc tatcacggct ggggcttcgg	540
ctccaacggg gaactgcaga gcgttcatt tgaaaaagat ctgtacggcg agtcgctcaa	600
taaaaaatgt ctggggttga aagaagtcgc tcgctggag agcttccatg gcttcatcta	660
cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggtg	720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctctc caggcaagg	780
tgtgatcaag gccaaactgga aggcacccgc ggaaaacttt gtgggagatg cataccacgt	840
gggttgagc cacgcgtctt cgtctcgcgc gggggagtct atcttctcgt cgtcgcctgg	900
caatgcggcg ctaccacctg aaggcgcagg cttgcaaatg acctcaaat acggcagcgg	960
catgggtgtg ttgtgggacg gatattcagg tgtgcatagc gcagactggg tccggaatt	1020
gatggcattc ggaggcgcaa agcaggaaa gctgaacaaa gaaattggcg atgttcgcgc	1080
tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tctgacctg	1140
ctcgggtgtt tcaaaagtat ggaaccgat cgacgcaaac accaccgagg tctggacctg	1200
cgccattgtc gaaaaagaca tgcctgagga tctcaagcgc cgcttgcccg actctgttca	1260
gcgaacgatc gggcctgctg gcttctggga aagcgcgac aatgacaata tggaaacagc	1320
ttcgcaaac ggcaagaaat atcaatcaag agatagtgat ctgctttcaa accttggttt	1380
cggtagggac gtatacggcg acgcggctca tccaggcgtc gtcggcaaat cggcagcgg	1440
cgagaccagt tatcgtggtt tctacgggca ttaccaggca cacgtcagca gctccaactg	1500
ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg	1560
ctaacagacg agtcgacct gatgatcaat attcaagaag acaagctggg ttcgcccac	1620
gacgccgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc	1680
actacgctgc tgaccaggga agcgcatttg ttggacattc aggcttaccg tgcttggtta	1740
gagcactgcg tggggtcaga ggtgcaatat caggtcattt cacgcgaact ggcgcagct	1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaa ttttcagcaa	1860
ctgaaagtcc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg	1920
cgtttactc gctttatcac caacgtccag gccgcaatgg acgtaaatga caaagagcta	1980
cttcacatcc gctccaactg cattctgcac cgggcacgac gtggcaatca ggtogatgc	2040
ttctacgccg cccgggaaga taaatggaaa cgtggcgaag gtggagtacg aaaattggtc	2100
cagcgattcg tcgattaccg agagcgcata cttcagacgc acaatctgat ggtctttctg	2160
tgattcagtg accattttta caaatggtca ctgcaaccgc ggtcaccatt aatcaaagg	2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg	2265

&lt;210&gt; SEQ ID NO 32

&lt;211&gt; LENGTH: 449



-continued

---

```

<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:27.

<400> SEQUENCE: 32

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln
 1          5          10          15

Lys His Leu Ile His Gly Asp Glu Leu Phe Gln His Glu Leu Lys
 20          25          30

Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile
 35          40          45

Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val
 50          55          60

Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val
 65          70          75          80

Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala
 85          90          95

Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly
100          105          110

Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu
115          120          125

Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe
130          135          140

His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met
145          150          155          160

Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His
165          170          175

Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys
180          185          190

Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His
195          200          205

Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe
210          215          220

Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu
225          230          235          240

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly
245          250          255

Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe
260          265          270

Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg
275          280          285

Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn
290          295          300

Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp
305          310          315          320

Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met
325          330          335

Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Gly
340          345          350

Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr
355          360          365

Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu
370          375          380

```

-continued

---

Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415  
 Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430  
 Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445  
 Arg  
 <210> SEQ ID NO 33  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:28.  
 <400> SEQUENCE: 33  
 Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln  
 1 5 10 15  
 Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys  
 20 25 30  
 Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45  
 Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
 50 55 60  
 Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80  
 Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala  
 85 90 95  
 Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
 100 105 110  
 Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu  
 115 120 125  
 Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140  
 His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145 150 155 160  
 Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175  
 Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190  
 Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205  
 Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220  
 Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240  
 Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270  
 Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn

-continued

290				295				300							
Ser	Met	Leu	Thr	Cys	Ser	Gly	Val	Phe	Lys	Val	Trp	Asn	Pro	Ile	Asp
305				310						315				320	
Ala	Asn	Thr	Thr	Glu	Val	Trp	Thr	Tyr	Ala	Ile	Val	Glu	Lys	Asp	Met
				325					330					335	
Pro	Glu	Asp	Leu	Lys	Arg	Arg	Leu	Ala	Asp	Ser	Val	Gln	Arg	Thr	Ala
			340					345					350		
Gly	Pro	Ala	Gly	Phe	Trp	Glu	Ser	Asp	Asp	Asn	Asp	Asn	Met	Glu	Thr
		355					360					365			
Ala	Ser	Gln	Asn	Gly	Lys	Lys	Tyr	Gln	Ser	Arg	Asp	Ser	Asp	Leu	Leu
	370					375					380				
Ser	Asn	Leu	Gly	Phe	Gly	Glu	Asp	Val	Tyr	Gly	Asp	Ala	Val	Tyr	Pro
385					390					395					400
Gly	Val	Val	Gly	Lys	Ser	Ala	Ile	Gly	Glu	Thr	Ser	Tyr	Arg	Gly	Phe
				405					410					415	
Tyr	Arg	Ala	Tyr	Gln	Ala	His	Val	Ser	Ser	Ser	Asn	Trp	Ala	Glu	Phe
			420					425					430		
Glu	His	Ala	Ser	Ser	Thr	Trp	His	Thr	Glu	Leu	Thr	Lys	Thr	Thr	Asp
		435					440					445			
Arg															
<210> SEQ ID NO 34															
<211> LENGTH: 449															
<212> TYPE: PRT															
<213> ORGANISM: Artificial Sequence															
<220> FEATURE:															
<223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:29.															
<400> SEQUENCE: 34															
Met	Asn	Tyr	Asn	Asn	Lys	Ile	Leu	Val	Ser	Glu	Ser	Gly	Leu	Ser	Gln
1				5					10					15	
Lys	His	Leu	Ile	His	Gly	Asp	Glu	Glu	Leu	Phe	Gln	His	Glu	Leu	Lys
			20					25					30		
Thr	Ile	Phe	Ala	Arg	Asn	Trp	Leu	Phe	Leu	Thr	His	Asp	Ser	Leu	Ile
		35					40					45			
Pro	Ala	Pro	Gly	Asp	Tyr	Val	Thr	Ala	Lys	Met	Gly	Ile	Asp	Glu	Val
		50				55					60				
Ile	Val	Ser	Arg	Gln	Asn	Asp	Gly	Ser	Ile	Arg	Ala	Phe	Leu	Asn	Val
65					70					75				80	
Cys	Arg	His	Arg	Gly	Lys	Thr	Leu	Val	Ser	Val	Glu	Ala	Gly	Asn	Ala
				85					90					95	
Lys	Gly	Phe	Val	Cys	Ser	Tyr	His	Gly	Trp	Gly	Phe	Gly	Ser	Asn	Gly
			100					105					110		
Glu	Leu	Gln	Ser	Val	Pro	Phe	Glu	Lys	Asp	Leu	Tyr	Gly	Glu	Ser	Leu
		115					120					125			
Asn	Lys	Lys	Cys	Leu	Gly	Leu	Lys	Glu	Val	Ala	Arg	Val	Glu	Ser	Phe
				130			135				140				
His	Gly	Phe	Ile	Tyr	Gly	Cys	Phe	Asp	Gln	Glu	Ala	Pro	Pro	Leu	Met
145					150					155					160
Asp	Tyr	Leu	Gly	Asp	Ala	Ala	Trp	Tyr	Leu	Glu	Pro	Met	Phe	Lys	His
				165					170					175	
Ser	Gly	Gly	Leu	Glu	Leu	Val	Gly	Pro	Pro	Gly	Lys	Val	Val	Ile	Lys
			180					185					190		
Ala	Asn	Trp	Lys	Ala	Pro	Ala	Glu	Asn	Phe	Val	Gly	Asp	Ala	Tyr	His
			195				200					205			

-continued

---

Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220  
 Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240  
 Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270  
 Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300  
 Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320  
 Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335  
 Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Thr  
 340 345 350  
 Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365  
 Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380  
 Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415  
 Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430  
 Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 35  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:30.

&lt;400&gt; SEQUENCE: 35

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln  
 1 5 10 15  
 Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys  
 20 25 30  
 Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile  
 35 40 45  
 Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val  
 50 55 60  
 Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val  
 65 70 75 80  
 Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala  
 85 90 95  
 Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly  
 100 105 110

-continued

Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu  
 115 120 125  
 Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe  
 130 135 140  
 His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met  
 145 150 155 160  
 Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His  
 165 170 175  
 Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys  
 180 185 190  
 Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His  
 195 200 205  
 Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe  
 210 215 220  
 Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu  
 225 230 235 240  
 Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270  
 Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300  
 Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320  
 Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335  
 Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Leu  
 340 345 350  
 Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365  
 Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380  
 Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415  
 Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430  
 Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 36  
 <211> LENGTH: 449  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:31.

&lt;400&gt; SEQUENCE: 36

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln  
 1 5 10 15  
 Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys

-continued

20					25					30					
Thr	Ile	Phe	Ala	Arg	Asn	Trp	Leu	Phe	Leu	Thr	His	Asp	Ser	Leu	Ile
		35					40					45			
Pro	Ala	Pro	Gly	Asp	Tyr	Val	Thr	Ala	Lys	Met	Gly	Ile	Asp	Glu	Val
	50					55					60				
Ile	Val	Ser	Arg	Gln	Asn	Asp	Gly	Ser	Ile	Arg	Ala	Phe	Leu	Asn	Val
65						70					75				80
Cys	Arg	His	Arg	Gly	Lys	Thr	Leu	Val	Ser	Val	Glu	Ala	Gly	Asn	Ala
				85					90					95	
Lys	Gly	Phe	Val	Cys	Ser	Tyr	His	Gly	Trp	Gly	Phe	Gly	Ser	Asn	Gly
			100					105						110	
Glu	Leu	Gln	Ser	Val	Pro	Phe	Glu	Lys	Asp	Leu	Tyr	Gly	Glu	Ser	Leu
		115					120					125			
Asn	Lys	Lys	Cys	Leu	Gly	Leu	Lys	Glu	Val	Ala	Arg	Val	Glu	Ser	Phe
	130					135					140				
His	Gly	Phe	Ile	Tyr	Gly	Cys	Phe	Asp	Gln	Glu	Ala	Pro	Pro	Leu	Met
145						150					155				160
Asp	Tyr	Leu	Gly	Asp	Ala	Ala	Trp	Tyr	Leu	Glu	Pro	Met	Phe	Lys	His
				165					170					175	
Ser	Gly	Gly	Leu	Glu	Leu	Val	Gly	Pro	Pro	Gly	Lys	Val	Val	Ile	Lys
			180					185						190	
Ala	Asn	Trp	Lys	Ala	Pro	Ala	Glu	Asn	Phe	Val	Gly	Asp	Ala	Tyr	His
		195					200					205			
Val	Gly	Trp	Thr	His	Ala	Ser	Ser	Leu	Arg	Ser	Gly	Glu	Ser	Ile	Phe
	210						215					220			
Ser	Ser	Leu	Ala	Gly	Asn	Ala	Ala	Leu	Pro	Pro	Glu	Gly	Ala	Gly	Leu
225						230					235				240
Gln	Met	Thr	Ser	Lys	Tyr	Gly	Ser	Gly	Met	Gly	Val	Leu	Trp	Asp	Gly
				245					250					255	
Tyr	Ser	Gly	Val	His	Ser	Ala	Asp	Leu	Val	Pro	Glu	Leu	Met	Ala	Phe
			260					265						270	
Gly	Gly	Ala	Lys	Gln	Glu	Arg	Leu	Asn	Lys	Glu	Ile	Gly	Asp	Val	Arg
		275					280					285			
Ala	Arg	Ile	Tyr	Arg	Ser	His	Leu	Asn	Cys	Thr	Val	Phe	Pro	Asn	Asn
	290					295					300				
Ser	Met	Leu	Thr	Cys	Ser	Gly	Val	Phe	Lys	Val	Trp	Asn	Pro	Ile	Asp
305						310					315				320
Ala	Asn	Thr	Thr	Glu	Val	Trp	Thr	Tyr	Ala	Ile	Val	Glu	Lys	Asp	Met
				325					330					335	
Pro	Glu	Asp	Leu	Lys	Arg	Arg	Leu	Ala	Asp	Ser	Val	Gln	Arg	Thr	Ile
			340					345						350	
Gly	Pro	Ala	Gly	Phe	Trp	Glu	Ser	Asp	Asp	Asn	Asp	Asn	Met	Glu	Thr
		355					360					365			
Ala	Ser	Gln	Asn	Gly	Lys	Lys	Tyr	Gln	Ser	Arg	Asp	Ser	Asp	Leu	Leu
	370					375					380				
Ser	Asn	Leu	Gly	Phe	Gly	Glu	Asp	Val	Tyr	Gly	Asp	Ala	Val	Tyr	Pro
385						390					395				400
Gly	Val	Val	Gly	Lys	Ser	Ala	Ile	Gly	Glu	Thr	Ser	Tyr	Arg	Gly	Phe
				405					410					415	
Tyr	Arg	Ala	Tyr	Gln	Ala	His	Val	Ser	Ser	Ser	Asn	Trp	Ala	Glu	Phe
			420					425						430	
Glu	His	Ala	Ser	Ser	Thr	Trp	His	Thr	Glu	Leu	Thr	Lys	Thr	Thr	Asp
		435					440					445			

-continued

Arg

<210> SEQ ID NO 37  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
<400> SEQUENCE: 37  
ttcagcgaac ggtcgggcct gc 22

<210> SEQ ID NO 38  
<211> LENGTH: 27  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A tetracycline repair oligonucleotide.  
  
<400> SEQUENCE: 38  
gccgggcctc ttgcgggata tcgtcca 27

<210> SEQ ID NO 39  
<211> LENGTH: 27  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: An ampicillin knockout oligonucleotide.  
  
<400> SEQUENCE: 39  
gttgccattg ctgcaggcat cgtggtg 27

<210> SEQ ID NO 40  
<211> LENGTH: 33  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
<400> SEQUENCE: 40  
gaggcacccg cggaagcttt tgtgggat gca 33

<210> SEQ ID NO 41  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
<400> SEQUENCE: 41  
gcacccgcgg aacaatttgt gggagatgca 30

<210> SEQ ID NO 42  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
<400> SEQUENCE: 42  
ccgcgaaag ctttgtggga g 21

<210> SEQ ID NO 43  
<211> LENGTH: 24  
<212> TYPE: DNA

-continued

---

<213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 43  
  
 ccgcggaaaa gcttgtggga gatg 24

<210> SEQ ID NO 44  
 <211> LENGTH: 23  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 44  
  
 cgcggaaaac gttgtgggag atg 23

<210> SEQ ID NO 45  
 <211> LENGTH: 23  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 45  
  
 atattcaggt gcgcatagcg cag 23

<210> SEQ ID NO 46  
 <211> LENGTH: 34  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 46  
  
 ggacggatat tcagggctcc atagcgcaga cttg 34

<210> SEQ ID NO 47  
 <211> LENGTH: 33  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 47  
  
 gacggatatt cagtaacca tagcgcagac ttg 33

<210> SEQ ID NO 48  
 <211> LENGTH: 30  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 48  
  
 ggtgttttca aagtcgcaa cccgatcgac 30

<210> SEQ ID NO 49  
 <211> LENGTH: 26  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.  
  
 <400> SEQUENCE: 49  
  
 ctgttcagcg aaacttcggg cctgct 26



-continued

---

<210> SEQ ID NO 50  
<211> LENGTH: 26  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 50

ctgttcagcg aaggttcggg cctgct 26

<210> SEQ ID NO 51  
<211> LENGTH: 26  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 51

ctgttcagcg aagcttcggg cctgct 26

<210> SEQ ID NO 52  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 52

ttcagcgaac gctcgggcct gc 22

<210> SEQ ID NO 53  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 53

ggcctgctgg cttcgcgaa agcgacgaca 30

<210> SEQ ID NO 54  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 54

gaaagcgacg ccaatgacaa t 21

<210> SEQ ID NO 55  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 55

acgacaatga caattgggaa acagcttcgc 30

<210> SEQ ID NO 56  
<211> LENGTH: 2265  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:

-continued

---

 <223> OTHER INFORMATION: A sequence encoding an NDO mutant.

&lt;400&gt; SEQUENCE: 56

```

gagggtagag aaatcgaatg ccccttgcat caaggtcggt ttgacgtttg cacaggcaaa    60
gccctgtgcg caccctgtgac acagaacatc aaaacatatc cagtcaagat tgagaacctg    120
cgcgtaatga ttgatttgag ctaagaatth taacaggagg caccctgggc cctagagcgt    180
aatcaccccc attccatctt ttttagtgta aaacatgaat tacaataata aaatcttggt    240
aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac tttccaaca    300
tgaactgaaa accatttttg cgcggaactg gctttttctc actcatgata gcctgattcc    360
tgccccggcg gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctccccgca    420
gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt    480
gagcgtggaa gccggcaatg ccaaaggtht tgtttgcagc tatcacggct ggggcttcg    540
ctccaacggt gaactgcaga gcgttcattt tgaaaaagat ctgtacggcg agtcgctcaa    600
taaaaaatgt ctggggttga aagaagtcgc tcgctgggag agcttccatg gcttcatcta    660
cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggt    720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggctctc caggcaaggt    780
tgtgatcaag gccaaactga aggcacccgc ggaaaacttt gtgggagatg cataccacgt    840
gggttgagcg cacgctctct cgcttcgctc gggggagtct atcttctcgt cgctcgtgg    900
caatgcggcg ctaccacctg aaggcgcagg cttgcaaatg acctccaaat acggcagcgg    960
catgggtgtg ttgtgggacg gatattcagg tgtgcatagc gcagacttgg ttccggaatt   1020
gatggcattc ggaggcgcaa agcaggaaaag gctgaacaaa gaaattggcg atgttcgcg    1080
tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tgctgacctg   1140
ctcgggtgth ttcaaagtat ggaacccgat cgacgcaaac accaccgagg tctggacct    1200
cgccattgtc gaaaaagaca tgcctgagga tctcaagcgc cgcttggccg actctgttca   1260
gcgaacgtgg gggcctgctg gcttctggga aagcgacgac aatgacaata tggaaacagc   1320
ttcgcaaac ggcaagaaat atcaatcaag agatagtgat ctgctttcaa accttggttt   1380
cggtagggac gtatacggcg acgcggtcta tccaggcgtc gtcggcaaat cggcgatcgg   1440
cgagaccagt tatcgtggtt tctaccgggc ttaccaggca cacgtcagca gctccaactg   1500
ggctgagttc gagcatgctt ctagtacttg gcatactgaa cttacgaaga ctactgatcg   1560
ctaacagacg agtcgacctt gatgatcaat attcaagaag acaagctggt ttccgcccac   1620
gacgccgaag agattcttgg tttcttcaat tgccacgact ctgctttgca acaagaagcc   1680
actacgctgc tgaccagga agcgcatttg ttggacattc aggttaaccg tgcttggtta   1740
gagcactgcg tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgcgacgct   1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaaa ttttcagcaa   1860
ctgaaagttc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg   1920
cgctttactc gctttatcac caacgtccag gccgcaatgg acgtaaatga caaagagcta   1980
cttcacatcc gctccaacgt cattctgcac cgggcacgac gtggcaatca ggtcgatgct   2040
ttctacgccg cccgggaaga taaatggaaa cgtggcgaag gtggagtacg aaaattggtc   2100
cagcgattcg tcgattaccg agagcgcata cttcagacgc acaatctgat ggtctttctg   2160
tgattcagtg accattttta caaatggtca ctgcaaccgc ggtcaccatt aatcaaaggg   2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg                    2265

```

-continued

---

```

<210> SEQ ID NO 57
<211> LENGTH: 2265
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A sequence encoding an NDO mutant.

<400> SEQUENCE: 57
gagggtagag aaatcgaatg ccccttgcac caaggtcggg ttgacgtttg cacaggcaaa    60
gccctgtgag caccctgtac acagaacatc aaaacatata cagtcaagat tgagaacctg    120
cgcgtaataa ttgatttgag ctaagaattt taacaggagg caccctgggc cctagagcgt    180
aatcaccccc attccatcct ttttagtgta aaacatgaat tacaataata aaatcttggt    240
aagtgaatct ggtctgagcc aaaagcacct gattcatggc gatgaagaac ttttccaaca    300
tgaactgaaa accatttttg cgcggaaact gctttttctc actcatgata gcctgattcc    360
tgcccccggc gactatgtta ccgcaaaaat ggggattgac gaggtcatcg tctccccgca    420
gaacgacggt tcgattcgtg cttttctgaa cgtttgccgg catcgtggca agacgctggt    480
gagcgtggaa gccggcaatg ccaaagggtt tgtttgacgc taccacggct ggggcttcgg    540
ctccaacggt gaactgcaga gcgttccatt tgaaaaagat ctgtacggcg agtcgctcaa    600
taaaaaatgt ctggggttga aagaagtcgc tcgcgtggag agcttccatg gcttcatcta    660
cggttgcttc gaccaggagg cccctcctct tatggactat ctgggtgacg ctgcttggtg    720
cctggaacct atgttcaagc attccggcgg tttagaactg gtcggtcctc caggcaaggt    780
tgtgatcaag gccaaactga aggcacccgc ggaaaacttt gtgggagatg cataccacgt    840
gggttgagc cagcgcgtct cgcttcgctc gggggagtct atcttctcgt cgctcgctgg    900
caatgcggcg ctaccacctg aagcgcagcg cttgcaaatg acctccaaat acggcagcgg    960
catgggtgtg ttgtgggagc gatattcagg tgtgcatagc gcagacttgg ttcgggaatt    1020
gatggcattc ggaggcgcga agcaggaaa gctgaacaaa gaaattggcg atgttcgcgc    1080
tcggatttat cgcagccacc tcaactgcac cgttttcccg aacaacagca tgctgacctg    1140
ctcgggtggt ttcaaagtat ggaacccgat cgcgcgcaac accaccgagg tctggacctg    1200
cgccattgtc gaaaaagaca tgccctgagga tctcaagcgc cgcttgcccg actctgttca    1260
gcgaacggtc gggcctgctg gcttctggga aagcgcgac aatgacaata tggaacagc    1320
ttcgcaaac gccaaagaa atcaatcaag agatagtgat ctgcttcaa accttggttt    1380
cggtgaggac gtatacggcg acgcggtcta tccaggcgtc gtcggcaaat cggcgatcgg    1440
cgagaccagt tatcgtggtt tctaccgggc ttaccaggca cacgtcagca gctccaactg    1500
ggctgagttc gagcatgcct ctagtacttg gcatactgaa cttacgaaga ctactgatcg    1560
ctaacagacg agtcgacct gatgatcaat attcaagaag acaagctggt ttcgcccac    1620
gacgccgaag agattcttcg tttcttcaat tgccacgact ctgctttgca acaagaagcc    1680
actacgctgc tgaccagga agcgcatttg ttggacattc aggttaccg tctttggtta    1740
gagcactcgc tggggtcaga ggtgcaatat caggtcattt cacgcgaact gcgocgact    1800
tcagagcgtc gttataagct caatgaagcc atgaacgttt acaacgaaaa ttttcagcaa    1860
ctgaaagtgc gagttgagca tcaactggat ccgcaaaact ggggcaacag cccgaagctg    1920
cgctttactc gctttatcac caacgtccag gccgcaatgg acgtaatga caaagacta    1980
cttcacatcc gctccaacgt cattctgcac cgggcacgac gtggcaatca ggtcogatgc    2040

```

-continued

```

ttctacgccg cccggaaga taaatgaaa cgtggcgaag gtggagtacg aaaattggtc 2100
cagcgattcg tcgattacc agagcgata cttcagacgc acaatctgat ggtctttctg 2160
tgattcagtg accattttta caaatggta ctgcaaccgc ggtcaccatt aatcaaagg 2220
aatgtacgtg tatgggcaat caacaagtcg tttcgataac cgggtg 2265
    
```

```

<210> SEQ ID NO 58
<211> LENGTH: 449
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A polypeptide encoded by SEQ ID NO:56.
    
```

<400> SEQUENCE: 58

```

Met Asn Tyr Asn Asn Lys Ile Leu Val Ser Glu Ser Gly Leu Ser Gln
 1           5           10          15
Lys His Leu Ile His Gly Asp Glu Glu Leu Phe Gln His Glu Leu Lys
 20          25          30
Thr Ile Phe Ala Arg Asn Trp Leu Phe Leu Thr His Asp Ser Leu Ile
 35          40          45
Pro Ala Pro Gly Asp Tyr Val Thr Ala Lys Met Gly Ile Asp Glu Val
 50          55          60
Ile Val Ser Arg Gln Asn Asp Gly Ser Ile Arg Ala Phe Leu Asn Val
 65          70          75          80
Cys Arg His Arg Gly Lys Thr Leu Val Ser Val Glu Ala Gly Asn Ala
 85          90          95
Lys Gly Phe Val Cys Ser Tyr His Gly Trp Gly Phe Gly Ser Asn Gly
 100         105        110
Glu Leu Gln Ser Val Pro Phe Glu Lys Asp Leu Tyr Gly Glu Ser Leu
 115        120        125
Asn Lys Lys Cys Leu Gly Leu Lys Glu Val Ala Arg Val Glu Ser Phe
 130        135        140
His Gly Phe Ile Tyr Gly Cys Phe Asp Gln Glu Ala Pro Pro Leu Met
 145        150        155        160
Asp Tyr Leu Gly Asp Ala Ala Trp Tyr Leu Glu Pro Met Phe Lys His
 165        170        175
Ser Gly Gly Leu Glu Leu Val Gly Pro Pro Gly Lys Val Val Ile Lys
 180        185        190
Ala Asn Trp Lys Ala Pro Ala Glu Asn Phe Val Gly Asp Ala Tyr His
 195        200        205
Val Gly Trp Thr His Ala Ser Ser Leu Arg Ser Gly Glu Ser Ile Phe
 210        215        220
Ser Ser Leu Ala Gly Asn Ala Ala Leu Pro Pro Glu Gly Ala Gly Leu
 225        230        235        240
Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly
 245        250        255
Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe
 260        265        270
Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg
 275        280        285
Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn
 290        295        300
Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp
 305        310        315        320
Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met
    
```



-continued

Gln Met Thr Ser Lys Tyr Gly Ser Gly Met Gly Val Leu Trp Asp Gly  
 245 250 255  
 Tyr Ser Gly Val His Ser Ala Asp Leu Val Pro Glu Leu Met Ala Phe  
 260 265 270  
 Gly Gly Ala Lys Gln Glu Arg Leu Asn Lys Glu Ile Gly Asp Val Arg  
 275 280 285  
 Ala Arg Ile Tyr Arg Ser His Leu Asn Cys Thr Val Phe Pro Asn Asn  
 290 295 300  
 Ser Met Leu Thr Cys Ser Gly Val Phe Lys Val Trp Asn Pro Ile Asp  
 305 310 315 320  
 Ala Asn Thr Thr Glu Val Trp Thr Tyr Ala Ile Val Glu Lys Asp Met  
 325 330 335  
 Pro Glu Asp Leu Lys Arg Arg Leu Ala Asp Ser Val Gln Arg Thr Tyr  
 340 345 350  
 Gly Pro Ala Gly Phe Trp Glu Ser Asp Asp Asn Asp Asn Met Glu Thr  
 355 360 365  
 Ala Ser Gln Asn Gly Lys Lys Tyr Gln Ser Arg Asp Ser Asp Leu Leu  
 370 375 380  
 Ser Asn Leu Gly Phe Gly Glu Asp Val Tyr Gly Asp Ala Val Tyr Pro  
 385 390 395 400  
 Gly Val Val Gly Lys Ser Ala Ile Gly Glu Thr Ser Tyr Arg Gly Phe  
 405 410 415  
 Tyr Arg Ala Tyr Gln Ala His Val Ser Ser Ser Asn Trp Ala Glu Phe  
 420 425 430  
 Glu His Ala Ser Ser Thr Trp His Thr Glu Leu Thr Lys Thr Thr Asp  
 435 440 445

Arg

<210> SEQ ID NO 60  
 <211> LENGTH: 26  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 60

gttcagcgaa cgggcgggcc tgctgg

26

<210> SEQ ID NO 61  
 <211> LENGTH: 26  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 61

gttcagcgaa cggccgggcc tgctgg

26

<210> SEQ ID NO 62  
 <211> LENGTH: 26  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 62

gttcagcgaa cgaccgggcc tgctgg

26

-continued

---

```

<210> SEQ ID NO 63
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 63

gttcagcgaa cgatcgggcc tgctgg                26

<210> SEQ ID NO 64
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 64

gttcagcgaa cgtgggggcc tgctgg                26

<210> SEQ ID NO 65
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: A mutagenic oligonucleotide.

<400> SEQUENCE: 65

ttcagcgaa gtacgggcct gctgg                25

```

---

What is claimed is:

1. A dioxygenase complex comprising a plurality of polypeptides, wherein the complex catalyzes the oxidation of an aromatic substrate and comprises at least one alpha-subunit polypeptide selected from the group consisting of:
  - (a) a polypeptide comprising SEQ ID NO: 26 with a substituted amino acid at position 352 of SEQ ID NO: 26,
  - (b) a polypeptide comprising SEQ ID NO: 26 with a substituted amino acid at position 201, 202, 260, 316, 351, 358, 362, or 366 of SEQ ID NO: 26,
  - (c) a polypeptide comprising SEQ ID NO: 26 with a substituted amino acid at position 352 of SEQ ID NO: 26 and a substituted amino acid at position 201, 202, 260, 316, 351, 358, 362, or 366 of SEQ ID NO: 26, or a fragment of said dioxygenase complex that catalyzes oxidation of an aromatic substrate.
2. The dioxygenase complex of claim 1 having an alpha-subunit that comprises SEQ ID NO:26 with an amino acid other than phenylalanine at position 352 of SEQ ID NO: 26, or a fragment thereof that catalyzes oxidation of an aromatic substrate.
3. The dioxygenase complex of claim 1 having an alpha-subunit that comprises SEQ ID NO:26 with a substituted acid at position 201, 202, 260, 316, 351, 352, 358, 362, or 366 of SEQ ID NO: 26, or a fragment thereof that catalyzes oxidation.
4. The dioxygenase complex of claim 1 having an alpha-subunit that comprises a substituted amino acid at the position corresponding to position 352 of SEQ ID NO:26, and a substituted amino acid at the position corresponding to position 201, 202, 260, 316, 351, 358, 362, or 366 of SEQ ID NO: 26; or a fragment thereof that catalyzes oxidation of an aromatic substrate.
5. The dioxygenase complex of claim 2 wherein the amino acid at position 352 is a naturally occurring amino acid.
6. The dioxygenase complex of claim 2 wherein the alpha-subunit comprises SEQ ID NO:2, 32, 33, 34, 35, or 36.
7. The dioxygenase complex of claim 2 wherein the alpha-subunit comprises SEQ ID NO:2.
8. The dioxygenase complex of claim 3 having an alpha-subunit that comprises alanine, glutamine, or serine at position 201.
9. The dioxygenase complex of claim 3 having an alpha-subunit that comprises leucine or valine at position 202.
10. The dioxygenase complex of claim 3 having an alpha-subunit that comprises alanine, leucine, or asparagine at position 260.
11. The dioxygenase complex of claim 3 having an alpha-subunit that comprises alanine at position 316.
12. The dioxygenase complex of claim 3 having an alpha-subunit that comprises asparagine, arginine, or serine at position 351.
13. The dioxygenase complex of claim 3 having an alpha-subunit that comprises alanine at position 358.
14. The dioxygenase complex of claim 3 having an alpha-subunit that comprises alanine at position 362.
15. The dioxygenase complex of claim 3 having an alpha-subunit that comprises tryptophan at position 366.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,794,167 B2  
DATED : September 21, 2004  
INVENTOR(S) : Parales et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Lines 54-57, delete "The invention also provides an isolated and purified DNA segment encoding a polypeptide of the invention, or a variant or fragment thereof." and insert the same as a new paragraph on line 55.

Column 7,

Line 45, delete "4dihydrobiphenyl" and insert -- 4-dihydrobiphenyl --, therefor.

Column 12,

Line 35, delete "coil" and insert -- coli. --, therefor.

Column 13,

Line 5, delete "3 pi" and insert -- 3  $\mu$ I --, therefor.

Column 14,

Line 2, delete " $\beta$ D-thiogalactopyranoside" and insert --  $\beta$ -D-thiogalactopyranoside --, therefor.

Columns 19-20,

Line 7, in "Table 5" delete "CCGCGGAAAAGCTTTGTGGGAG" and insert -- CCGCGGAAAAGCTTTGTGGGAG --, therefor.

Column 21,

Line 12, delete "Thr-35 1" and insert -- Thr-351 --, therefor.  
Line 15, delete "a" and insert --  $\alpha$  --, therefor.

Column 22,

Line 5, delete "phenylcyclohexa4" and insert -- phenylcyclohexa-4 --,

Columns 23-24,

Line 3, "Table 3", delete "putida" and insert -- putida --, therefor.

Column 25,

Line 23, delete "Asn-20 1" and insert -- Asn-201 --, therefor.

Column 26,

Line 57, in "Table 8" delete "F3521" and insert -- F352I --, therefor.



UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,794,167 B2  
DATED : September 21, 2004  
INVENTOR(S) : Parales et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 27,

Line 48, delete "F3521" and insert -- F352I --, therefor.

Column 29,


Line 51, delete "Amax" and insert --  $\lambda_{\max}$  --, therefor.

Column 30,

Line 32, delete "F3521" and insert -- F352I --, therefor.

Signed and Sealed this

Fifth Day of April, 2005

A handwritten signature in black ink on a light gray dotted background. The signature reads "Jon W. Dudas" in a cursive style.

JON W. DUDAS

*Director of the United States Patent and Trademark Office*